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Abstract 
Although haemopoietic stem cells (HSCs) represent one of the best-defined 
stem cell systems, the pathways regulating HSC development and 
maintenance are not fully understood. HSCs reside in the hypoxic niche and 
maintain intracellular hypoxia. Hypoxia and hypoxia signalling pathways are 
thought to play a vital role in HSC maintenance. Hypoxia inducible factors 
(Hifs) are evolutionarily conserved and are the key regulators of hypoxia. 
Hifs consist of an unstable, oxygen-dependent α-subunit and an oxygen-
independent stable β-subunit. The two main isoforms of Hif-α, namely Hif-
1α and Hif-2α, are critical for the response to hypoxia. Hif-mediated 
pathways have been extensively studied and have been shown to regulate 
metabolic adaptation and to influence various cellular mechanisms, 
including cell growth, survival, differentiation and apoptosis, erythropoiesis 
and angiogenesis. Hif-1α has been shown to be essential for maintenance of 
HSC functions under stressful conditions of serial transplantation and aging, 
but the role of Hif-2α and the interplay between Hif-1α and Hif-2α in 
regulating HSC functions and their niche is not known. Hence, in this study, I 
have investigated the role of Hif-α in HSC functions. Furthermore, published 
evidence suggested that leukaemic stem cells (LSC) share the hypoxic 
properties with HSCs. Cited2, a hypoxia-inducible Hif-1α and Hif-2α target 
gene, is critical for embryonic and adult haemopoiesis and possesses 
oncogenic properties. I have investigated the role of Cited2 in AML 
generation. 
The results demonstrate that Hif-2α is not essential for maintenance of HSC 
functions in a cell-autonomous manner under steady state and stressful 
conditions of serial transplantation and aging. It is also evident that HSCs 
lacking Hif-2α together with Hif-1α successfully maintain normal 
haemopoiesis. However, the data in this thesis show that Hif-2α is essential 
for non-cell-autonomous maintenance of HSC functions, particularly in 
males and current work also indicate that a previously unappreciated 
complex interplay between Hif-1α- and Hif-2α-dependent signalling is 
required for adult HSC maintenance in a non-cell-autonomous manner. 
Additionally, the data demonstrate that haemopoietic stem and progenitor 
cells (HSPCs) lacking Cited2 display reduced transformation potential and 
failure to generate transplantable AML in vivo. Overexpression of Mcl-1 (an 
anti-apoptotic gene), in Cited2Δ/Δ cells bypassed their defective 
transformation potential forming transformed colonies in vitro. Hence, the 
data in this thesis provide evidence that Cited2 is essential for leukaemic 
transformation at least in part via Mcl-1 regulation. 
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Definitions/Abbreviations 
2-HG – 2-Hydroxygluterate 
5-FU – 5-Flurouracil 
ADM – Adrenomedullin 
AGM – Aorta-gonad mesonephros 
ALL – Acute lymphobastic leukaemia 
AML – Acute myeloid leukaemia 
AML1 – Acute myelogenous leukaemia-1 
Ang-1 – Angiopoietin-1 
ARNT – Aryl hydrocarbon nuclear translocator 
bHLH – Basic Helix-loop-helix 
BM – Bone marrow 
CAD – C-terminal transactivation domain 
CAR – Cxcl12-abundant reticular cells 
CEBPA – CCAAT/enhancer binding protein alpha 
CFU-S – Colony-forming unit - Spleen 
CH1-3 – Cysteine-histidine-rich domain 1-3 
CITED – CBP/p300 interacting transactivators with glutamic acid (E) and 
aspartic acid (D)-rich tail 
Cited2 – CBP/p300 interacting transactivators with glutamic acid (E) and 
aspartic acid (D)-rich tail 2 (Murine) 
CITED2 – CBP/p300 interacting transactivators with glutamic acid (E) and 
aspartic acid (D)-rich tail 2 (Human) 
CKO – Conditional knockout 
CLL – Chronic lymphocytic leukaemia 
CLP – Common lymphoid progenitor 
CML – Chronic myeloid leukaemia  
CMP – Common myeloid progenitor 
CODDD – Carboxy-terminal oxygen-dependent degradation domain 
dHSC – Definitive haemopoietic stem cells 
DMEM – Dulbecco’s Modified Eagle’s Medium 
Epo – Erythropoietin 
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EpoR – Erythropoietin receptor 
ETO – Eight Twenty One 
Ets – E- twenty six 
Evi1 – Ecotropic proviral integration site 1 
FAB – French-American-British classification 
FACS – Fluorescence-activated cell sorting 
FBS – Feotal bovine serum 
FDG – Fluorescein di[β-D-galactopyranoside] 
FIH – Factor inhibiting HIF 
Flt3 – FMS-like tyrosine kinase 3 
G-CSF – Granulocyte colony-stimulating factor 
GEM – Genetically engineered mice models 
Gfi1 – Growth Factor independent 1 
GLUT1 – Glucose transporter 1 
GMP – Granulocyte/macrophage progenitor 
HAF – Hypoxia-associated factor 
HAT – Histone acetyl transferase 
HDAC – Histone deacetylase 
HIF – Hypoxia inducible factor (Human) 
Hif – Hypoxia inducible factor (murine) 
HK1, HK2 – Hexokinase 1 and 2  
Hox – Homeobox 
HRE – Hypoxia responsive element 
HSC – Haemopoietic stem cell 
HSPCs – Haemopoietic stem and progenitor cells 
iCre- Improved Cre recombinase 
IDH1/2 – Isocitrate dehydrogenase1/2 
IL – Interleukin 
IMDM – Iscove's modified Dulbecco's medium 
IRES – Internal-ribosome-entry-site 
ITD – Internal tandem mutation 
JHDM – Jumonji histone lysine demethylases 
LDHA – Lactate dehydrogenase A 
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LIF – Leukaemia initiating factor 
LMPP – Lymphoid-primed multipotent progenitors 
LSC – Leukaemic stem cell 
LSK – Lineage-Sca-1+c-Kit+ 
LT-HSC – Long-term haemopoietic stem cell 
LTC-IC – Long-term culture initiating cell 
LTR – Long terminal repeat 
Ly-bi – Lymphoid-biased 
MDS – Myelodysplastic syndrome 
MEFs – Mouse embryonic fibroblasts 
Meis – Myeloid ectropic insertion site 
MEP – Megakaryocyte/erythroid progenitors 
mHSC – Murine haemopoietic stem cell  
MLL – Mixed lineage leukaemia 
MPN – Myeloproliferative neoplasm 
MSC – Mesenchymal stem cell 
MSCV – Murine stem cell virus 
My-bi – Myeloid-biased 
NAD – N-terminal transactivation domain 
NO – Nitric oxide 
NOD-SCID – Non-obese diabetes-severe combined immunodeficient mice 
NODDD – Amino-terminal (N) oxygen-dependent degradation domain 
O2 – Oxygen 
OB – Osteoblasts  
OC – Osteoclasts 
ODDD – Oxygen-dependent degradation domain 
P300/CBP – p300/Creb-binding protein 
PAS – Per-ARNT-Sim domain 
PB – Peripheral blood 
PBX – pre-B-cell leukaemia homeobox 
PDK1 – Pyruvate dehydrogenase kinase 1 
PGK1 – Phosphoglycerate kinase 1 
PHD – Prolyl hydroxylase 
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Pimo - Pimonidazole 
PLZF – Promyelocytic leukaemia zinc finger 
pO2 – Partial pressure of oxygen 
PPR – Parathyroid hormone/parathyroid hormone related peptide receptor 
pVHL – von-Hippel-Lindau 
RBC – Red blood cells 
ROS – Reactive oxygen species 
Runx1 – Runt-related transcription factor 1 
Scf – Stem cell factor 
Scl/Tal1 - Stem cell leukaemia gene 
SEP – Super elongation complex 
Sirt – Sirtuins 
ST-HSC – Short-term-haemopoietic stem cell 
TAD – Transactivation domain 
TBP – TATA-binding protein 
TET2 – Ten-eleven-translocation gene 2 
TF – Transcription factor 
TGF-β – Transforming growth factor- β 
TKD – Tyrosine kinase domain 
Vegf – Vascular endothelial growth factor 
WHO – World health organisation 
WT – Wild type 
WT1 – Wilm’s tumour 1 
α- KG – alpha keto-gluterate 
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 Haemopoietic stem cells (HSCs) 1.1
Haemopoiesis is the process of formation and maintenance of the blood 
system and serves as a model for the understanding of the biology and fates 
of other tissue stem cells (Jacobson et al. 1951; Till and Mc 1961; Wu et al. 
1967; Kondo et al. 2003; Orkin and Zon 2008). Haemopoiesis is conserved in 
vertebrates and occurs throughout one’s lifetime to replenish short-lived 
mature blood cells (Orkin and Zon 2008). Haemopoiesis critically depends on 
rare multipotent stem cells called HSCs (Jacobson et al. 1951; Lorenz et al. 
1952; Till and Mc 1961; Tanaka 1966; Wu et al. 1967; Wu et al. 1968). 
Indeed, HSCs were demonstrated to be capable of rescuing the fatal BM 
failure in lethally irradiated mice upon transplantation, confirming their 
multipotent ability (Jacobson et al. 1951; Lorenz et al. 1952; Till and Mc 
1961; Tanaka 1966; Wu et al. 1967; Wu et al. 1968). Till and McCulloch were 
the pioneers in establishing the ability of the BM cell fraction to form 
colony-forming unit Spleen (CFU-S) in irradiated mice (Till and Mc 1961). In 
1963, Becker et al first reported the clonal origin of HSCs from the BM that 
generated mixed lineage CFU-S in irradiated host mice (Becker et al. 1963). 
However, it was later shown that CFU-S were formed by committed 
progenitors and not HSCs (Schofield 1978). These experiments opened up 
the field of adult stem cells and exploration of their self-renewal and 
multipotent characteristics.  
1.1.1 Properties of HSCs 
HSCs are localised within the hypoxic BM and have a unique capability to 
self-renew, sustaining a critical pool of HSCs that can subsequently 
differentiate to form multipotent progenitors or self-renew again (Jacobson 
et al. 1951; Lorenz et al. 1952; Till and Mc 1961; Tanaka 1966; Wu et al. 
1967; Wu et al. 1968; Kondo et al. 1997; Akashi et al. 2000; Orkin 2000; 
Adolfsson et al. 2001; Reya et al. 2001; Adolfsson et al. 2005; Parmar et al. 
2007; Simsek et al. 2010; Takubo et al. 2010). HSCs regulate haemopoietic 
homeostasis by maintaining a strict balance between fate choices of self-
renewal, quiescence, differentiation and apoptosis (Orkin and Zon 2008). In 
vitro studies showed that HSCs undergo symmetric or asymmetric cell 
division to maintain the HSC pool and differentiate into mature blood 
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lineages (Morrison and Kimble 2006; Wu et al. 2007). During early 
embryogenesis, following injury or transplantation, HSCs divide 
symmetrically to produce two HSCs or two progenitors (Morrison et al. 1995; 
Bodine et al. 1996; Morrison et al. 1997b; Wright et al. 2001; Morrison and 
Kimble 2006). Alternatively, HSCs divide asymmetrically to produce two 
daughter cells destined to different fate choices; one that retains the 
characteristics of the mother HSC and the other that commits to 
differentiate (Suda et al. 1984; Takano et al. 2004; Giebel et al. 2006; Ting 
et al. 2012) (Figure 1.1). Cell intrinsic (Beckmann et al. 2007; Ting et al. 
2012) and cell extrinsic factors influence the choices of symmetrical or 
asymmetrical cell division, thus signifying the role of the BM niche in 
regulating HSC fate choices (Osawa et al. 1996; Takano et al. 2004; Wu et 
al. 2007).  
Figure1. 1: Model of properties of HSCs. 
HSCs undergo symmetric cell division to produce identical daughter cells (both HSCs or 
both progenitor cells) or asymmetric cell division to produce two daughter cells that are 
destined to different fate choices.  One daughter cell retains the characteristics of the mother 
HSC and the other daughter cell commits to differentiate. 
Quiescent)HSC)
Symmetric)division)
into)two)HSCs)
Symmetric)division)
into)two)progenitors)
Asymmetric)division)
into)one)HSC)and)one)
progenitor)
Cell division 
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1.1.2 Embryonic haemopoiesis 
Early haemopoiesis in mammals occurs sequentially at multiple sites giving 
rise to less lineage-committed progenitors during early haemopoiesis (Green 
1966; Moore and Metcalf 1970; Johnson and Moore 1975; Silver and Palis 
1997; Palis et al. 1999). The yolk sac supports the production of an initial 
wave of blood cells, termed primitive haemopoietic cells, that are mainly 
erythrocytes at E7.5 (embryonic day 7.5) followed by early myeloid cells at 
E8.25 (Silver and Palis 1997; Palis et al. 1999). At E9.5, primitive progenitors 
with the potential of reconstitution are restricted to neonatal murine 
embryos (Moore and Metcalf 1970; Cumano et al. 2001). The primitive 
haemopoiesis is later replaced by definitive haemopoiesis (Medvinsky and 
Dzierzak 1996). Definitive HSC (dHSCs) activity is established in the aorta-
gonad mesonephros (AGM) region at E10.5 (Muller et al. 1994; Medvinsky 
and Dzierzak 1996), although there is evidence that they can also be found 
in other regions, such as the yolk sack and placenta (Samokhvalov et al. 
2007; Rhodes et al. 2008). The dHSCs from the AGM region migrate to the 
foetal liver that is the predominant site of haemopoiesis by E12.5 
(Kumaravelu et al. 2002). Subsequently, at around E16-E17, foetal liver 
HSCs colonise the BM, making it the ultimate haemopoietic site (Morrison et 
al. 1995; Wright et al. 2001). 
The embryonic origin of murine adult haemopoietic system is controversial. 
Some studies suggest that the common precursor population for both 
primitive and dHSCs arises in the yolk sac and then colonises the AGM and 
foetal liver regions, forming adult HSCs (Moore and Metcalf 1970; Johnson 
and Moore 1975; Samokhvalov et al. 2007). Other studies provide proof for 
the embryonic origin of dHSCs through endothelial precursors (Dieterlen-
Lievre 1975; Dzierzak and Medvinsky 2008). Early studies of the origin of 
haemopoiesis suggest that HSCs arise from endothelial cells termed 
haemangioblasts (Maximow 1909; Sabin 1920). In concordance with this, 
studies utilising mouse and zebra fish models, recent imaging and lineage 
tracing experiments, have gathered direct evidence for the existence of 
endothelial precursors of haemopoietic cells (Dieterlen-Lievre 1975; Zovein 
et al. 2008; Lancrin et al. 2009; Beerman et al. 2010; Bertrand et al. 2010; 
Rybtsov et al. 2011). Research involving human embryos provided evidence 
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of haemopoiesis in the AGM region, followed by yolk sac, foetal liver and 
placenta (Ivanovs et al. 2011). 
1.1.3 Hierarchy of differentiation of HSCs 
Various studies have focused on the multipotent differentiation potential of 
HSCs by evaluating the expression of cell surface markers and performing 
functional assays (Spangrude et al. 1988; Morrison and Weissman 1994; 
Uchida et al. 1994; Adolfsson et al. 2001; Weissman et al. 2001; Kiel et al. 
2005; Kim et al. 2006b; Kiel et al. 2007). These studies suggest that self-
renewal and multipotency potential is progressively lost as cells proceed 
down the haemopoietic hierarchy (Papathanasiou et al. 2009; Beerman et 
al. 2010; Morita et al. 2010; Oguro et al. 2013). The resultant data suggest 
that haemopoietic progeny are defined by the formation of Long-term HSCs 
(LT-HSCs) that undergo division to give rise to multipotent short-term HSCs 
(ST-HSCs) with reduced self-renewal potential (Adolfsson et al. 2001; Reya 
et al. 2001; Adolfsson et al. 2005). ST-HSCs divide asymmetrically to form 
lymphoid-primed multipotent progenitors (LMPPs) (Akashi et al. 2000; 
Adolfsson et al. 2005) and common myeloid progenitors (CMPs) (Adolfsson et 
al. 2005). Further down the hierarchy, LMPPs generate committed 
granulocyte/macrophage progenitors (GMPs) and common lymphoid 
progenitors (CLPs) (Adolfsson et al. 2001; Adolfsson et al. 2005; Oguro et al. 
2013).  CMPs give rise to committed GMPs and megakaryocyte/erythroid 
progenitors (MEPs) (Akashi et al. 2000; Adolfsson et al. 2005; Nutt et al. 
2005). However, the existence of LMPPs that are Lin-Sca-1+c-Kit+ Flt3+ (LSK 
Flt3+) is controversial (Forsberg et al. 2006; Boyer et al. 2011). The lineage 
restricted GMPs, CLPs and MEPs differentiate into mature blood cells, 
including myeloid cells (granulocytes, monocytes), lymphocytes (B- and T-
cells, natural killer cells), dendritic cells, erythrocytes, megakaryocytes and 
platelets, respectively (Figure 1.2). LT-HSCs also generate MEPs (Pronk et 
al. 2007) and a recent publication showed that platelet-biased stem cells 
reside at the top of the HSC hierarchy adding to the evidence of 
heterogeneity of HSCs (Moignard et al. 2013).     
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Figure 1. 2: Schematic representation of haemopoietic hierarchy. 
LT-HSCs sit at the top of the differentiation hierarchy and maintain adult haemopoiesis. LT-HSCs 
self-renew and undergo division to give rise to downstream progenitors and eventually terminally 
differentiate to mature blood lineages. Immunophenotypic markers have been developed to 
identify HSCs and downstream hierarchical populations. LT-HSC-Long-term HSC; ST-HSC-
Short-term HSC; LMPP-Lymphoid primed multipotent progenitor; CMP-Common myeloid 
progenitor; CLP-Common lymphoid progenitor; GMP-Granulocyte/macrophage progenitor; MEP-
Megakaryocyte/erythroid progenitor; NK cells-Natural killer cells; CD-Cluster of differentiation; 
Lin-Lineage; LSK-Lineage-Sca-1+c-Kit+ and LK-Lineage- c-Kit+.  
1.1.4 Heterogeneity of HSCs 
Previous studies involving transplantation of limiting doses of BM and 
analysis of purified individual HSCs revealed functional heterogeneity in 
self-renewal, differentiation and repopulation potential (Abkowitz et al. 
2000; Muller-Sieburg et al. 2002; Uchida et al. 2003; Takano et al. 2004; 
Sieburg et al. 2006; Dykstra et al. 2007).  In addition, HSCs have been shown 
to possess heterogeneity at the molecular level with regard to gene 
expression (Glotzbach et al. 2011; Moignard et al. 2013). Muller-Sieburg et 
al defined the different subtypes of HSCs based on their contribution to 
donor-derived mature cells as myeloid-biased (My-bi), lymphoid-biased (Ly-
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bi) or balanced (Bala) (Muller-Sieburg et al. 2012). Another study classified 
the HSCs based on their differentiation potential to become circulating 
mature blood cells, and resultantly termed HSCs as lymphoid-deficient (α), 
myeloid-deficient (γ and δ) or balanced (β) (Dykstra et al. 2007). Serial 
transplantation experiments showed that α- and β-HSCs retained long-term 
reconstitution potential and their distinctive differentiation properties 
(Dykstra et al. 2007; Benz et al. 2012). It has been reported that secondary 
clonal progeny resulting from α- and β-HSCs maintain the unique 
differentiation pattern (Dykstra et al. 2007; Dykstra et al. 2011; Muller-
Sieburg et al. 2012). But in some instances, primary α-clones generate 
secondary β-clones and vice versa as shown by Benz et al (Benz et al. 2012). 
Recent evidence identified a distinct fraction of HSCs that expresses a 
megakaryocyte gene termed von Willebrand factor that are primed to 
generate platelets (Sanjuan-Pla et al. 2013). The study reported that 
platelet-primed HSCs are at the apex of the cellular hierarchy with self-
renewal potential and ability to generate myeloid biased and lymphoid 
biased HSCs (Sanjuan-Pla et al. 2013). Based on the expression of cell 
surface marker-CD150, Morita et al showed that CD150high HSCs maintained 
long-term self-renewal properties and upon transplantation, generated 
heterogeneous sub-fractions of HSCs: CD150med and CD150neg (Morita et al. 
2010). This study also showed that reduced CD150 expression was correlated 
with reduced erythroid/megakaryocyte differentiation (Morita et al. 2010).  
Molecular mechanisms that influence the fate choice and clonal origin of 
different subtypes of HSCs were examined by high-throughput single cell 
gene expression analysis (Challen et al. 2010; Moignard et al. 2013). Studies 
revealed both cell-intrinsic and cell-extrinsic cues that differentially 
influence HSC subtypes (Challen et al. 2010; Benz et al. 2012; Moignard et 
al. 2013). TGF-β1 (Transforming growth factor- β1) exhibited differential 
effects on the HSC subtypes as it enhanced the proliferation of My-bi HSCs, 
but had an inhibitory effect on Ly-bi HSCs (Challen et al. 2010). A recent 
publication provided more insight into the differential gene expression 
profile of 18 key haemopoietic transcription factors (TFs) (Moignard et al. 
2013). This study, with profiling of 597 single cells, showed that genes like 
Erg, Lmo2 and Meis1, were differentially expressed in HSCs and progenitors, 
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while Runx1 and Fli1 had similar expression profiles across different cell 
types (Moignard et al. 2013). In addition, Moignard et al established a strong 
negative correlation between Gfi1 and Gata2 that was specific to HSCs 
(Moignard et al. 2013). In GMPs and CLPs, Gfi1b and Gata1 negatively 
correlated with Pu.1, Gfi1, Lyl1 and Lmo2, but not in primitive progenitors 
and MEPs (Moignard et al. 2013). This dynamic regulatory pathway 
illustrates the distinct correlation between TFs among HSCs and progenitor 
cells that are vital for cell fate transition. The BM microenvironment is 
suggested to play a role in favouring the enrichment of α-HSCs over β-HSCs 
(Benz et al. 2012). Another study revealed that the DNA damage responsive 
gene, Btaf aided maintenance of α-HSCs compared to β-HSCs, suggesting 
the role of epigenetic regulators in HSC heterogeneity (Wang et al. 2012). 
Together these studies suggest that the heterogeneity of HSC is determined 
by cell-intrinsic factors that are influenced by cell-extrinsic cues. However, 
more research is essential to understand the mechanisms regulating 
heterogeneity of the HSC population and its lineage commitment properties. 
1.1.5 Immunophenotypic characterisation of HSCs and 
primitive progenitors 
1.1.5.1 Murine HSCs and downstream progenitors 
HSCs are identified by cell surface makers and their self-renewing capability 
(Spangrude et al. 1988; Ikuta and Weissman 1992; Morrison and Weissman 
1994; Uchida et al. 1994; Morrison et al. 1997a; Kondo et al. 2003; Adolfsson 
et al. 2005; Yang et al. 2005). Fluorescence-activated cell sorting (FACS) is 
widely used to identify and isolate HSCs and progenitors based on their 
expression of surface markers, or cluster of differentiation molecules (CDs). 
Studies showed that heterogeneous populations of HSCs and primitive 
progenitors capable of self-renewal and long-term reconstitution were 
confined within the Thy-1.1low and Lineagelow/-Sca-1+c-Kit+ (LSK) 
compartment in the BM (Spangrude et al. 1988; Ikuta and Weissman 1992; 
Uchida et al. 1994). To further purify HSCs, several cell surface markers 
have been employed. Primarily, Thy-1.1low LSKs were purified as HSCs that 
lacked the expression of Mac-1 and CD4, while multipotent progenitors 
expressed low levels of Mac-1 and CD4 (Morrison and Weissman 1994; 
Chapter 1 
27 
Morrison et al. 1997a). Using Flt3 expression, LSKs categorised as LSK Flt3- 
with extensive self-renewal potential were identified (Christensen and 
Weissman 2001; Kondo et al. 2003; Adolfsson et al. 2005; Yang et al. 2005). 
Further, LSKs were demonstrated to acquire the expression of Flt3 (LSK 
Flt3+) and differentiate to generate LMPPs with limited self-renewal 
potential (Christensen and Weissman 2001; Adolfsson et al. 2005). Also, chst 
33342 (Ho), a fluorescent dye that stains live cells by DNA binding was used 
to differentiate the LSK side population (SP LSK) enriched for HSCs (Goodell 
et al. 1996). Murine HSCs were demonstrated to lack or express very low 
levels of CD34 (Osawa et al. 1996). Slam family markers, such as CD150, 
CD224 and CD48, were used to further classify LSKs into LT-HSCs 
(CD150+CD224-CD48-), multipotent primitive progenitor (CD150-CD224+CD48-) 
and committed progenitors (CD150+CD224+CD48+ and CD150-CD224+CD48+) 
(Kiel et al. 2005; Kim et al. 2006b). Additionally, cells with declining 
expression of CD150 exhibited gradual loss of self-renewal and 
reconstitution ability (Kiel et al. 2005; Papathanasiou et al. 2009; Morita et 
al. 2010; Oguro et al. 2013). Collectively, current literature describes the 
purification of HSCs and multipotent progenitors from LSKs by using 
combinations of either CD34 and Flt3 (Osawa et al. 1996; Kranc et al. 2009; 
Takubo et al. 2010) or CD150 and CD48 (Kiel et al. 2005; Yilmaz et al. 2006; 
Nakada et al. 2010; Buza-Vidas et al. 2011; Magee et al. 2012). Additional 
cell surface markers, such as CD244.2, CD229, CD127 and CD16/32, have 
been used and have shown that both HSCs and primitive progenitors possess 
heterogeneous populations with varying quiescence, self-renewal and 
differentiation potential (Kiel et al. 2007; Kent et al. 2009; Morita et al. 
2010) (Figure 1.2).  
1.1.5.2 Human HSCs and downstream progenitors 
Human HSCs, similar to murine HSCs (mHSCs), are classified based on their 
self-renewal and differentiation potential, using cell surface markers and 
functional assays (Civin et al. 1984; McCune et al. 1988; Baum et al. 1992; 
Krause et al. 1996). Early studies demonstrated that a heterogeneous 
population of HSCs expressing the CD34 cell surface marker displayed 
multipotency (Civin et al. 1984; Krause et al. 1996). More recent publication 
showed that self-renewing Lin-CD34-CD38-CD93hi cells were placed above the 
Chapter 1 
28 
haemopoietic hierarchy (Anjos-Afonso et al. 2013). Isolating the lineage 
negative population and additionally considering cell surface markers CD38, 
CD90, Baum and colleagues showed that HSCs were enriched within Lin-
CD34+CD38-CD90+ cells (Baum et al. 1992). In addition, HSCs expressing Lin-
CD34+CD38-CD90+ cell surface markers included long-term culture-initiating 
cells (LTC-IC) and cells with repopulation potential in non obese diabetic-
severe combined immunodeficient (NOD-SCID) mice (Baum et al. 1992; 
Huang and Terstappen 1994; Larochelle et al. 1996; Bhatia et al. 1997). 
Furthermore, the functional heterogeneity of CD34+CD38-CD90+ HSCs was 
studied using xenotransplant models, which showed that the repopulation 
potential varied between clonal stem cells, and they also displayed 
extensive variability in the lifespan and proliferative capacity (Guenechea 
et al. 2001; McKenzie et al. 2006). Using CD45RA (an isoform of CD45 with 
repressive regulatory effects on some classes of cytokines), Majeti et al 
identified a multipotent progenitor population downstream of HSCs with 
restricted self-renewal properties (Lin-CD34+CD38-CD90-CD45RA-) (Majeti et 
al. 2007). Moreover, Goardan et al identified a population of progenitor 
cells that functionally resembled LMPPs of mHSCs expressing Lin-CD34+CD38-
CD90-CD45RA+ (Goardon et al. 2011). More committed progenitors 
(CD34+CD38+) were differentiated based on CD10, CD123 and CD45RA into 
CMPs (Lin-CD34+CD38+CD123lowCD45RA-), MEPs (Lin-CD34+CD38+CD123-
CD45RA-), GMPs (Lin-CD34+CD38+CD123+CD45RA-) and CLPs (Lin-
CD34+CD38+CD10+) (Ogawa 1993; Galy et al. 1995; Manz et al. 2002) (Figure 
1.2).  
 Haemopoietic TFs 1.2
Haemopoietic TFs play a key role in HSC fate decisions from self-renewal to 
differentiation and apoptosis (Pimanda et al. 2007; Challen et al. 2010; 
Pimanda and Gottgens 2010; Wilson et al. 2010; Moignard et al. 2013). TFs 
are connected to the wider regulatory network and several studies have 
explored the interaction between TFs and co-factors by an analysis of global 
expression of TFs (Pimanda et al. 2007; Pimanda and Gottgens 2010; Wilson 
et al. 2010; Novershtern et al. 2011). A recent publication on single cell 
gene analysis profiles of haemopoietic stem and progenitor cells (HSPCs) 
revealed more insight into TF regulatory pathways and their characteristic 
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expression in different cell types, contributing to the heterogeneity of HSCs 
and primitive progenitors (Moignard et al. 2013). The section below 
describes TFs that are key to haemopoiesis. 
1.2.1 Homeobox TFs 
Hox genes belong to the homeodomain-containing family of TFs and are 
important during embryogenesis (Gellon and McGinnis 1998; Wilson et al. 
2010). The Hox gene cluster in mammals consists of 39 genes divided into 
four clusters (A-D) based on the chromosomal location (Amores et al. 1998). 
Specificity and selectivity of Hox TFs are modulated by binding to DNA co-
factors, such as pre-B-cell leukaemia (Pbx) and myeloid ectopic insertion 
site (Meis) families (Moens and Selleri 2006). Hox gene expression is 
restricted to HSCs and progenitor cells and is important in HSC homeostasis 
(Argiropoulos and Humphries 2007) and Hox clusters display a lineage-
restricted expression pattern (Giampaolo et al. 1994; Pineault et al. 2002). 
HOXA is expressed in the myeloid lineage, while HOXB is expressed in the 
erythroid and HOXC in lymphoid lineages (Giampaolo et al. 1994; Pineault et 
al. 2002).  Irrespective of haemopoietic specific expression of Hox genes, 
loss of Hoxb4 or the entire Hoxb cluster only mildly affected the self-
renewal ability of HSCs and their lineage commitment (Thorsteinsdottir et 
al. 2002). This could be explained by the functional redundancy of Hox 
genes that have overlapping roles in HSC functions. However, Hoxa9 is 
highly expressed in HSCs and genetic knockout studies showed defective 
myeloid and lymphoid lineages, along with severely impaired reconstitution 
ability, both in adult and foetal liver HSCs (Bijl et al. 2006; Magnusson et al. 
2007). Additional studies revealed that loss of other Hox genes, like Hoxa5, 
Hoxa7 and Hoxc3, led to defective committed progenitor compartments 
down the HSC hierarchy (Crooks et al. 1999; So et al. 2004). Gain-of-
function studies showed that overexpression of Hox genes (Hoxb3, Hoxb6, 
HOXA5, HOXA10) resulted in expansion of HSCs and progenitor cells and led 
to block in differentiation (Sauvageau et al. 1997; Buske et al. 2001; So et 
al. 2004). Overexpression of Hoxa9 led to an increase in proliferation of 
HSCs and myeloid progenitor cells with a partial block in pre-B cell 
development, eventually resulting in the development of leukaemia 
(Thorsteinsdottir et al. 2002).  
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Pbx and Meis families are important Hox cofactors and have three amino 
acid loop extension proteins that play an important role in embryonic 
development and haemopoiesis (Thorsteinsdottir et al. 2001; Moens and 
Selleri 2006). Pbx1 null mice are embryonic lethal and were shown to have 
severe anaemia due to haemopoietic defects, hence Pbx1 is required for 
dHSCs maintenance in the foetal liver (DiMartino et al. 2001). Conditional 
deletion of Pbx1 in adult mice resulted in the progressive loss of LT-HSCs, 
due to reduced quiescence and defective self-renewal properties, possibly 
via a defective TGF-beta signalling pathway (Ficara et al. 2008).  
Meis1 belongs to the TALE subfamily of homeobox proteins and interacts 
with Hox TFs, modulating their DNA binding ability. A loss-of-function 
approach reported that Meis1 deficient mice were embryonic lethal with 
defective early haemopoiesis causing haemorrhage and liver hypoplasia 
(Hisa et al. 2004). In Meis1 deficient embryos, HSCs were decreased in the 
foetal liver with defective repopulation potential (Azcoitia et al. 2005). The 
conditional deletion of Meis1 in adult mice resulted in loss of quiescence 
and repopulation potential of HSCs mediated through reactive oxygen 
species (ROS) (Kocabas et al. 2012). 
1.2.2 Ets TFs 
The Ets family of TFs are vital in regulating haemopoiesis and HSC functions 
and include TFs such as Fli-1, Tel/Etv6, Pu.1, Elf4, GABPα and Erg (Hock et 
al. 2004b; Lacorazza et al. 2006; Loughran et al. 2008; Kruse et al. 2009; Yu 
et al. 2011). Pu.1 (Sfpi-1) expression is restricted to HSCs and mature 
monocytes, granulocytes, B-cells, with low or no expression in CLPs, CMPs 
and T-cells (Nutt et al. 2005). The transcriptional activity of Pu.1 and Pu.1-
dependent cell fate choices are guided by cell-specific expression of Pu.1 
and interaction of Pu.1 with various TFs, including GATA-1, GATA-2, Runx1, 
c-Jun, C/EBPα and C/EBPβ, (Rekhtman et al. 1999; Zhang et al. 1999; Walsh 
et al. 2002; Hoogenkamp et al. 2007; Yeamans et al. 2007). Deletion of Pu.1 
is embryonic lethal with loss of mature lineages as well as reduced HSCs and 
progenitor cells (Scott et al. 1994; Kim et al. 2004). The conditional ablation 
of Pu.1 in mice showed a reduction in monocyte and lymphoid lineages and 
an increase in granulocytic cells, revealing a Pu.1 dose-dependent 
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regulation of cell fate choice in progenitor cells (Iwasaki et al. 2005). 
Additionally, an 80% decrease in the expression of Pu.1 protein, by deleting 
a 14kb URE element upstream of its promoter region, resulted in the 
development of AML (acute myeloid leukaemia) and defective cytokine 
response in HSCs and myeloid progenitors (Rosenbauer et al. 2004; 
Rosenbauer et al. 2006). These studies provide evidence that altered levels 
of TFs regulate HSC functions to cause detrimental effects on haemopoiesis, 
leading to leukaemia. 
1.2.3 Core binding TF – Runx1 
Runt-related transcription factor 1 (RUNX1), also known as acute myeloid 
leukaemia-1 (AML1), regulates the expression of various haemopoietic-
specific genes, by binding to their consensus sequences TGTGGT or TGCGGT 
(Meyers et al. 1993). Runx1 has been shown to be critical for embryonic 
haemopoiesis (Okuda et al. 1996; Chen et al. 2009; Boisset et al. 2010), but 
continuous expression of Runx1 is dispensable for the maintenance of adult 
haemopoiesis, as shown by conditional knockout (CKO) studies (Ichikawa et 
al. 2004; Chan et al. 2009). However, contradictory studies showed that 
Runx1-conditional deletion resulted in HSC expansion and an increase in 
their long-term reconstitution potential (Motoda et al. 2007; Ichikawa et al. 
2008). In agreement, another study showed that expression of a truncated 
isoform of Runx1 promoted HSC engraftment, while overexpression of full-
length Runx1 resulted in the HSC loss (Tsuzuki et al. 2007). On the other 
hand, a recent study demonstrated that haemopoietic specific deletion of 
Runx1 had minimal effects on LT-HSCs (Cai et al. 2011). However, Runx1 is 
one of the commonly mutated genes in AML (M0 FAB classification and 
myelodysplastic syndrome) and forms chimeric gene fusions that cause 
leukaemia (Osato et al. 1999; Imai et al. 2000; Yan et al. 2006; Ding et al. 
2009). Further research is essential to enhance our understanding of the 
role of Runx1 in normal haemopoiesis.      
1.2.4 Zinc finger TFs 
A wide range of TFs, including Gata2, Gata3, Evi-1, Klf4, Ikaros, Gfi1, 
Gfi1b, Sall4, Zfx and Prdm16, contain zinc finger domains. The zinc finger 
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TFs play a critical role in regulating HSC homeostasis (Tsai et al. 1994; Orlic 
et al. 1995; Hock et al. 2004a; Zeng et al. 2004; Rodrigues et al. 2005; 
Galan-Caridad et al. 2007; Goyama et al. 2008; Ng et al. 2009; Yang et al. 
2011; Ku et al. 2012). 
Growth Factor independent 1 (Gfi1) is a transcriptional repressor that has 
been shown to maintain quiescence, self-renewal and reconstitution 
potential of HSCs (Hock et al. 2004a; Zeng et al. 2004). Gfi1-/- HSCs 
displayed enhanced proliferation and defective reconstitution during serial 
transplantation (Hock et al. 2004a). Gfi1 and its paralogue Gfi1b exhibit 
complimentary expression patterns in haemopoietic lineages, but both TFs 
were expressed in HSCs (Yucel et al. 2004; Vassen et al. 2005). While Gfi1 
was shown to be important for development of lymphoid and myeloid 
lineages, Gfi1b was important for erythroid and megakaryocyte 
development (Moroy 2005; Hock and Orkin 2006; Anguita et al. 2010). 
Analysis of Gfi1b-/- mice demonstrated that HSCs lacking Gfi1b lost their 
quiescent state, but maintained the ability to self-renew and differentiate 
(Khandanpour et al. 2010). However, deletion of both Gfi1 and Gfi1b led to 
a complete loss of HSCs (Khandanpour et al. 2010). 
Gata2 is expressed in HSCs, myeloid progenitors and mast cells and 
regulates the functions of HSCs and progenitor cells (Tsai et al. 1994; Orlic 
et al. 1995; Rodrigues et al. 2005). Gata2-/- mice are embryonic lethal with 
defective haemopoiesis and severe anaemia (Tsai et al. 1994; Tsai and Orkin 
1997). Deletion of one allele of Gata2 in Gata2+/- mice led to reduced HSCs 
with an increase in their apoptosis and increased quiescence (Rodrigues et 
al. 2005). Gata2+/- mice also showed specific reduction of GMPs with 
defective functionality, but no effect on other committed progenitors, such 
as CMPs or CLPs (Rodrigues et al. 2008). Overexpression of Gata2 led to 
severe loss of HSCs and differentiation defects (Heyworth et al. 1999; 
Persons et al. 1999).     
Evi-1 (Ecotropic proviral integration site 1) is a TF expressed specifically in 
HSCs with long-term reconstitution potential and has been shown to be 
important in regulating haemopoiesis (Mucenski et al. 1988; Goyama et al. 
2008; Zhang et al. 2011). Evi1-/- mice were embryonic lethal with severe 
Chapter 1 
33 
defects in dHSCs (Yuasa et al. 2005). Conditional deletion of Evi-1 in adult 
mice resulted in reduced HSCs, with loss of their quiescence and 
reconstitution potential, coupled with an increase in the number of cycling 
HSCs (Zhang et al. 2011). Expression levels of Evi-1 are of prime importance 
in regulating HSC self-renewal (Goyama et al. 2008). Heterozygous deletion 
of Evi-1 led to the partial loss of HSCs, whereas overexpression of Evi-1 
resulted in enhanced HSC self-renewal with reduced differentiation 
potential (Goyama et al. 2008). Evi1 acts as an oncoprotein and elevated 
expression of Evi1 has been reported at high frequency in AML and in 
myelodysplasia (Buonamici et al. 2004; Jin et al. 2007). Evi1-/- transformed 
cells displayed loss of proliferation potential (Goyama et al. 2008). Thus, 
Evi1 is a common regulator of normal and leukaemic HSCs.  
1.2.5 Basic helix-loop-helix (bHLH) TFs 
Stem cell leukaemia gene (Scl/Tal1) is a member of the bHLH family of TFs 
that play a vital role in the development of the vascular and central nervous 
systems and regulate haemopoiesis (Begley et al. 1989; Robb et al. 1995; 
Shivdasani et al. 1995). Gene profiling of HSCs revealed that increased 
expression of Scl and Cdkn1a was a characteristic feature of quiescent HSCs 
(Venezia et al. 2004). Scl is expressed at high levels in LT-HSCs and has been 
shown to impede G0-G1 transition in HSCs (Lacombe et al. 2010). In foetal 
liver and adult haemopoiesis, Scl forms a regulatory complex with TFs Gata2 
and E2A, along with co-factors Lmo2 and Ldb1 that are essential for normal 
HSC functions (Yamada et al. 1998; Li et al. 2011). Scl also regulates the 
short-term reconstitution potential of HSCs, but has no effect on their long-
term reconstitution ability (Mikkola et al. 2003; Curtis et al. 2004). 
Conditional deletion of Scl impaired the differentiation potential, 
particularly of myeloid lineages (Mikkola et al. 2003). These studies suggest 
that Scl is critical in regulating HSC and progenitor functions. In human 
cells, low expression levels of Scl impaired the reconstitution property of 
HSCs when transplanted to SCID recipients (Brunet de la Grange et al. 2006). 
Lyl1, a paralogue of Scl, is expressed in HSCs, myeloid and B-cell lineages 
(Capron et al. 2006). Lyl1 deficient HSCs displayed defects in lymphoid 
lineage formation, but normal myeloid differentiation upon transplantation 
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(Capron et al. 2006). Conditional deletion of both Lyl1 and Scl resulted in 
the loss of repopulation potential of HSCs and an increase in apoptotic HSCs 
and progenitor cells (Souroullas et al. 2009). This study revealed a genetic 
interaction between Scl and Lyl1 and their partial overlapping roles in the 
maintenance of HSC functions (Souroullas et al. 2009). Additionally, bHLH E-
proteins, E47 and E12 have been shown to be important in regulating HSC 
functions (Semerad et al. 2009). 
Myc family members, c-Myc, N-Myc and L-Myc, are oncogenes (DePinho et 
al. 1987). Myc proteins play an important role in various biological 
processes, including proliferation, cellular growth, angiogenesis, 
differentiation and apoptosis, as well as in the reprogramming of adult 
fibroblasts to iPS cells (Eisenman 2001; Murphy et al. 2005; Lewitzky and 
Yamanaka 2007). Deletion of c-Myc or N-myc resulted in embryonic 
lethality, while overexpression of Myc promoted tumourigenesis (Charron et 
al. 1992; Pelengaris et al. 2002; Dubois et al. 2008). Conditional deletion of 
c-Myc in the adult BM led to impaired self-renewal properties of HSCs and 
resulted in their accumulation with defective differentiation (Wilson et al. 
2004). The forced localisation of HSCs in the BM niche caused by the 
increased expression of adhesion receptors resulted in the accumulation of 
these mutant HSCs (Wilson et al. 2004). Deletion of both c-Myc and N-myc 
resulted in rapid lethality due to haemopoietic failure, including loss of 
HSCs (Laurenti et al. 2008). Hence, bHLH TFs are essential for normal 
functioning of HSCs.  
 Hypoxia 1.3
The placenta, respiratory and circulatory systems collectively contribute to 
the complex oxygen-regulating system in multicellular organisms (Bunn and 
Poyton 1996; Webb et al. 2009). During hypoxia, defined as the reduced 
availability of oxygen to cells, tissue or organism, the cells undergo adaptive 
mechanisms, such as altered expression of TFs or posttranslational 
modifications of proteins in order to survive the hypoxic conditions (Kaelin 
and Ratcliffe 2008; Simon and Keith 2008). The existence of low oxygen 
tension was revealed by the direct measurement of partial pressure of 
oxygen in the tissues during embryonic development (Mitchell and Yochim 
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1968). Physiological hypoxia in organs like thymus, kidney medulla and BM is 
defined as 1% (7.2mm Hg) or less partial pressure of oxygen (pO2) compared 
to normoxic conditions with pO2 ranging between 2-9% (14.4-64.8 mm Hg 
(Brahimi-Horn and Pouyssegur 2007; Simon and Keith 2008). The role of 
hypoxia in embryogenesis was first demonstrated by Morriss et al in 1979 
(Morriss and New 1979). Hypoxia occurs during embryonic development as 
well as in adults (Schofield 1978; Cipolleschi et al. 1993; Braun et al. 2001; 
Mohyeldin et al. 2010). Hypoxic conditions are characteristic of specialised 
microenvironments, such as the niche, which harbours stem cells (Schofield 
1978; Cipolleschi et al. 1993; Braun et al. 2001; Mohyeldin et al. 2010). The 
increase in characteristic features of stem cells, such as self-renewal and 
quiescence, under hypoxic culture conditions provides evidence that the O2 
gradient in the stem cell niche regulates stem cell dynamics (Krohn et al. 
2008; Mohyeldin et al. 2010; Takubo et al. 2010; Winkler et al. 2010). 
However, recent studies have challenged the BM O2 gradient in regulating 
HSC functions and showed that the hypoxic nature of HSCs was a cell-
intrinsic phenomenon (Nombela-Arrieta et al. 2013). Hypoxia is also 
reported in pathological conditions, such as tissue inflammation and 
ischaemia and is associated with tumour formation (Simon and Keith 2008). 
1.3.1 Hypoxic stem cell niche 
The stem cell niche is composed of distinct cell types, blood vessels, 
glycoproteins and an intricate three-dimensional architecture that provides 
a complex microenvironment in which stem cells can function (Schofield 
1978; Calvi et al. 2003; Zhang et al. 2003; Kiel et al. 2005; Scadden 2006; 
Morrison and Spradling 2008; Wang and Wagers 2011). The cellular and 
acellular components of the niche contribute to the maintenance of stem 
cell abilities of self-renewal and multilineage differentiation (Scadden 2006; 
Jones and Wagers 2008). Several years of intense research have been 
undertaken to characterise the HSC niche and its role in regulating HSC fate 
decisions (Schofield 1978; Calvi et al. 2003; Zhang et al. 2003; Kiel et al. 
2005; Scadden 2006; Morrison and Spradling 2008; Wang and Wagers 2011). 
HSCs reside in the specialised niches, that are broadly classified as 
endosteal, vascular and perivascular niches, based on different cell types 
including osteoblasts (OBs), osteoclasts (OCs), monocytes and macrophages, 
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endothelial cells, mesenchymal stem cells (MSCs) and pericytes (Gong 1978; 
Schofield 1978; Calvi et al. 2003; Zhang et al. 2003; Kiel et al. 2005; Nilsson 
et al. 2005; Scadden 2006; Morrison and Spradling 2008; Ellis et al. 2011; 
Wang and Wagers 2011) (Figure 1.3). 
1.3.1.1 Endosteal niche 
Several studies have supported the idea of localisation of primitive 
haemopoietic cells in close proximity to OBs (Gong 1978; Zhang et al. 2003; 
Nilsson et al. 2005; Ellis et al. 2011). Transgenic murine studies with 
targeted activation of OBs led to the expansion and increased mobilisation 
of HSPCs (Calvi et al. 2003; Zhang et al. 2003). Early studies reported that 
ablation of OBs resulted in haemopoietic defects, including reduced BM 
cellularity and HSPCs with induction of extramedullary haemopoiesis in the 
spleen, while expansion of OBs resulted in elevated HSPC numbers (Zhang et 
al. 2003; Visnjic et al. 2004). These studies support the osteoblastic 
localisation of HSPCs. Other studies demonstrated that the HSC homeostasis 
was supported by immature OBs and not the mature OBs, hence providing 
evidence of MSC activity as a regulator of HSC functions (Calvi et al. 2012). 
However, several publications showed that impairment of OBs alone was not 
sufficient to disrupt HSC functions (Lymperi et al. 2008; Ma et al. 2009; 
Schepers et al. 2012), suggesting that the effect of OBs on HSCs was 
influenced by additional factors, including the specific stage of OB 
differentiation and their mode of activation (Nakamura et al. 2010). Live 
imaging studies of the calvarium following induced activation of OBs showed 
closer association of HSC-enriched cells with the endosteum compared to 
the controls (Lo Celso et al. 2009). Together, these studies provide evidence 
of endosteal localisation of HSCs. 
OCs that belong to the osteolineage cell type have a complex role in the 
maintenance of HSCs (Mansour et al. 2012). Kollet and colleagues reported 
that an increase in OC activity by G-CSF administration resulted in HSPC 
mobilisation (Kollet et al. 2006). However, in contradiction, a recent study 
showed that increased osteocalcination by serial treatment with G-CSF 
reduced the HSPC mobilisation (Miyamoto et al. 2011). Hence, more 
research investigating OCs’ role within the HSC niche is essential.   
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Macrophages and monocytes in the endosteal niche are associated with 
HSPC mobilisation in response to the G-CSF administration, thus contributing 
to the localisation of HSCs within their niche (Winkler et al. 2010). Recent 
investigation discovered that BM macrophages expressing α-smooth muscle 
actin are involved in the maintenance of HSCs in the endosteal niche (Ludin 
et al. 2012).  
1.3.1.2 Vascular niche 
Endothelial cells have been shown to play an important role in 
developmental haemopoiesis and in regulating HSC functions (Medvinsky and 
Dzierzak 1996). Kiel et al showed that HSCs were in close proximity to BM 
sinusoids (Kiel et al. 2005). Additional studies reported that depletion of 
endothelial cells impaired the transplantability of HSCs (Hooper et al. 2009; 
Butler et al. 2010). Transgenic mice studies showed that the interactions of 
endothelial cells and HSCs were mediated by notch signalling (Duncan et al. 
2005). Co-culture of HSCs with immortalised endothelial cells enhanced 
their expansion (Soki et al. 2013). Altogether, these studies supported the 
hypothesis of endothelial cells forming the unique HSC niche. 
Perivascular stromal cells are defined by the heterogeneous population of 
cells, including Nestin+ mesenchymal cells, Scf (Stem cell factor)-expressing 
perivascular cells and Cxcl12-abundant reticular cells (CAR) (Barker 1997; 
Sugiyama et al. 2006; Mendez-Ferrer et al. 2010; Ding et al. 2012). Gene 
expression studies showed that the Scf-expressing perivascular cells had 
high levels of Cxcl12, alkaline phosphatase, Vcam1, Pdgfra, and Pdgfrb 
expression, thus attributing to their origin from mesenchymal and stromal 
cells (Ding et al. 2012). Gene deletion studies in murine models showed that 
the ablation of Scf expression from Tie2+ endothelial and Lepr+ perivascular 
cells specifically impaired HSC functions (Ding et al. 2012). CxCl12 is 
expressed in all stromal cells in the BM niche (Greenbaum et al. 2013). 
However deletion of Cxcl12, specifically from early mesenchymal progenitor 
cells (negative for nestin expression), led to detrimental loss of HSCs with 
reduced quiescence and defective long-term reconstitution ability 
(Greenbaum et al. 2013).  Deletion of CxCl12 from OBs, CAR cells or 
endothelial cells had no or modest effect on HSC functions (Greenbaum et 
Chapter 1 
38 
al. 2013). Thus, it is evident that the perivascular niche is heterogeneous 
and has a varied effect on HSC maintenance based on the cell type.      
MSCs are implicated as a component of the HSC niche (Masuda et al. 2009; 
Mendez-Ferrer et al. 2010). Published evidence suggests that nestin+ MSCs 
regulate HSC maintenance genes, like Cxcl12, c-Kit ligand, angiopoietin-1 
(Ang-1), interleukin-7 (IL-7), and vascular cell adhesion molecule-1 
(Mendez-Ferrer et al. 2010). The depletion of nestin+ MSCs resulted in 
reduced HSCs and displayed extramedullary haemopoiesis in mice (Mendez-
Ferrer et al. 2010). Additionally, purified HSCs when transplanted were 
shown to home in close proximity to nestin+ MSCs in lethally irradiated mice 
(Mendez-Ferrer et al. 2010). Human HSPCs co-cultured with MSCs showed 
enhanced self-renewal and better engraftment potential in non-human 
primates (Masuda et al. 2009).  
1.3.1.3 Periendosteum-perivascular HSC niche 
Advanced live-imaging studies of mouse calvarium have revealed the co-
existence of both endosteal and vascular cells forming the periendosteal-
perivascular HSC niche (Lo Celso et al. 2009). Another recent publication by 
Nombela-Arrieta et al showed the vascular architecture of the HSC niche to 
be highly vascularised at proximal bone regions by laser scanning microscopy 
and confocal imaging techniques (Nombela-Arrieta et al. 2013). This study 
also reported enriched HSPCs in the endosteal zone with close association to 
the BM perivasculature region (Nombela-Arrieta et al. 2013). Altogether, 
these studies provide evidence that the endosteal and vascular cells co-exist 
forming the specialised HSC niche. 
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Figure 1. 3: The HSC niche.  
HSPCs are localised in the specialised BM microenvironment referred to as the HSC niche. The 
HSC niche consists of various cell types including osteoblasts, osteoclasts, mesenchymal stem 
cells (MSCs) and endothelial cells along with blood vessels. 
1.3.2 Hypoxia and HSCs 
HSCs are localised in the niche within the BM, which exhibits low pO2 
compared to other tissues (Harrison et al. 2002; Takubo and Suda 2012). The 
HSC niche is characterised by the endosteal zone, vascular and perivascular 
zones, with several cell types, including OBs, OCs, endothelial, MSCs and 
reticular cells (Gong 1978; Zhang et al. 2003; Kiel et al. 2005; Lo Celso et 
al. 2009; Mendez-Ferrer et al. 2010; Omatsu et al. 2010; Ellis et al. 2011; 
Suda et al. 2011; Nombela-Arrieta et al. 2013) (Figure 1.3). The three 
dimensional vascular organisation of the BM examined with the scanning 
electron microscope revealed an enlarged canonical arrangement of arterial 
capillaries in the sinusoids enabling easy movement of HSCs (Draenert and 
Draenert 1980). The arterial capillaries were shown to arise from the 
arterioles that were formed by the branching of the smaller arteries from 
the metaphysis region in the BM niche (Draenert and Draenert 1980). This 
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unique vascularisation of the endosteal niche in the BM attributed to the 
limited perfusion and low pO2 in the endosteal region of the BM (Draenert 
and Draenert 1980). Additionally, due to abundant haemopoietic cells in the 
BM the blood flow is coupled with high O2 consumption (Chow et al. 2001). 
Live animal imaging of the BM in the calvarium of mice showed that the 
transplanted HSC-enriched cells migrate deep into the BM that is believed to 
be hypoxic (Lo Celso et al. 2009). Furthermore, the localisation of 
transplanted HSPCs closer to the endosteum improved their engraftment 
potential (Lo Celso et al. 2009). These data suggested the importance of 
niche components in regulating HSC functions (Lo Celso et al. 2009). Further 
studies in humans showed that the average pO2 in BM aspirates of healthy 
individuals measured 55mmHg ± 0.95 and mean O2 saturation of 87.5% ± 
1.1% (Harrison et al. 2002). Simulation studies of O2 diffusion in the BM 
suggested a 90% drop in the pO2 in close proximity of 100µm from the BM 
vasculature (Chow et al. 2001). A more recent publication demonstrated 
that the peri-sinusodial niche is the most hypoxic with lower pO2 value 
compared to the endosteal niche in the calvarium of the mice (Spencer et 
al. 2014). These studies provide evidence supporting the hypoxic nature of 
the HSC niche. 
The hypoxic nature of BM haemopoietic cells was analysed by injecting mice 
with a perfusion dye, pimonidazole (Pimo) and nucleic acid dye Ho (Parmar 
et al. 2007; Simsek et al. 2010; Takubo et al. 2010). Pimo is a 2-
nitroimidazole-hypoxia probe, that when reduced in a hypoxic environment, 
forms hydroxylamine that covalently binds to thiol-containing proteins in 
hypoxic cells. The protein adducts can be detected by immunostaining 
(Varia et al. 1998). These experiments showed that the lowest end of the Ho 
perfusion dye gradient was enriched with HSCs and these low perfused cells 
highly retained the Pimo suggesting the hypoxic nature of the HSCs (Parmar 
et al. 2007; Simsek et al. 2010; Takubo et al. 2010). HSCs that were 
localised in the low-oxygenated niche remained quiescent and expressed 
high levels of Notch1, N-cadherin, telomerase and cell cycle inhibitor p21, 
compared to cells that were close to the well-oxygenated vasculature (Jang 
and Sharkis 2007). In agreement with the above study, human CD34+CD38- 
cord blood cells cultured in 1% O2 re-acquired the hypoxic property before 
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induction of quiescence and exhibited improved reconstitution potential 
with enhanced expression of p21 when transplanted into immunodeficient 
mice (Danet et al. 2003; Shima et al. 2009; Shima et al. 2010). Also, under 
extreme hypoxic conditions (0.1%), CD34+ cells acquired a quiescent state 
(Hermitte et al. 2006). ROS generated through O2 mediated mitochondrial 
electron transport chain or NADPH oxidase during cytosolic or phagosomal 
activity regulates stem cell functions (Jang and Sharkis 2007). The hypoxic 
niche favours the immature state of HSCs by limiting the production of ROS 
to low levels (Jang and Sharkis 2007; Simsek et al. 2010). A more detailed 
description of the hypoxic nature of HSCs and their niche is included in 
Chapter 4. 
 Hypoxia inducible factors (Hifs) 1.4
Hypoxia inducible factor (Hifs) are evolutionarily conserved TFs that are the 
key regulators of oxygen homeostasis in all mammalian cells (Kaelin and 
Ratcliffe 2008; Majmundar et al. 2010). The elevated levels of 
erythropoietin (EPO) production in renal fibroblasts at high altitude or 
during anaemia led to the discovery of a protein complex that bound at the 
3’ end of the EPO gene, specifically during hypoxia, and was named HIF-1 
(Semenza and Wang 1992). Hifs consist of two subunits, an α− subunit that is 
highly unstable and dependent on oxygen concentration and a stable, 
oxygen-independent β-subunit (Wang et al. 1995). In mammals, there are 
three isoforms of Hifs, namely Hif-1α, Hif-2α and Hif-3α that form dimers 
with the Hif-1β paralogue, Arnt1, Arnt2 and Arnt3 (Ema et al. 1997; Flamme 
et al. 1997; Hogenesch et al. 1997; Tian et al. 1997; Gu et al. 1998; 
Semenza 2000; Wenger 2002). Unlike the less-studied Hif-3α,  Hif-1α and 
Hif-2α have been found to be critical for the response to changing oxygen 
concentrations (Kaelin and Ratcliffe 2008). Although, the role of Hif-
3α is not well understood, it has been reported that alternative splice forms 
of Hif-3α bind to Hif-1α and block its transcriptional activity (Makino et al. 
2001; Wenger 2002). Hif-mediated pathways have been extensively studied 
and have been shown to regulate metabolic adaptation and influence 
various cellular mechanisms, including cell growth, survival, differentiation 
Chapter 1 
42 
and apoptosis, erythropoiesis and angiogenesis (Weidemann and Johnson 
2008; Majmundar et al. 2010).      
1.4.1 Structure of Hif heterodimers 
HIFs are heterodimers with a DNA binding protein complex composed of a 
basic helix-loop-helix (bHLH) domain and a PAS (PER-ARNT-SIM) protein 
domain that are associated with DNA binding and dimerisation (Wang et al. 
1995). The heterodimer consists of a 150 kDa hypoxia-inducible, unstable α-
subunit and a stable nuclear β-subunit of size 91-94 kDa (Aryl hydrocarbon 
nuclear translocator, ARNT). Both α and β subunits bind to DNA of the target 
genes at the specific core sequence (G/ACGTG), termed the hypoxia 
responsive element (HRE) (Wang et al. 1995). Hif-α isoforms contain two 
independently functioning central oxygen-dependent degradation domains 
(ODDD) namely, the amino-terminal ODD domain (NODDD) and carboxy-
terminal ODD (CODDD) domain. Hif-1α and Hif-2α also possess an N-terminal 
transactivation domain (NAD) and C-terminal transactivation domain (CAD), 
while the Hif-3α isoform lacks the CAD (Jiang et al. 1997; Pugh et al. 1997; 
Gu et al. 1998; Huang et al. 1998; O'Rourke et al. 1999; Hara et al. 2001). 
Hif-3α is less closely related with N-terminal bHLH and PAS domains, but 
lacks TAD (transactivation domain) (Makino et al. 2001). Both Hif-1α and 
Hif-2α  share a degree of sequence homology and a similar structural domain 
with subtle variances in the transactivation domain that contribute to their 
unique characteristics (Wiesener et al. 2003; Dayan et al. 2006; Hu et al. 
2007). Hif-1α and Hif-2α differ in the NAD region that determines the 
expression of specific target genes of the two isoforms (Hu et al. 2007). 
However, CAD is homologous in both Hif-1α and Hif-2α and is involved in the 
binding of transcriptional co-factors, such as p300/CBP, activating 
transcription of common target genes (Hu et al. 2007).  
Chapter 1 
43 
Figure 1. 4: Structure of the Hif protein-α and β subunits of Hifs. 
Hifs are heterodimers with oxygen sensitive, highly unstable Hif-α subunits and a stable Hif-ß 
subunit. Both the isoforms have a DNA binding domain however, Hif-3α and Hif-ß subunits lack 
a transactivation domain. bHLH-basic helix-loop-helix; PAS-Per-Arnt-Sim; ODDD- oxygen 
dependent degradation domain; NAD- N-terminal transactivation domain; CAD-C-terminal 
transactivation domain; aa-amino acid. 
1.4.2 Mechanism of regulation of Hif signalling 
The Hif-α subunit is transcribed constitutively and the translated protein is 
highly unstable in normoxia with a half-life of 5-8 minutes (Huang et al. 
1996; Berra et al. 2001). Despite the differences, both Hif-1α and Hif-2α 
isoforms share similar regulatory mechanisms that are reflected in their 
similar domain structures (Schofield and Ratcliffe 2004) (Figure 1.4). Hif-α 
protein levels are strictly regulated by both oxygen-dependent and oxygen-
independent mechanisms.  
1.4.2.1 Oxygen-dependent mechanisms of Hif-α regulation 
Under well-oxygenated conditions, Hif-α subunits undergo proteasomal 
degradation by the ubiquitin-dependent pathway (Schofield and Ratcliffe 
2004). In normoxia, Hif-α is hydroxylated by prolyl hydroxylase domain 
family (PHDs) members at conserved proline residues (in Hif-1α, Pro402 and 
Pro564 and in Hif-2α, Pro405 and Pro531) within the ODDD, positioned in the 
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NAD region (Epstein et al. 2001; Ivan et al. 2001; Jaakkola et al. 2001; 
Masson et al. 2001; Schofield and Ratcliffe 2004). Hydroxylation of specific 
prolyl residues by PHDs prompts the binding of von-Hippel-Lindau (pVHL) (a 
tumour suppressor protein) and other components of the ubiquitin ligase 
complex, including elongin B, elongin C, pVHL, RBX-1 and Cul2. The binding 
of the ubiquitin ligase complexes to Hif-α subunits results in 
polyubiquitination and proteasomal degradation of Hif-α (Maxwell et al. 
1999; Ohh et al. 2000; Ivan et al. 2001; Jaakkola et al. 2001; Masson et al. 
2001) (Figure 1.5). Multiple isoforms of PHDs (PHD1, PHD2 and PHD3) have 
been identified and the activities of these dioxygenases are dependent on 
the availability of oxygen and 2-oxoglutarate, as well as co-factors like iron 
(Fe-II) and ascorbate (Bruick and McKnight 2001; Epstein et al. 2001).  
Hif-α stability is also mediated by nitric oxide (NO) and Krebs cycle 
metabolic intermediates, such as fumarate, succinate and ROS that inhibit 
PHDs (Brunelle et al. 2005; Kaelin 2005; Koivunen et al. 2007; Kaelin and 
Ratcliffe 2008). Under hypoxic conditions, E3 ubiquitin ligases, Siah1/2 
mediate the proteasomal degradation of PHDs, thereby stabilising Hif-α 
expression (Nakayama et al. 2004) (Figure 1.5).  
Factor inhibiting HIF (FIH1), another member of the Fe(II) and 2-OG-
dependent dioxygenase family regulates Hif-α stability by hydroxylation of 
conserved single asparaginyl residue in the CAD domain of Hif-α (Mahon et 
al. 2001; Hewitson et al. 2002; Lando et al. 2002) (Figure 1.5). The 
hydroxylation at the CAD domain of Hif-α prevents the binding of the 
essential co-activator p300/Creb-binding protein (CBP/p300) and inhibits 
the transcription of CAD dependent genes that regulate adaptive cellular 
responses to hypoxia (Mahon et al. 2001; Hewitson et al. 2002; Lando et al. 
2002). FIH1, unlike PHDs, is active in low-oxygen concentration and hence 
regulates Hif-α protein degradation that survived hydroxylation by PHDs 
(Koivunen et al. 2004; Dayan et al. 2006). Also, Hif-1α isoform is relatively 
less resistant to FIH1-mediated hydroxylation compared to Hif-2α (Yan et al. 
2007). Hence factors including depth of hypoxia and the requirement of 
different isoforms of Hif-α determine the activation of HIF-responsive 
genes. 
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Under hypoxic conditions, or during loss of PHDs or pVHL, Hif-α stabilises 
and relocates to the nucleus where the Hif-β isoform dimerises with Hif-α by 
binding to the HRE element in its promoter region (Wenger et al. 2005). The 
Hif-α and Hif-β dimerisation is coupled with the binding of transcriptional 
co-factor, p300/CBP to the CAD domain of the Hif-heterodimer that 
activates the transcription of a specific subset of genes involved in 
angiogenesis, erythropoiesis, energy metabolism and autophagy (Firth et al. 
1994; Ebert et al. 1995; Firth et al. 1995; Gleadle et al. 1995; Liu et al. 
1995; Arany et al. 1996) (Figure 1.5). 
Figure 1. 5: Oxygen-dependent regulation of Hif-α  protein and downstream target 
genes.  
Under normoxic conditions, Hif-α subunit undergoes proteolitic degradation mediated by Hif 
prolyl hydroxylases (PHDs) and factor inhibiting Hifs (FIH). Whereas during hypoxia, stabilised 
Hif-α is translocated to the nucleus. Inside the nucleus, the two isoforms of Hif-α and Hif-1β form 
heterodimers along with p300/CBP and activate the transcription of various target genes involved 
in vital developmental pathways. HIF=Hypoxia inducible factor; VHL=von-Hippel-Lindau 
protein; OH=Hydroxylase; NO=Nitric oxide; O2=Oxygen; Fe2+=Iron; Ub=Ubiquitin; 
HRE=Hypoxia response element. 
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1.4.2.2 Other mechanisms of Hif-α regulation 
Several pVHL-independent pathways regulate Hif-α stability (Isaacs et al. 
2002; Kong et al. 2006; Luo et al. 2010). Inhibitors of Hsp90 (an 
extracellular heat shock protein) and histone acetylase inhibitors promote 
pVHL-independent Hif-α protein degradation (Isaacs et al. 2002; Kong et al. 
2006). Evidence also exists that Hsp70/CHIP regulates degradation of Hif-1α, 
but not Hif-2α in hypoxia (Luo et al. 2010).  
Hif-1α-specific E3 ligase co-factor, termed hypoxia-associated factor (HAF), 
exhibits a unique domain-specific binding to Hif-α isoforms, hence 
differentially regulates the two Hif-α isoforms. The binding of HAF (654-800 
aa) and Hif-1α (298-400 aa) leads to Hif-1α protein degradation, but binding 
of Hif-2α (604-750 aa) and HAF (300-500 aa) results in increased 
transactivation of Hif-2α (Koh et al. 2011). Additional studies using cell lines 
derived from normal and tumour tissues reveal that the binding of HAF and 
Hif-1α results in the ubiquitination and proteasomal degradation of Hif-1α 
(Koh et al. 2008).  
Additionally, Hif-α can be sumoylated, which has been shown to be 
associated with both increased and decreased Hif-α stability (Carbia-
Nagashima et al. 2007; Cheng et al. 2007). Hif-α may undergo sumoylation 
by binding to hypoxia induced small ubiquitin like modifier (SUMO) feeding 
to the oxygen-dependent pVHL-mediated degradation pathway in a 
hydroxylation-independent manner (Cheng et al. 2007). It has been shown 
that SUMO1 is induced by hypoxia and that hypoxic responses are modified 
by sumoylation of Hif-α (Comerford et al. 2003). Additional studies using 
mouse models lacking SUMO-specific protease 1 (SENP1) display a lack of 
stabilised Hif-α causing anaemia (Cheng et al. 2007).  
Sirtuins (Sirts) are histone deacetylases that belong to the nicotinamide 
adenine dinucleotide (NAD+)-dependent stress responsive family (Haigis and 
Sinclair 2010). Dioum et al showed that Sirt1 modulated the expression of 
Hif-2α by deacetylation of a lysine residue in Hif-2α protein (Dioum et al. 
2009). Sirt1 has been shown to be involved in the regulation of Epo 
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expression in the hepatic and renal systems mediated via Hif-2α (Dioum et 
al. 2009). Sirt1 has been reported to interact with the Epo promoter and 
Hif-2α resulting in the increased transcription of Hif-2α (Dioum et al. 2009). 
On the other hand, Sirt6 has been shown to negatively regulate Hif-1α 
stability and protein synthesis (Zhong et al. 2010). Although a weak 
interaction of Hif-1α and Sirt6 has been established, their interaction 
mechanisms are yet to be defined (Zhong et al. 2010). 
1.4.3 Tissue expression and transcriptional targets of Hifs 
Irrespective of the similarities in the structure and regulatory mechanisms 
of the Hif-α isoforms, their tissue specific expression patterns are distinct 
(Ema et al. 1997; Tian et al. 1997; Wiesener et al. 2003; Gordan et al. 2007; 
Mole and Ratcliffe 2008). Hif-1α is ubiquitously expressed, while the 
expression of Hif-2α  is more restricted to kidney, heart, lung and small 
intestine (Ema et al. 1997; Tian et al. 1997; Wiesener et al. 2003; Gordan et 
al. 2007). A recent study showing the microarray analysis of gene expression 
in human embryonic stem cells (ESCs), HSCs, and MSCs discovered HIF-1α as 
the only TF common in these stem cells (Kim et al. 2006a). Expression of 
Hif-1α and Hif-2α in some organs like kidney are cell-type specific 
(Rosenberger et al. 2002). Hif-2α is expressed in kidney endothelial cells 
and Epo-producing interstitial fibroblasts, while Hif-1α is expressed only in 
tubular epithelial cells (Rosenberger et al. 2002). In the lung, under hypoxic 
conditions Hif-1α is undetectable, while Hif-2α is stabilised in type II 
pneumocytes and pulmonary endothelial cells (Compernolle et al. 2002; 
Wiesener et al. 2003). Hif-1α is expressed at very high levels in adult HSCs 
compared to more differentiated populations (Simsek et al. 2010; Takubo et 
al. 2010). Hif-2α is expressed in HSCs and progenitor cells with high levels of 
expression in the lineage depleted population (Takubo et al. 2010). 
Hif-α subunits regulate the expression of hundreds of downstream genes 
involved in angiogenesis, proteolysis, metabolism, proliferation and survival, 
autophagy and pH regulation (Lee et al. 2004; Ke and Costa 2006; Mazure 
and Pouyssegur 2010). Hif-1α specifically stimulates transcription of 
glycolytic enzymes, such as phosphoglycerate kinase and lactate 
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dehydrogenase-A, carbonic anhydrase-9 and Bnip-3 (pro-apoptotic gene), 
glucose transporters and glycolytic inducing factors like Cripto (Hu et al. 
2003; Hu et al. 2006; Miharada et al. 2011). Several Hif-1α target genes are 
known to be critical in HSC function and metabolism, such as Vegf, ADM, 
SDF1, Scf, Ang2, p53, Foxos and Cited2 (Bhattacharya and Ratcliffe 2003; 
Freedman et al. 2003; Chen et al. 2007; Kranc et al. 2009; Takubo et al. 
2010; Chou et al. 2012; Du et al. 2012; Zhang et al. 2012; Zhang and Sadek 
2013). Also, TFs like SDF1, p21, Foxos and Cripto, co-ordinate HSC 
quiescence in the BM niche (Cheng et al. 2000; Miyamoto et al. 2007; Nie et 
al. 2008; Thoren et al. 2008; Miharada et al. 2011; Zheng et al. 2011). Under 
hypoxia, Hif-2α stimulates the expression of embryonic TF Oct-4, Cyclin D1, 
TWIST1, transforming growth factor-α (TGF-α) and Epo (Raval et al. 2005; 
Covello et al. 2006; Patel and Simon 2008). Both Hif-1α and Hif-2α have 
unique target genes, but also jointly regulate Vegf, adrenomedullin (Adm) 
and Glucose transporter (Glut-1) (Wiesener et al. 1998; Hu et al. 2003).        
1.4.4 Differential functions of Hif- α  isoforms 
1.4.4.1 Hif regulatory system in embryonic development and early 
haemopoiesis 
Hypoxia and Hif signalling play crucial roles in embryonic development and 
haemopoiesis during ontogeny (Maltepe et al. 1997; Iyer et al. 1998; Ryan et 
al. 1998; Tian et al. 1998; Adelman et al. 1999; Peng et al. 2000; 
Compernolle et al. 2002; Yoon et al. 2006). A null mutation of Hif-1ß 
isoform in mice was found to be embryonic lethal at E10.5 with defective 
angiogenesis and haemopoiesis (Maltepe et al. 1997; Adelman et al. 1999). 
Furthermore, in vitro colony-forming assay from Hif-1ß-/- embryoid bodies 
showed a significant reduction in haemopoietic progenitor cells that failed 
to respond to hypoxia (Adelman et al. 1999). Hif-1ß-/- ESCs displayed a lack 
of hypoxic responses and Hif-1ß deficient embryos had decreased 
haemopoietic progenitors in the yolk sac (Maltepe et al. 1997; Adelman et 
al. 1999). Adelman et al reported that defective haemopoietic progenitors 
in the yolk sac were due to a decease in cell-extrinsic Hif-1ß-dependent 
Vegf expression (Adelman et al. 1999; Schuh et al. 1999). Similar defects 
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were observed in the Flk-1 (Vegf receptor) null mice with reduced number 
of ESCs and an expansion of haemopoietic progenitors (Schuh et al. 1999).  
It was also demonstrated that Hif-1α knockout mice displayed multiple 
defects, including neural tube malformation, cardiovascular defects and 
haemopoietic defects, with enhanced tissue hypoxia resulting in embryonic 
lethality at E10.5 (Iyer et al. 1998; Ryan et al. 1998; Yoon et al. 2006). The 
analysis of yolk sac at E9.5 revealed a decrease in myeloid and erythroid 
progenitors, as well as impaired terminal erythroid differentiation (Yoon et 
al. 2006). Furthermore, Hif-1α-/- embryos had reduced haemoglobin content 
in erythroid colonies (Yoon et al. 2006). In addition, gene expression 
analyses revealed dysregulated expression of Epo, EpoR, Vegf and iron 
regulatory proteins in the Hif-1α-/- yolk sac and embryos (Yoon et al. 2006). 
Another study showed that Vhl-deficient embryos, an upstream regulator of 
Hif-α, died at the age of E10.5 to E12 due to severe placental dysgenesis 
(Gnarra et al. 1997). Other studies showed that a heterozygous deletion of 
Hif-1α in mice resulted in impaired physiological responses to chronic 
hypoxia and displayed defective carotid body function (Yu et al. 1999; Kline 
et al. 2002).   
To understand the role of Hif-2α during early development, knockout mouse 
models were created. Deletion of Hif-2α generated a range of phenotypes, 
from embryonic lethality to perinatal death, depending on the mouse 
genetic background (Peng et al. 2000). Global deletion of Hif-2α led to 
embryonic lethality between E9.5 and E12.5 due to defective vasculature in 
the yolk sac and embryos (Peng et al. 2000). Hif-2α knockout mice died at 
mid-gestation due to bradycardia and decreased noradrenaline levels (Tian 
et al. 1998). An exogenous substitution of a metabolic intermediate that is 
converted to noradrenaline were born though dint survive to the adulthood 
(Tian et al. 1998). The above study, along with a study by Norris et al, who 
showed Hif-2α expression in the neural crest derivatives, collectively 
suggested that Hif-2α was involved in the regulation of embryonic 
catecholamine synthesis in response to physiological hypoxia (Norris and 
Millhorn 1995; Tian et al. 1998). Another study reported respiratory distress 
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syndrome and perinatal death of mice lacking Hif-2α expression due to 
defects in lung maturation (Compernolle et al. 2002).    
Under pathological conditions, Hif-2α appears to regulate blood vessel 
dynamics (Brusselmans et al. 2003). It was demonstrated that a 
heterozygous deletion of Hif-2α protected mice against pulmonary 
hypertension and right ventricular dysfunction induced by chronic hypoxia, 
possibly mediated by increased expression of endothelin-1 (Brusselmans et 
al. 2003). Additionally, a gain-of-function approach of Hif-2α revealed early 
embryonic lethality due to increased Oct-4 expression (Covello et al. 2006). 
Xenograft assays using Hif-2α knock-in ESCs derived from tumours 
demonstrated an elevated growth and increased angiogenesis. The increased 
fraction of undifferentiated ESCs was reversed by knockdown of Oct-4 
(Covello et al. 2006) (Table 1.1). Moreover, a Hif-2α knock-in mouse model 
that has the Hif-1α promoter driving the expression of Hif-2α, showed that 
increased expression of Hif-2α did not rescue the phenotype of the Hif-1α-/- 
mice (Covello et al. 2006). This demonstrated the non-redundant role of Hif 
proteins in embryonic development.   
1.4.4.2 Hif regulatory system in adult haemopoiesis 
1.4.4.2.1 Role of Hif-1α  in adult haemopoiesis 
Studies mentioned in the previous section showed that deletion of Hif-1α, 
Hif-2α or Hif-1ß subunit in mice was embryonic lethal (Maltepe et al. 1997; 
Iyer et al. 1998; Ryan et al. 1998; Tian et al. 1998; Adelman et al. 1999; 
Peng et al. 2000; Compernolle et al. 2002; Yoon et al. 2006). Hence, a CKO 
approach was utilised to decipher the role of Hifs in adult haemopoiesis. 
This model demonstrated that Hif-1α expression was enriched in murine 
HSCs (Simsek et al. 2010; Takubo et al. 2010). An inducible cre (Mx1-Cre) 
transgene was employed to conditionally delete Hif-1α (Takubo et al. 2010). 
Within this model, the administration of pIpC (polyinosic-polycytidylic acid, 
synthetic double stranded RNA) activates the Mx1 promoter, thus driving the 
expression of Cre recombinase in various tissues, including kidney, liver, 
haemopoietic cells and their microenvironment (Takubo et al. 2010). Under 
steady state conditions, HSCs lacking Hif-1α were shown to be capable of 
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sustaining multilineage haemopoiesis (Takubo et al. 2010). However, under 
stressful conditions, like serial BM transplantation, treatment with 
chemotherapeutic agents (5-Flurouracil treatment) and aging, Hif-1α 
deletion in HSCs resulted in a reduced tolerance to stress and induced a loss 
of the HSC pool within the BM (Takubo et al. 2010). HSCs from conditional 
Hif-1α knockout mice lost the capability to reconstitute the BM of lethally 
irradiated mice during serial transplantation (Takubo et al. 2010). A gene 
expression analysis profile of transplanted HSCs lacking Hif-1α showed 
elevated levels of p16Ink4a and p19Arf, the products of Ink4a/Arf locus that 
contribute to cellular senescence (Takubo et al. 2010). Furthermore, 
suppression of p16Ink4a and p19Arf reinstated the BM reconstitution 
potential in the Hif-1α CKO HSCs (Takubo et al. 2010). Hence, Hif-1α is 
involved in the protection of HSCs from stress-induced senescence (Table 
1.1). 
Conditional deletion of Vhl, an E3 ubiquitin ligase mediating Hif-α protein 
degradation, gave more insight into the regulatory mechanisms of Hifs in 
HSCs (Takubo et al. 2010). Heterozygous deletion of Vhl protein and 
consequent over-stabilisation of Hif-1α resulted in enhanced quiescence in 
HSCs (Takubo et al. 2010). Haemopoietic progenitor cell fractions, which 
expressed very low levels of Hif-1α protein entered into unusual cell cycle 
quiescence from a rapid proliferative state with deletion of Hif-1α (Takubo 
et al. 2010). Furthermore, induced deletion of both alleles of Vhl maximised 
Hif-1α stabilisation and resulted in increased HSC quiescence (Takubo et al. 
2010). However, over-quiescent HSCs from Vhl∆/∆ mice displayed defective 
BM reconstitution ability (Takubo et al. 2010). Co-deletion of Hif-1α in the 
HSCs lacking Vhl expression reversed the abnormal increase in HSC 
quiescence and rescued the defective BM reconstitution phenotype (Takubo 
et al. 2010). Hence, the defective stem and progenitor phenotype in the Vhl 
deficient mice was Hif-1α-dependent (Takubo et al. 2010). These results 
suggested that Vhl/Hif-1α-mediated regulatory pathways play a key role in 
regulating the cell cycle quiescence of HSPCs (Table 1.1).   
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1.4.4.2.2 Role of Hif-2α  in adult haemopoiesis 
A null deletion of Hif-2α proved to be embryonic or neonatal lethal (Peng et 
al. 2000; Compernolle et al. 2002). Hence, a conditional deletion approach 
was used to understand the role of Hif-2α in adult physiology (Gruber et al. 
2007). A mouse model was generated, whereby, acute deletion of Hif-2α 
was achieved using an ubiquitously expressed Cre (Ubc) induced by 
tamoxifen (Gruber et al. 2007). Acute deletion of Hif-2α in adult mice 
between 6-8 weeks of age resulted in anaemia with reduced levels of Epo 
production demonstrating that Hif-2α is a major regulator of adult 
erythropoiesis (Gruber et al. 2007).  Deletion of Hif-2α also impaired Epo 
production under stressful conditions in adult mice (Gruber et al. 2007). Hif-
2α was implicated in regulation of Epo production in other organs, such as 
astrocytes of the central nervous system and was shown to play an 
important role in the survival of neurons during ischaemia (Chavez et al. 
2006). Furthermore, hepatocyte-specific deletion of Hif-2α, using albumin-
Cre, revealed Hif-2α dependent hepatic Epo production, underscoring the 
importance of Hif-2α in Epo regulation (Gruber et al. 2007; Rankin et al. 
2007). 
Another study generated a small number of viable adult mice that globally 
lacked the expression of Hif-2α by crossing Hif-2α knockout mice from 
different genetic backgrounds (Scortegagna et al. 2003a). Scrotegagna et al. 
took the approach of generating speed congenic, a marker-assisted strategy 
that recognises the simple sequence length polymorphism between donor 
and recipient to find the progeny with the highest percentage of recipient 
genome to be backcrossed to generate speed congenic strain 
(jaxcommunications 2001). The cross between heterozygous 129S6/SvEvTac 
Hif-2α knockout mice and heterozygous C57BL/6 (C57 black/6) Hif-2α 
knockout mice using speed congenics generated adult F1 hybrid Hif-2α 
knockout mice at one-fourth of the expected Medelian ratio (Scortegagna et 
al. 2003a). The F1 hybrid from this genetic background displayed significant 
perinatal mortality within the first two days of life, but bypassed the 
embryonic lethality that was observed when Hif-2α null mice were inbred 
within either of the strains (Scortegagna et al. 2003b). The surviving 20% of 
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the expected Hif-2α-/- adult mice had lower body weights and a short life 
span of 1-2 months (Scortegagna et al. 2003a). Hif-2α-/- adult mice exhibited 
multiorgan dysfunctions, such as pancytopenia, mitochondrial defects, overt 
cardiac hypertrophy, retinopathy and hepatosteatosis (Scortegagna et al. 
2003a). A study of Hif-2α-/- mice revealed biochemical abnormalities, 
suggesting the role of Hif-2α in regulating the expression of antioxidant 
enzymes, including catalase, glutathione and superoxidase dismutase 
(Scortegagna et al. 2003a). The study showed that Hif-2α-/- juvenile mice 
had reduced haematocrits and lower blood cells counts with decreased 
WBC, RBC and platelet counts (Scortegagna et al. 2003b). Conversely, 
transplantation of Hif-2α-/- BM cells successfully re-populated irradiated 
recipient mice and efficiently generated all the mature blood lineages, 
suggesting that the deletion of Hif-2α in non-haemopoietic cells is the cause 
of pancytopenia in Hif-2α-/- mice (Scortegagna et al. 2003b). In this study, 
Scrotegagna et al reported a reduction in renal Epo mRNA, and a lack of Epo 
upregulation in response to intermittent hypoxia, contributing to the 
defective haemopoiesis (Scortegagna et al. 2003b) (Table 1.1). However, 
the strain specific disparate phenotypes observed in Hif-2α-/- mice do not 
explain the differential requirement of Hif-2α in adult haemopoiesis. 
KO mouse 
model Hif expression Phenotype Reference 
Embryonic 
Arnt-/- 
Increased 
expression of 
Hif-α 
• Embryonic lethal at
E10.5
• Defective yolk sac
angiogenesis and
decreased
haemopoietic
progenitors
• Increased
expression of Vegf
• Lack of hypoxic
response of ESCs
• No differences in
the regulation of
glycolytic genes in
ESCs
(Maltepe et al. 
1997) 
(Adelman et al. 
1999) 
Hif-1α-/- 
Germline 
deletion of Hif-
1α expression 
• Embryonic lethal at
E10.5
• Malformation of
neural tube and
cardiovascular
defects
• Increased tissue
hypoxia
• Haemopoietic
defects including
reduced myeloid
and erythroid
progenitors
(Yoon et al. 
2006) 
(Ryan et al. 
1998) 
(Iyer et al. 1998) 
Hif-2α-/- 
Germline 
deletion of Hif-
2α expression 
• Embryonic lethal
between E9.5-E12.5
• Bradycardia
• Reduced level of
catecholamine
• Cardiac failure and
impaired lung
maturation
(Peng et al. 
2000) 
(Tian et al. 
1998) 
(Norris and 
Millhorn 
1995; Tian 
et al. 1998) 
(Compernolle et 
al. 2002) 
Hif-2α 
Knock-in 
Increased 
expression of 
Hif-2α with 
background 
deletion of Hif-
1α 
• Embryonic lethality
due to elevated Oct-
4 expression
• ESCs derived
tumours showed
increased growth
and angiogenesis
(Covello et al. 
2006) 
Adult 
Hif-1α Δ/Δ
(Mx-1 Cre) 
Conditional 
deletion of Hif-
1α 
• Loss of HSC cell
cycle quiescence
• Lower stress
resistance of HSCs
• Extramedullary
haemopoiesis
• ROS overproduction
• Elevated expression
of P16Ink4a P19Arf
cell senescent
genes
(Simsek et al. 
2010) 
(Takubo et al. 
2010) 
Vhl+/Δ (Mx-
1 Cre) 
Slight increase 
in Hif-
1α expression 
• Enhanced cell cycle
quiescence
• Resistant to aging
• Higher BM
chimerism after BM
transplantation
• ROS suppression
(Takubo et al. 
2010) 
VhlΔ/Δ (Mx-
1 Cre) 
Over 
stabilisation of 
Hif-1α 
• Aberrant
suppression of cell
cycle
• Homing defect of
HSCs
(Takubo et al. 
2010) 
Vegfα 
mutant 
(mutated 
HRE 
element) 
Defective 
binding of Hif-
1α to the HRE 
• Increase in HSC
numbers
• Defective BM
repopulation
potential of HSCs
(Miharada et al. 
2011) 
Hif-2α-/- 
Global deletion 
of Hif-2α with 
different genetic 
background 
• Significant perinatal
death with 20%
surviving till
adulthood of 1-2
months
• Pancytopenia,
mitochondrial
defects, over
cardiac hypertrophy
• Retinopathy and
hepatosteatosis
• Reduced
haematocrits, WBC,
RBC and platelets
• Reduced Epo levels
with defective Epo
regulation during
intermittent hypoxia
(Scortegagna et 
al. 2003a) 
Hif-2α Δ/Δ
(Ubc-Cre) 
Induced global 
deletion of Hif-
2α 
• Anaemia with
defective Epo
production and
erythropoiesis
(Gruber et al. 
2007) 
Meis1Δ/Δ
(Mx-1 Cre) 
Decreased 
expression of 
Hif-1α and Hif-
2α 
• Loss of HSC
quiescence and
increased apoptosis
• Defective BM
repopulation
potential
• Elevated ROS
production
• Increased
mitochondrial
oxidative
phosphorylation
(Kocabas et al. 
2012) 
PHD1-/- 
and PHD3-
/-
Increased Hif-
2α expression 
• Erythrocytosis
mediated by Epo
pathway
• Elevated Epo
expression
(Takeda et al. 
2008) 
PHD2Δ/Δ
(CD68 Cre) 
Stabilisation of 
Hif-1α and Hif-
2α 
• Increased
proliferation of
haemopoietic
progenitors
mediated by TGF-β
• Reduced stress
response in HSCs
with defective
reconstitution during
BM transplantation
due to increased
self-renewal of
HSCs
(Singh et al. 
2013) 
Table 1. 1: Summary of phenotypes of genetic knockout/knockdown models of Hif-
regulatory genes.
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1.4.4.3 Role of Hifs in cellular metabolism 
Under hypoxia, Hif-1α mediates the switch from mitochondrial oxidative 
respiration to glycolysis to maintain tissue homeostasis (Iyer et al. 1998). 
Cells display an adaptive mechanism by low O2 consumption, reduction of 
mitochondrial respiration and an increase in glycolysis via active 
transcription of Hif-1α-dependent genes involved in the glycolytic pathway 
(Iyer et al. 1998). Hif-1α encodes enzymes regulating glycolysis and 
metabolism, such as lactate dehydrogenase A (LDHA) and pyruvate 
dehydrogenase kinase 1 (PDK1), respectively. Hif-1α regulates 
transcriptional activation of glucose transporters like Glut-1 (Iyer et al. 
1998). A recent study demonstrated the effect of Hif-1α on HSC metabolism 
(Simsek et al. 2010; Kocabas et al. 2012). Conditional deletion of Hif-1α in 
HSCs resulted in decreased glycolysis and an increase in oxygen consumption 
rate with a shift towards oxidative metabolism (Kocabas et al. 2012).  
Meis1 has been shown to be essential for the transcriptional activation of 
Hif-1α in HSCs (Kocabas et al. 2012). The study also suggested that cell-
intrinsic characteristics of HSCs included predominant anaerobic metabolism 
and increased Hif-1α expression (Kocabas et al. 2012). Meis1 belongs to the 
Hox family of homeobox genes that encodes DNA-binding TFs and is 
expressed in the primitive haemopoietic subpopulation in both foetal liver 
and adult mice (Krumlauf 1994; Pineault et al. 2002; Azcoitia et al. 2005; 
Argiropoulos et al. 2007). Multiple studies showed that Meis1 is essential for 
both embryonic and adult haemopoiesis (Pineault et al. 2002; Azcoitia et al. 
2005; Argiropoulos et al. 2007). Kocabas et al reported that conditional 
deletion of Meis1 resulted in decreased expression of both Hif-1α and Hif-2α 
in HSCs, resulting in increased mitochondrial oxidative phosphorylation and 
increased ROS production (Kocabas et al. 2012). Inducible deletion of Meis1 
led to dysregulated HSC function, including loss of quiescence and increased 
apoptosis, coupled with lack of their repopulation potential (Kocabas et al. 
2012). The severe defects in HSC functions in Meis1 CKO were mediated 
through ROS, as systemic administration of ROS scavenger N-acetylcysteine 
restored the HSC quiescence and functions (Kocabas et al. 2012). Hence, 
HSC metabolism is governed by a transcriptional network, where Meis1 
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induced Hif-1α expression inhibited mitochondrial metabolism and 
stimulated glycolysis (Table 1.1). 
Several downstream targets of Hif-1α are reported to play a role in Hif-1α-
dependent maintenance of HSC quiescence and their metabolic properties 
(Miharada et al. 2011). Vegf, a well-known Hif-downstream target gene, was 
mutated at the HRE in its promoter region to generate a mutant mouse 
model (Miharada et al. 2011). This mutation interrupted the binding of the 
Hif-1 complex to the HRE causing down-regulation of Vegfα expression 
particularly in HSCs and not in the progenitor cells (Miharada et al. 2011). 
Loss of Vegfα expression in the Vegfα-mutated mouse model displayed a 
defective HSC phenotype, with an increase in the number of HSCs, but 
displayed defective BM reconstitution potential upon transplantation 
(Miharada et al. 2011) (Table 1.1). 
 Another study showed that Hif-1α induced Cripto/GRP78 signalling is 
essential for HSC maintenance (Miharada et al. 2011). Miharda et al found a 
sub-population of HSCs that expressed a heat shock protein, GRP78 
(Miharada et al. 2011). GRP78+ HSCs localised in the hypoxic endosteal 
region of the BM (Miharada et al. 2011). Miharda et al demonstrated that 
GRP78+ HSCs were quiescent with lower mitochondrial potential compared 
to GRP78- HSCs (Miharada et al. 2011).  Further, blocking GRP78 by 
neutralising antibody caused significant reduction in the GRP78+ HSCs in the 
endosteal region (Miharada et al. 2011). Additionally, GRP78, together with 
its ligand Cripto, induced high glycolytic activity in HSCs (Miharada et al. 
2011). Further evidence showed that Cripto is expressed in HSCs as well as 
in various niche cells, including OBs and MSCs (Miharada et al. 2011). 
Moreover, Hif-1α CKO mice demonstrated a decrease in the number of 
GRP78+ HSCs and a reduction in the expression of Cripto in the endosteal 
niche cells (Miharada et al. 2011). Hence, the Cripto/GRP78 signalling 
pathway with Hif-1α as the intermediary regulates HSC quiescence and 
maintains HSCs in hypoxia (Table 1.1) (Figure 1.6). 
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Figure 1. 6: Schematic representation of mechanism by which Hif-1α regulates cell 
metabolic pathway.  
Hif-1α transcriptional activity is induced by Meis1 and also by hypoxia or cytokine signalling, 
including SCF or TPO, thus activating the Hif-1α downstream target genes, including Cripto or 
Vegf. Cripto accumulated from osteoblasts, MSCs or HSCs binds to GRP78 and plays a vital role 
in maintaining HSC quiescence. 
1.4.4.4  Role of Hif-prolyl hydroxylases (PHDs) in haemopoiesis 
Under normoxia, Hif-α are regulated by prolyl hydroxylase family members 
namely PHD-1, PHD-2 and PHD-3 (Epstein et al. 2001; Ivan et al. 2001; 
Masson et al. 2001; Yu et al. 2001). Of the three PHD isoforms, PHD2 
majorly governs the HIF-prolyl hydroxylation in normoxic cells thereby 
maintaining normal levels of Hif-α expression (Berra et al. 2003; 
Minamishima et al. 2008; Takeda et al. 2008). PHD3 is known to be 
relatively more efficient in Hif-2α suppression and hence might favour the 
role in maintaining balanced expression of Hif-2α than Hif-1α (Appelhoff et 
al. 2004). Deletion of PHD2 resulted in dysregulated embryonic 
development, leading to embryonic lethality, similar to mice deficient of 
pVhl or Hif-α (Takeda et al. 2006). Somatic mutation of PHD2 resulted in 
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erythrocytosis and congestive cardiac failure (Takeda et al. 2008). PHD1 null 
mice and PHD3 null mice were viable with normal erythropoiesis, but mice 
lacking both PHD1 and PHD3 developed moderate erythrocytosis (Takeda et 
al. 2008). Hif-2α expression was elevated in the liver of mice lacking both 
PHD1 and PHD3, suggesting that the Hif-2α/Epo pathway mediates 
erythrocytosis (Takeda et al. 2008). In mice deficient of PHD2, Hif-1α, but 
not Hif-2α levels were elevated in liver and kidney causing dramatic 
increase in Epo expression levels (Takeda et al. 2008). However, a recent 
study showed that conditional deletion of PHD2 using CD68-Cre, known to 
delete in the haemopoietic system and in a subset of epithelial cells, 
resulted in Hif-2α-dependent erythrocytosis (Franke et al. 2013). Under 
steady state, conditional deletion of PHD2 using CD68-Cre demonstrated 
increased proliferation in primitive haemopoietic progenitors, but did not 
affect the quiescent HSC population (Singh et al. 2013). Loss of PHD2 under 
physiological conditions resulted in increased cycling of HSCs mediated by 
inhibition of the TGF-ß pathway, due to stabilisation of Hif-1α (Singh et al. 
2013). Under stressful conditions of transplantation, the reconstitution 
potential of HSCs lacking PHD2 was hampered with significantly lower PB 
blood chimerism, however an increase in self-renewal properties of HSCs 
was reported (Singh et al. 2013). In contrast to the defective homing 
phenotype of HSCs with over-stabilised Hif-1α due to loss of Vhl, PHD2 
lacking HSCs showed normal homing ability in the BM (Takubo et al. 2010; 
Singh et al. 2013). Bearing in mind the complexity of the Hif regulatory 
system, more insight into various hypoxia-regulated pathways is essential to 
understand the differential role of Hifs and its regulators in haemopoiesis 
(Table 1.1) 
 Cited2 1.5
Cited2 (p35srj) is one of the founding members of a family of transcriptional 
co-activators termed CITED (CBP/p300 interacting transactivators with 
glutamic acid (E) and aspartic acid (D)-rich tail) (Shioda et al. 1997; 
Bhattacharya et al. 1999). The CITED family was identified as the p300/CBP 
interacting protein and the conserved p300-binding domain defines the 
CITED family (Shioda et al. 1997; Bhattacharya et al. 1999). The CITED 
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family includes CITED1 (Msg-1, melanocyte-specific gene 1) (Shioda et al. 
1996), CITED2 (Shioda et al. 1997; Bhattacharya et al. 1999), CITED3 
(Andrews et al. 2000) and CITED4 (Braganca et al. 2002; Yahata et al. 2002). 
Human CITED family homologues have been found in other species but are 
restricted to vertebrates (Shioda et al. 1997; Bhattacharya et al. 1999). All 
CITED family members except CITED3 are evolutionarily conserved in 
placental mammals (Shioda et al. 1997; Bhattacharya et al. 1999).  
1.5.1 Tissue expression of Cited2 
Cited2 is ubiquitously expressed in murine tissues and has 95% homology 
between human and mouse (Shioda et al. 1997; Bhattacharya et al. 1999). 
Cited2 expression is induced by hypoxia and multiple stimuli, such as serum, 
growth factors (granulocyte/macrophage colony-stimulating factor, 
interferon-γ, platelet-derived growth factor), cytokines IL-1α, IL-2, IL-4, IL-
6, IL-9 and IL-11), insulin and lipopolysaccharide (Sun et al. 1998; 
Bhattacharya et al. 1999; Xu et al. 2008). Cited2 functions as a 
transcriptional co-activator and also as an inhibitor of hypoxia-activated 
gene transcription by interrupting the binding of Hif-1α to p300/CBP 
(Bhattacharya et al. 1999; Bamforth et al. 2001; Braganca et al. 2003). 
Cited2 plays a pivotal role in various biological and biochemical processes, 
including embryonic development, foetal and adult haemopoiesis and 
hypoxia-signalling pathways (Bhattacharya and Ratcliffe 2003; Chen et al. 
2007; Kranc et al. 2009; Chou et al. 2012; Du et al. 2012).  
1.5.2 Structure 
Mrg1 (Shioda et al. 1997) and p35srj (Bhattacharya et al. 1999) are two 
alternatively spliced isoforms encoded by the CITED2 gene (Leung et al. 
1999). Mrg1 is a cytokine-inducible factor with transformation activity (Sun 
et al. 1998) and p35srj is a nuclear protein that binds to p300/CBP, 
regulating the transcriptional response to hypoxia (Bhattacharya et al. 
1999). The CITED2 gene encodes both Mrg1 and p35Srj (Leung et al. 1999) 
(Figure 1.7).  
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Figure 1. 7: Structure of CITED2 gene.  
CITED2 gene is composed of three exons and two introns that encode both Mrg1 and p35Srj. 
Exon-open boxes, Open reading frame (ORF) – Filled boxes.   
CITED2 is an unstable nuclear protein with a half-life of 20 minutes 
(Bhattacharya et al. 1999). Sequence analysis of the CITED family revealed 
the presence of three conserved regions (CR), namely CR1, CR2 and CR3 
(Shioda et al. 1996; Shioda et al. 1997; Sun et al. 1998; Bhattacharya et al. 
1999). While CR2 is conserved in all CITED family members, the CR1 domain 
is present in CITED1, 2 and 3 and the CR3 motif is conserved in CITED2, 3 
and 4 (Yahata et al. 2000; Bamforth et al. 2001; Braganca et al. 2002). The 
CITED2 protein encompasses 270 amino acid (aa) residues. It consists of TAD 
domain in the carboxy-terminal region with CR1 domain (residues 110-123) 
and the CR2 domain (residues 215-270) and CR3 domain (residues 1-11) that 
corresponds to the amino-terminal region. CITED2 consists of an unusual 
serine-glycine rich junction (Srj, residues 161-199) that is exclusive to 
CITED2 (Shioda et al. 1997; Bhattacharya et al. 1999). The functions of the 
CR1, CR3 and Srj domain are not known. Although point mutations and 
variant clustering has been reported in the Srj domain in congenital heart 
disease patients (Sperling et al. 2005; Yang et al. 2010), a recent study has 
shown that the Srj domain is dispensable for Cited2 function in mice and 
suggested that the Srj mutation is not the sole cause of the malformation 
reported in these patients (Chen et al. 2012). TAD of CITED2 functions as 
the p300/CBP-binding site, whereas the CR2 motif of CITED2 binds to the 
CH1 domain of p300/CBP that co-activates CITED2 (Bhattacharya et al. 
1999; Freedman et al. 2003) (Figure 1.8).  
Exon 1 Exon 2 
Cited2 gene 
p35Srj cDNA 
Mrg1 cDNA 
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Figure 1. 8: Structure and interaction partners of Cited2 protein. 
Cited2 consists of three conserved regions (CR1, CR2 and CR3). A unique SRJ domain is 
exclusive to Cited2 and TAD at the CR2 domain in C-terminal is the binding site of Cited2 
interacting partners like TFAP2, HNF4, Smad2/3 and p300/CBP (that co-activates Cited2). CR1, 
CR2, CR3= Conserved region 1,2,3; SRJ = serine-glycine rich junction; TAD= transactivation 
domain. 
1.5.3 Cited2 as a negative regulator of Hif-1α  
Cited2 competes with Hif-1α for the conserved binding region in the CH1 
domain of p300/CBP (Bhattacharya et al. 1999). Cited2 inhibits the 
interaction of Hif-1α and p300 resulting in the blockade of Hif-1-mediated 
transcription (Bhattacharya et al. 1999). Under normoxic conditions, Hif-1α 
undergoes hydroxylation of prolyl or asparagyl residues (Jaakkola et al. 
2001; Lando et al. 2002). The asparagyl hydroxylation of Hif-1α prevents the 
interaction of Hif-1α with p300 (Lando et al. 2002), while prolyl 
hydroxylation leads to proteasomal degradation mediated via Vhl ubiquitin 
ligase (Jaakkola et al. 2001).  Under hypoxic conditions, stabile Hif-1α 
dimerises with its heterodimeric partner Hif-1β isoform in the nucleus and 
binds the DNA at the HRE region (Semenza 1999). The Hif-dimer complex 
recruits p300/CBP by binding to the CH1 domain, thus activating the 
transcription of various hypoxia target genes involved in cellular and 
systemic responses to hypoxia (Semenza 1999). Cited2 expression is 
SRJ TAD 
CR3 CR1 
N-terminal C-terminal 
P300/CBP 
(CH1) 
TFAP2 
HNF4α 
Smad2/3 
HNF-1α 
P53 
NF-kB 
1 6 109 123 160 198 213 269 
CR2 
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activated by hypoxia via Hif-1α recognition sites in its promoter region 
(Bhattacharya et al. 1999). Additionally, binding of Cited2 to p300 is 33-fold 
stronger compared to Hif-1α favouring the inhibitory effect of Cited2 on Hif-
1α-p300 complex formation (Freedman et al. 2003). Hence, Cited2 may 
function to auto-regulate Hif-1α transactivation by inhibiting Hif-1α-p300 
interaction (Bhattacharya et al. 1999). The p300-CH1 complex either with 
Cited2 or with Hif-1α forms a very similar secondary structure and exhibits a 
degree of plasticity to accommodate different transactivation domains 
(Freedman et al. 2003). Hence, the CH1 domain of p300 functions as a 
scaffold supporting the folding of unstructured Cited2 and Hif-1α 
transactivation domains (Freedman et al. 2003).   
Genetic evidence showed that loss of Cited2 in murine embryonic tissues 
and cultured cells enhanced the expression of Hif-1α target genes, such as 
Vegf, Glut-1 and phosphoglycerate kinase (PGK-1) (Yin et al. 2002). Cited2-
deficiency results in embryonic lethality and develop various developmental 
defects, including cardiac defects, adrenal agenesis, haemopoietic defects, 
neural crest defects and excencephaly (Bamforth et al. 2001; Braganca et 
al. 2002; Yin et al. 2002; Schneider et al. 2003).  The cardiac defects of 
outflow tract, interventricular septum, cardiac vasculature and hyposplenia 
in the Cited2-/-embryo was rescued by Hif-1α haploinsufficiency (Xu et al. 
2007). Also, heterozygous deletion of Hif-1α reverted the overexpression of 
Vegfα reported in Cited2-/- hearts, suggesting a negative feedback role of 
Cited2 in regulating Hif-1 activity during cardiac developmental stages (Xu 
et al. 2007). Mouse embryonic fibroblasts (MEFs) from Cited2-/- embryos, 
when cultured in hypoxia, showed elevated levels of Hif-1α target genes, 
such as Vegf, Glut-1 and PGK-1 (Yin et al. 2002). Cited2-/- embryos displayed 
hyaloid hyper cellularity with abnormal vasculature in the eye (Huang et al. 
2012). The abnormal hyaloid system (HVS) was in part due to Cited2-
mediated overexpression of Hif-1α and Vegf (Huang et al. 2012). Indeed, 
deletion of Hif-1α or Vegf in the vasculature of eyes in Cited2 knockout 
embryos partially rescued the abnormal HVS (Huang et al. 2012). Another 
recent publication reported that Cited2 was essential for the maintenance 
of HSC quiescence at least partially in a Hif-1α dependent manner (Du et al. 
2012). Deletion of Cited2 in HSCs resulted in the loss of quiescence, 
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increased apoptosis and defective reconstitution potential upon 
transplantation (Kranc et al. 2009; Du et al. 2012). However, additional 
deletion of Hif-1α in Cited2 CKO mouse models partially rescued the 
defective HSC quiescence and reconstitution capacity (Du et al. 2012). 
Foxo3a-stimulated expression of Cited2 in fibroblasts and breast cancer cells 
resulted in reduced Hif-1α-induced apoptosis (Bakker et al. 2007). Also, a 
recent study demonstrated that p57 and Hes1 regulated HSC quiescence via 
Cited2 (Du et al. 2012). The deletion of Hif-1α in Cited2 CKO mice restored 
the expression of these genes to normal levels (Du et al. 2012). Collectively, 
it is plausible to conclude that Cited2 acts as a negative regulator of Hif-1α, 
thus regulating hypoxia-responsive pathways. 
1.5.4 p300/CBP, a transcriptional co-activator 
p300 and its paralogue CREB-binding protein (CBP) are histone acetylases 
and transcriptional co-activators that bind various TFs to the core 
transcriptional machinery (Shiama 1997; Goodman and Smolik 2000; Bedford 
et al. 2010). p300 and CBP are ubiquitously expressed, evolutionarily 
conserved and play a fundamental role in cellular growth (Goodman and 
Smolik 2000). More than 400 interacting partners have been identified for 
p300 and CBP proteins and are essential for normal cardiovascular, neural 
and haemopoietic development. They consist of an enzymatic histone acetyl 
transferase (HAT) domain and three cysteine-histidine-rich domains (CH1, 
CH2 and CH3), a KIX-domain and a glutamine rich region. These conserved 
functional domains interact with multiple nuclear proteins and activate core 
transcriptional machinery. Cited2 was identified as a high affinity p300/CBP 
binding protein similar to hypoxia-induced Hif-1α (Bhattacharya et al. 1999; 
Semenza 1999). Cited2 and Hif-1α compete with each other to bind to the 
common conserved region in the CH1 domain of p300/CBP (Bhattacharya et 
al. 1999; Semenza 1999).   
1.5.4.1 Functions of p300 and CBP during early development and cancer 
Genetic evidence showed that embryos lacking both alleles of CBP were 
lethal between E9.5 to E10.5 due to anaemia, open neural tube defects and 
defective vasculature (Oike et al. 1999). Monoallelic deletion of CBP (CBP+/-) 
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in mice resulted in splenomegaly, severe defects in multilineage 
differentiation and an increased incidence of haematological malignancies 
with age (Kung et al. 2000). Embryos lacking p300 were lethal and died 
between E9 to E11.5 with various complications, including retarded growth, 
cardiac malformation and poor vasculature, but p300 heterozygous mice 
were born normally without any functional defects (Yao et al. 1998). Double 
heterozygocity of p300 and CBP was embryonic lethal (Yao et al. 1998). 
Hence p300/CBP are crucial for early stages of embryonic development. 
p300 and CBP play a vital role in the maintenance of normal haemopoiesis 
by jointly regulating various critical haemopoietic TFs, including cJun, p53 
and MyoD (Lill et al. 1997; Puri et al. 1997; Shiama 1997; Grossman 2001). 
p300 and CBP individually interact with members of the Ets family, C/EBP 
family and EKLF, AML1, c-Myb, GATA-1, E2F (Lill et al. 1997; Puri et al. 
1997; Shiama 1997; Grossman 2001). Heterozygous mice for p300 and CBP 
showed that CBP, but not p300, was vital for self-renewal properties of 
HSCs. Additionally, p300 was crucial for haemopoietic differentiation, but 
CBP was dispensable for haemopoietic differentiation (Rebel et al. 2002). 
Hence, p300 and CBP have differential roles in regulating haemopoiesis. 
Lineage-specific conditional deletion of p300 and CBP uncovered their role 
in B and T-cell development (Kasper et al. 2006; Xu et al. 2006). Expression 
of both p300 and CBP were essential for B-cell homeostasis, while individual 
expression only mildly affected the B-cells (Kasper et al. 2006). p300 and 
CBP are critical for T-cell development (Xu et al. 2006). A study by Kimbrel 
et al showed that mutant p300 with a deleted CH1 domain or KIX domain 
resulted in severe defects in haemopoiesis, including loss of reconstitution 
ability (Kimbrel et al. 2009). Hence, p300 and CBP regulate haemopoiesis 
and act as activators for various TFs.           
p300 and CBP have also been shown to play a role in tumourigenesis. CBP is 
a tumour suppressor and patients with mutated CBP have Rubinsein-Taybi 
syndrome and are at high risk of development of tumours (Miller and 
Rubinstein 1995; Petrij et al. 1995). Consistent with this, p300 and CBP are 
co-activators of p53 (tumour suppressor) (Avantaggiati et al. 1997; Lill et al. 
1997). MLL (Mixed Lineage leukaemia) and AML (M4 and M5 subtypes) are 
caused by somatic mutations in p300 and CBP (Iyer et al. 2004). More recent 
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studies showed the frequent occurrence of mutations in p300 and CBP in B-
cell lymphoma and acute lymphoblastic leukaemia (ALL) (Mullighan et al. 
2011; Pasqualucci et al. 2011). Thus, p300 and CBP contribute to 
pathological conditions, including leukaemia.  
1.5.5 Functions of Cited2 
1.5.5.1 Role of Cited2 during early development and embryonic 
haemopoiesis 
Cited2 plays a fundamental role in embryonic development (Bamforth et al. 
2001; Braganca et al. 2002; Yin et al. 2002; Chen et al. 2007; Xu et al. 2007) 
and regulates various vital biological and biochemical functions (Freedman 
et al. 2003; Kranc et al. 2003; Chou and Yang 2006; Bakker et al. 2007; Qu 
et al. 2007; Kranc et al. 2009; Lou et al. 2011; Chou et al. 2012). The tissue-
restricted expression of Cited2 has been reported in the visceral endoderm 
before gastrulation and appears in the cranial neuroectoderm, neural crest, 
mesoderm and mesodermal tissues during gastrulation (Dunwoodie et al. 
1998). During later stages of embryogenesis, Cited2 is ubiquitously 
expressed (Dunwoodie et al. 1998). Deletion of Cited2 resulted in embryonic 
lethality between E13.5 and E18.5 (Bamforth et al. 2001; Braganca et al. 
2002). Embryos lacking Cited2 displayed cardiac malformation, adrenal 
agenesis, neural crest defects, abnormal cranial ganglia and exencephaly 
(Bamforth et al. 2001; Braganca et al. 2002; Yin et al. 2002; Schneider et al. 
2003). Cardiac defects in Cited2 null embryos included defects in atrial and 
ventricular septum, cardiac outflow tract and aortic arch malformation 
(Bamforth et al. 2001). Loss of Cited2 in murine embryos resulted in the 
malformation of anterio-posterior axis due to fusion of cranial ganglia and 
the cervical vertebrae (Bamforth et al. 2001; Bamforth et al. 2004). Cited2 
is also essential for formation of hyaloid vasculature, lens morphogenesis 
and development of liver and lungs (Qu et al. 2007; Chen et al. 2008; Xu et 
al. 2008). Hence, Cited2 regulates various developmental stages during 
embryogenesis. Murine ESC studies showed that Cited2 overexpression 
maintained ESCs in an undifferentiated state in the absence of leukaemia 
initiating factor (LIF), a growth factor activating the gp130/Stat3 signalling 
pathway (Pritsker et al. 2006). Loss of Cited2 did not affect the 
pluripotency of murine ESCs in the presence of LIF (Li et al. 2012). However, 
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in differentiating ESCs Cited2 deletion resulted in delayed silencing of 
genes, including Oct4, Klf4, Sox2 and c-Myc, that are involved in the 
maintenance of pluripotency and self-renewal (Li et al. 2012). Impaired 
Oct4 expression, mediated in part through Cited2, resulted in defective 
cardiomyocyte, haemopoietic and neuronal differentiation in ESCs lacking 
Cited2 (Li et al. 2012). Loss of Cited2 in MEFs resulted in impaired 
proliferation due to elevated expression of cell proliferation inhibitors 
p16Ink4a and p19ARF mediated partially via polycomb-group genes Bmi1 and 
Mel18 (Kranc et al. 2003). In MEFs, Cited2 controls cell proliferation and 
INK4a/ARF expression (Kranc et al. 2003). This phenotype is in part 
mediated by Bmi1 and Mel18 as exogenous expression of Bmi1 and Mel18 
enhanced the proliferation of Cited2-/- fibroblasts (Kranc et al. 2003). Taken 
together, previous publications collectively suggest the requirement of 
Cited2 in the maintenance of primitive characteristics, such as self-renewal 
and pluripotency of stem cells. 
Chen et al showed the requirement of Cited2 for normal haemopoiesis in 
murine foetal liver (Chen et al. 2007). Cited2 is highly expressed in the 
primitive cells and has low expression in differentiated cells (Chen et al. 
2007; Kranc et al. 2009). Studies in the Cited2 null mice demonstrated that 
foetal liver haemopoiesis was severely impaired with reduced numbers of 
LSKs (consisting of HSCs and haemopoietic progenitors) (Chen et al. 2007). 
Furthermore, foetal liver cells lacking Cited2 failed to reconstitute the BM 
of lethally irradiated mice (Chen et al. 2007). Hence, Cited2 plays a vital 
role in pathways regulating foetal liver HSC functions. 
1.5.5.2 Role of Cited2 during adult haemopoiesis 
Cited2 has been shown to be essential in HSC function and maintenance 
(Kranc et al. 2009; Du et al. 2012). Conditional deletion of Cited2 using an 
inducible cre, Mx1-Cre (activated by pIpC administration), resulted in severe 
HSC loss and fatal BM failure (Kranc et al. 2009; Du et al. 2012). HSCs 
lacking Cited2 displayed defective multilineage repopulation potential 
during transplantation (Kranc et al. 2009; Du et al. 2012). The loss of HSCs 
in mice with acute deletion of Cited2 was partially due to increased 
apoptosis resulting from elevated p53 activity (Kranc et al. 2009). Deletion 
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of p53, a tumour suppressor, or Ink4a/ARF (encoding p16Ink4a and p19ARF), 
successfully restored HSC functions, including BM reconstitution (Kranc et 
al. 2009). Another study showed that induced deletion of Cited2 resulted in 
loss of HSC quiescence and additional deletion of Hif-1α partially rescued 
defective HSC functions (Du et al. 2012). Additionally, an increase in 
quiescent HSCs and donor derived LSK chimerism was observed in cells 
lacking both Cited2 and Hif-1α compared to cells from Cited2-deficient 
mice (Du et al. 2012). However, the defective apoptosis in Cited2-deficient 
mice was independent of Hif-1α (Du et al. 2012). Hence, Cited2 regulates 
adult HSC functions via both Hif-1α−dependent and  Hif-1α−independent 
pathways. 
1.5.5.3 Oncogenic properties of Cited2 
Cited2 has been shown to possess oncogenic properties and its role in cancer 
has not been fully elucidated. Cited2 (Mrg1) expression is induced by serum, 
multiple growth factors, several cytokines and insulin (Sun et al. 1998; Chou 
et al. 2012). Previous studies showed that overexpression of Cited2 in Rat1 
cells led to tumour formation after injection in nude mice (Sun et al. 1998). 
These data suggested that over-expression of Cited2 transformed cells 
encoding tumourigenic properties. In addition, solid tumour studies reported 
that in xenograft models, expression of CITED2 promoted the growth of lung 
tumours. Additionally, co-expression of CITED2 with m-Myc or E2F3 was 
associated with poor survival rate of lung cancer patients (Chou et al. 2012). 
On the other hand, several reports suggested that Cited2 might act as 
tumour suppressor in some cell types (Bai and Merchant 2007). For example, 
knockdown of Cited2 in vitro increased the invasiveness of colon cancer, 
whilst exogenous expression of Cited2 led to growth arrest in colon cancer 
cells (Bai and Merchant 2007). Similarly, in breast cancer patients, reduced 
Cited2 expression was related with poor prognosis (van Agthoven et al. 
2009). Taken together these studies suggest that Cited2 behaves as a 
tumour suppressor or as an oncogene depending on the cell type and cancer. 
More investigation into the role of Cited2 in cancer is therefore essential to 
understand its distinctive functions.  
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1.5.5.4 Molecular mechanisms regulated by Cited2 
At a molecular level, dysregulated downstream targets of Cited2 might 
contribute to some of the defective biological processes in Cited2-/- mice. 
Cited2 is involved in transactivation of Tfap2 (transcription factor AP2) 
(Bamforth et al. 2001). It was demonstrated that mice lacking Tfap2 died 
perinatally as a result of severe cardiac malformation, defects in neural 
tubes and neural crests (Brewer et al. 2002; Kuckenberg et al. 2012). Hence 
defective functions of Tfap2, at least in part, may contribute to the 
malformations in cardiac, neural tubes and crests that are observed in 
Cited2-/- mice.  
Also, Cited2 competes with Hif-1α for binding to the CH1 domain of 
p300/CBP and thus negatively regulates Hif-1α transactivation. Deletion of 
Hif-1α and its target gene, Vegf, in the eye of Cited2 knockout mice, 
partially rescued the defects in hyaloid vasculature (Xu et al. 2007). 
Similarly, deletion of Hif-1α in murine adult HSCs lacking Cited2 expression 
partially rescued their defective quiescence and reconstitution potential (Du 
et al. 2012) (Figure 1.9).   
Under hypoxia, Foxo3a has been shown to stimulate the transcription of 
Cited2 thereby reducing the expression of pro-apoptotic Hif-1α target genes 
NIX and RTP801 and inhibiting Hif-1α-induced apoptosis in fibroblast and 
breast cancer cells (Bakker et al. 2007). Loss of Cited2 in MEFs led to 
cessation of proliferation due to reduced expression of polycomb ring finger 
oncogenes, Bmi1 and Mel18, resulting in low expression levels of INK4a/ARF 
(Kranc et al. 2003). Exogenous expression of Bmi1 and Mel18 increased the 
proliferation of MEFs (Kranc et al. 2003). Furthermore, deletion of Cited2 in 
murine foetal liver cells was coupled with decreased expression of various 
genes involved in maintenance of HSC functions, such as Bmi1 (Lessard and 
Sauvageau 2003), GATA2 (Ling et al. 2004), p53 (Liu et al. 2009), Notch1 
(Panepucci et al. 2010), Mcl-1 (Campbell et al. 2010a) and LEF-1 (Chen et 
al. 2007) (Figure 1.9). These studies provide hints of distinctive molecular 
mechanisms governed by Cited2 in various cell types. However, further 
dissection into system-specific regulatory pathways of Cited2 is essential. 
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Figure 1. 9: Schematic representation of regulation of Cited2 at the molecular level. 
Cited2 has been shown to regulate various downstream target genes (Hif-1, Bmi1 and Smad2/3) 
by playing a key role in regulating HSC quiescence, self-renewal and apoptosis. Foxo3a and 
STAT5 regulate transcription of Cited2 in fibroblasts and Hela cells. Red arrow – Relationship 
shown in other systems yet to be tested in HSCs, Green arrow- Relationship that exists in other 
systems but not in HSCs. 
 
 Malignant haemopoiesis 1.6
Leukaemia is a clonal haemopoietic stem and progenitor cell malignancy 
characterised by excessive proliferation, survival and impaired 
differentiation (Jan and Majeti 2013). Based on the rapidity of the clinical 
course and cell of origin, leukaemia is broadly classified into chronic 
myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), AML and 
acute lymphoblastic leukaemia (ALL) (Vardiman 2010; Campo et al. 2011). 
Acute leukaemia are characterised by more immature cells in the BM and 
peripheral blood (PB) that progress over weeks to months resulting in BM 
failure (Lowenberg et al. 1999; Estey and Dohner 2006). Chronic leukaemia 
is characterised by more mature cells in the BM and PB and is less 
aggressive. AML is the most common form of acute leukaemia in adults 
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accounting for 80% of cases, while ALL accounts for the majority of 
leukaemia cases in children (Bhayat et al. 2009; Jemal et al. 2010). Due to 
specific interest and relevance to my work, here I will be focusing on AML.  
1.6.1 AML 
AML is a heterogeneous clonal disorder characterised by various 
chromosomal translocations resulting in the formation of oncogenic fusion 
proteins (Rabbitts 1994; Look 1997; Greaves and Wiemels 2003). Over 160 
non-random somatic chromosomal mutations are observed in patients 
contributing to the heterogeneity of the disease (Mrozek et al. 2001; Mrozek 
et al. 2004). The prognostic impact and disease pathogenesis of 
heterogeneous AML is intensely studied and distinct translocations are 
linked to subtypes of leukaemia (Grimwade et al. 1998; Wheatley et al. 
1999; Bullinger et al. 2004; Valk et al. 2004; Leroy et al. 2005; Coenen et al. 
2011). 
1.6.1.1 Classification of AML 
AML is classified based on morphological characteristics and extent of cell 
maturation by the French-American-British classification (FAB) system 
(Bennett et al. 1976). Using FAB classification, leukaemia is classified into 
subtypes from M0 through M7 (Bennett et al. 1976) (Table 1.2). Another 
system of classification by the world health organisation (WHO) is based on 
clinical data and biological characteristics encompassing morphology, 
genetics, immunological features and cytogenetics (Vardiman 2010). 
According to WHO classification, AML is sub-grouped into AML with recurrent 
genetic abnormalities, AML with multilineage dysplasia (MDS), therapy-
related myeloid neoplasms, AML not otherwise specified, myeloid sarcoma; 
myeloid proliferations related to Down's syndrome; and blastic plasmacytoid 
dendritic cell neoplasm (Bennett et al. 1976) (Table 1.3). 
AML Classification AML Subtypes 
1. AML	  with	  recurrent	  geneticabnormalities
t	  (8;	  21)	  (q22;	  q22);	  RUNX1-­‐RUNX1T1	  
Inv	  (16)	  (p13;	  1q22)	  or	  t(16;	  16)	  (p13.1;	  q22);	  CBFB-­‐MYH11	  
APL	  with	  t	  (15;	  17)	  (q22;	  q12);	  PML-­‐RARA	  
AML	  with	  t	  (9;	  11)	  (p22;	  q23);	  MLLT3-­‐MLL	  
AML	  with	  t	  (6;	  9)	  (p23;	  q34);	  DEK-­‐NUP214	  
AML	  with	  inv3	  (q21q26.2)	  or	  t	  (3;	  3)	  (q21;	  q26.2);	  RPN1-­‐EVI1	  
AML	  (megakaryoblastic)	  with	  t	  (1;	  22)	  (p13;	  q13);	  RBM15-­‐MKL1	  
Provisional	  entity:	  AML	  with	  mutated	  NPM1	  
Provisional	  entity:	  AML	  with	  mutated	  CEBPA	  
2. AML	  with	  myelodysplasia-­‐related
changes
3. Therapy-­‐related	  myeloid	  neoplasms
4. AML	  -­‐	  not	  otherwise	  specified	  (NOS)
AML	  with	  minimal	  differentiation	  
AML	  without	  maturation	  
AML	  with	  maturation	  
Acute	  myelomonocytic	  leukaemia	  
Acute	  monoblastic/monocytic	  leukaemia	  
Acute	  erythroid	  leukaemia	  
Pure	  erythroid	  leukaemia	  
Erythroleukaemia,	  erythroid/myeloid	  
Acute	  megakaryoblastic	  leukaemia	  
Acute	  basophilic	  leukaemia	  
Acute	  panmyelosis	  with	  myelofibrosis	  
5. Myeloid	  sarcoma
6. Myeloid	  proliferations	  related	  to
Down’s	  syndrome
Transient	  abnormal	  myelopoiesis 
Myeloid	  leukaemia	  associated	  with	  Down’s	  syndrome	  
7. Blastic	  plasmacytoid	  dendritic	  cell
neoplasm
8. Acute	  leukaemia	  of	  ambiguous
lineage
Acute	  undifferentiated	  leukaemia	  
Mixed	  phenotype	  acute	  leukaemia	  with	  t	  (9;	  22)	  (q34;	  q11.2);	  BCR-­‐ABL	  
Mixed	  phenotype	  acute	  leukaemia	  with	  t	  (v;	  11q23);	  MLL	  rearranged	  
Mixed	  phenotype	  acute	  leukaemia,	  B/myeloid,	  NOS	  
Mixed	  phenotype	  acute	  leukaemia,	  T/myeloid,	  NOS	  
Provisional	  entity:	  Natural	  killer	  (NK)–cell	  lymphoblastic	  
leukaemia/lymphoma	  
Table 1. 2: WHO (World health organisation) classification of AML. 
FAB 
subgroup Type of leukaemia 
Prognosis/ 
Frequency in AML Morphology M0	   Acute	  myeloblastic	  leukaemia	  without	  maturation	   Worse/<5%	   Immature	  myeloblasts,	  lacks	  definite	  myeloid	  differentiation	  by	  conventional	  morphology	  or	  cytochemical	  analyses	  M1	   Acute	  myeloblastic	  leukaemia	  with	  minimal	  maturation	   Average/20%	   Immature	  myeloblasts	  predominate,	  <10%	  promyelocytes,	  myelocytes	  or	  monocytes	  M2	   Acute	  myeloblastic	  leukaemia	  with	  maturation	   Better/30%	   Immature	  myeloblasts	  predominate,	  but	  more	  maturation	  than	  in	  M1	  M3	  and	  M3v	  (variant)	   Acute	  promyelocytic	  leukaemia	   Best/10%	   Promyelocytes	  predominate,	  marked	  granulation	  in	  more	  than	  30%	  cells,	  granules	  not	  visible	  by	  light	  microscopy	  in	  M3v	  M4	  and	  M4EO	   Acute	  myelomonocytic	  leukaemia	   Average;	  better/25%	   Mixture	  of	  abnormal	  monocytic	  cells	  (>20%)	  and	  myeloblasts/promyelocytes	  (>20%),	  30%	  eosinophils	  in	  M4EO	  M5a	  and	  M5b	   Acute	  monocytic	  leukaemia	   Average/10%	   Monocytic	  cells	  predominate	  (>80%)	  in	  M5a,	  >80%	  nonerythoid	  cells	  are	  immature	  monoblasts,	  >20%	  are	  mature	  monocytes	  in	  M5b	  M6	   Acute	  erythroleukaemia	   Worse/<5%	   Myeloblasts	  and	  erythroblasts	  predominate,	  abnormal	  multinucleated	  erythroblasts	  containing	  PAS-­‐positive	  blocks	  
M7	   Acute	  megakaryoblastic	  leukaemia	   Worse/<5%	   Megakaryocytic	  cells	  as	  shown	  by	  platelet	  peroxidase	  activity	  on	  electron	  microscopy	  or	  by	  tests	  with	  platelet-­‐specific	  antibodies,	  often	  myelofibrosis	  and	  increased	  BM	  reticulin	  Others	   Undifferentiated	  acute	  leukaemia,	  hypocellular	  AML	   Not	  known	  
Table 1. 3: AML classification based on the FAB (French-American-British classification) system. 
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1.6.1.2 The cell of origin in AML 
There is mounting evidence that AML is generated and sustained by a rare 
population of leukaemic stem cells (LSCs) that share common characteristics 
with normal HSCs. Like HSCs, LSCs follow a hierarchical organisation with 
quiescent LSCs at the apex, have the ability to self-renew and also to 
differentiate (Lapidot et al. 1994; Bonnet and Dick 1997; Appelbaum et al. 
2001). Initial studies suggested that LSCs originated from HSCs and shared 
common immunophenotypic characteristics (CD34+ CD38-) (Bonnet and Dick 
1997; Ishikawa et al. 2007). However, other research has challenged the 
HSC origin of LSCs (Cozzio et al. 2003; So et al. 2003; Huntly et al. 2004; 
Krivtsov et al. 2006; Taussig et al. 2008; Yoshimoto et al. 2009). Murine 
retroviral models provide more insight into the cell of origin. Studies 
conducted using retroviral models showed that fusion oncogenes (MLL-ENL, 
MOZ-TIF2 and MLL-AF9) reported in leukaemia successfully transformed 
committed progenitors (GMPs and LMPPs) to LSCs (Cozzio et al. 2003; So et 
al. 2003; Huntly et al. 2004; Krivtsov et al. 2006). It has also been 
demonstrated that retroviral transduction of MLL-fusion proteins (MLL-ENL 
and MLL-AF9) immortalised HSCs as well as committed progenitors that 
exhibit limited self-renewal potential (Akashi et al. 2000; (Na Nakorn et al. 
2002; Cozzio et al. 2003). Also, studies conducted by Sommervaille et al 
showed that MLL-AF9 transformed and immortalised downstream progenitor 
cells generating LSCs (Somervaille and Cleary 2006; Kelly et al. 2007). 
Hence, primitive progenitors acquire mutations and inherit self-renewal 
properties and transformation potential. On the other hand, a study 
reported that progenitor cells expressing oncogenes, including Flt3-ITD and 
co-expressing Meis1 and Hoxa9, failed to acquire self-renewal properties, 
thereby suggesting that the leukaemogenic properties of these oncogenes 
were confined to HSCs (Kvinlaug et al. 2011).  
Evidence from xenotransplantation models further support the evolution of 
LSCs from both HSCs and progenitor cells. Primary human AML cells purified 
for HSCs (CD34+CD38-) and progenitor cells (CD34+CD38+) both displayed LSC 
activity (Taussig et al. 2008; Yoshimoto et al. 2009). LSC activity was 
reported with transplantable leukaemic potential in both CD34+ and CD34- 
compartments from AML patients, suggesting LSCs possessed aberrant 
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immunophenotypic characteristics compared to HSCs (Martelli et al. 2010; 
Taussig et al. 2010). Goardon et al analysed primary human CD34+ AML 
samples (>5% of cells are CD34+) and showed that GMPs 
(CD34+CD38+CD110+CD45RA+) and LMPPs (CD34+CD38-CD90+CD45RA+) both 
possessed LSC activity and were capable of generating transplantable AML 
(Goardon et al. 2011). The study also showed the hierarchical organisation 
of CD38-CD45RA+ forming GMP-like cells with occurrence of higher frequency 
of LSCs than GMP-like cells (Goardon et al. 2011).  Together, the studies 
demonstrate that HSCs, LMPPs and/or GMPs can act as the cell of origin for 
LSCs in the majority of AML subtypes (Figure 1.10).                
 
Figure 1. 10: Ontogeny of leukemic stem cell.  
During normal haemopoiesis, LT-HSCs and ST-HSCs display self-renewal potential giving rise 
to primitive progenitors (LMPPs and CLPs) and more committed progenitors (GMPs, CLPs, 
MEPs) that differentiate into mature blood lineages.  The cell of origin in AML is either a HSC 
or a downstream progenitor cell. Formation of fusion proteins (AML-ETO, MLL-ENL), co-
expression of Meis1-Hoxa9 and mutations in LT-HSCs, or in the progenitor cells (represented 
by doted lines), result in the generation of Pre-LSC. Pre-LSCs acquire secondary mutations 
forming LSCs leading to leukaemic blasts. LT-HSC=Long-term haemopoietic stem cells; ST-
HSC=Short-term HSC; LMPP=Lymphoid primed multipotent progenitor; CMP=Common 
myeloid progenitor; CLP=Common lymphoid progenitor; GMP=Granulocyte/macrophage 
progenitor; MEP=Megakaryocyte/erythroid progenitors; LSC=Leukaemic stem cells.  
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1.6.1.3 Models of leukaemogenesis 
A heterogeneous population of cells that are phenotypically and functionally 
distinct are reported in leukaemia (Hope et al. 2004; Jan and Majeti 2013). 
Two different models are proposed to explain the heterogeneity of AML. 
According to the stochastic model, leukaemia consists of a homogenous 
population of immature cells that self-renew or proliferates in a stochastic 
manner influenced by cell intrinsic and extrinsic factors (Till et al. 1964; 
Korn et al. 1973; Reya et al. 2001). In contrast, the hierarchical model of 
leukaemia consists of a heterogeneous population of cells within which a 
small percentage of LSCs generate leukaemia and sustain the disease 
(Ravandi and Estrov 2006) (Figure 1.11). 
Figure 1. 11: Model of tumour heterogeneity 
Explaining the heterogeneity of tumours, two theories are proposed: Stochastic model and hierarchy 
model. According to the stochastic model, all tumour cells are capable of giving rise to tumours and 
their heterogeneity is influenced by cell intrinsic and extrinsic factors. In contrast, the hierarchy model 
proposes that tumour cells are biologically distinct with a subset of tumour-initiating cells that retain 
the tumourigenic potential while others are non-tumourigenic progeny.   
1.6.1.4 Molecular genetics of AML 
Genetic mutations in NPM1, FMS-like tyrosine kinase 3 (Flt3) and 
CCAAT/enhancer binding protein alpha (C/EBPα) that are reported in 
cytogenetically normal AML have improved the WHO classification of AML 
and are applied as molecular markers in disease prognostication (Nakao et 
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al. 1996; Kiyoi et al. 1998; Thiede et al. 2002; Falini et al. 2005; Thiede et 
al. 2006). Bearing in mind the vast number of genetic mutations that are 
reported in AML, I have described some of the commonly occurring genetic 
and epigenetic mutations. 
1.6.1.4.1 Flt3 
FLT3 gene encodes a class III tyrosine kinase protein expressed in 
haemopoietic progenitor cells regulating differentiation, proliferation and 
survival (Kiyoi and Naoe 2002). FLT3 internal tandem mutations (ITD) have 
been reported in 20%-27% of AML in younger adults and occur mostly in exon 
14 and 15 affecting the juxtamembrane region (Nakao et al. 1996; Kiyoi et 
al. 1998; Thiede et al. 2002). FLT3-ITD mutations have been associated with 
significantly inferior outcomes and high risk of relapse (Whitman et al. 2001; 
Frohling et al. 2002; Thiede et al. 2002). Another point mutation in the Flt3 
at TKD (tyrosine kinase domain) resulted in the activation of Flt3 receptor 
generating leukaemic blasts with uncontrolled proliferation (Mead et al. 
2007). Patients with FLT3-ITD mutations harbouring ITD integration in the 
TKD-1 domain and others with co-occurrence of WT1 (Wilm’s tumour 1) 
mutation have a particularly poor prognosis (Frohling et al. 2002; Thiede et 
al. 2002; Virappane et al. 2008). Patients with FLT3 mutations failed to 
respond to chemotherapy and allogeneic HSC transplant, and have a poor 
outcome due to the high risk of relapse (Dohner and Gaidzik 2011). 
However, molecular targeted therapy using FLT3 inhibitors with more 
selectivity against FLT3 have delivered promising results (Zarrinkar et al. 
2009).   
1.6.1.4.2 NPM1 
NPM1 gene mutations are common single gene mutations reported in AML 
and occur in one third of AML cases (Falini et al. 2005; Thiede et al. 2006). 
NPM1 mutations mostly occur in exon 12 with a frame shift resulting in the 
disruption of nucleolar localisation and functions of NPM1, including 
activation of tumour suppressors p53 and ARF (Falini et al. 2005; Grisendi et 
al. 2006). NPM1 mutations have been associated with mutations in FLT3-ITD, 
IDH1/2 and DNMT3α, but are rarely seen in association with C/EBPα 
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mutations (Schlenk et al. 2008; Green et al. 2010). However, treatments for 
patients with NPM1 mutations have favourable outcomes with lower risk of 
relapse (Dohner et al. 2005; Schlenk et al. 2008). 
1.6.1.4.3 CEBPA 
C/EBPα gene encodes C/EBPα, a TF that belongs to the basic region leucine 
zipper (bZIP) family and is involved in myelopoiesis (Radomska et al. 1998). 
With a frequency of 5%-10% of AML, C/EBPα mutations occur in the amino-
terminal region generating a truncated isoform of C/EBPα (p30) and loss of 
the full-length protein (p42) (Pabst et al. 2001). Mutations reported in the 
carboxy-terminal of C/EBPα resulted in defective dimerisation and DNA 
binding (Pabst et al. 2001). Studies involving murine models showed that 
loss of p42 or heterozygous mutations affecting both amino- and carboxy-
terminal regions generated AML with defective haemopoiesis (Kirstetter et 
al. 2008). Prognosis of AML patients harbouring a C/EBPα mutation, 
particularly in patients without FLT3-ITD, has been reported to be relatively 
better than patients with both C/EBPα and FLT3-ITD mutations (Wouters et 
al. 2009).     
1.6.1.5 Epigenetic modifiers in AML 
Recent studies using genome-wide sequencing of AML patient samples have 
discovered a series of recurrent mutations in genes, including DNA 
methyltransferase 3 alpha (DNMT3α), Isocitrate dehydrogenase1/2 (IDH1/2), 
ten-eleven-translocation gene 2 (TET2) and EZH2, that are involved in 
epigenetic regulation (Parsons et al. 2008; Delhommeau et al. 2009; Mardis 
et al. 2009; Abdel-Wahab et al. 2010; Gross et al. 2010; Ley et al. 2010; Yan 
et al. 2011). Some of the recently discovered epigenetic alterations have 
been summarised in the following paragraphs. 
1.6.1.5.1 DNMT3α  
DNA methyltransferases are coded by DNMT1, DNMT3α and DNMT3ß and 
have been shown to catalyse the methylation of cytosine residue of CpG 
(Cytosine-phosphate-Guanine) dinucleotide in the DNA (Bestor 2000). 
Mutations in DNMT3α are recurrent in 20%-22% of patients with de novo AML 
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and occur often with IDH mutations (Ley et al. 2010; Yan et al. 2011). 
DNMT3α mutations are also reported often in secondary AML and MDS 
patients (Walter et al. 2011). The somatic mutations include nonsense and 
missense of open-reading frame (ORF) of DNMT3α with a recurrent mutation 
at amino acid R882 that is often reported in AML and MDS patients (Ley et 
al. 2010; Walter et al. 2011). Several studies have associated DNMT3α 
mutations in AML with worse survival outcomes (Ley et al. 2010; Walter et 
al. 2011; Yan et al. 2011). 
1.6.1.5.2 IDH1/IDH2 
IDH1/IDH2 is a cytosolic enzyme in the Krebs cycle and catalyses the 
decarboxylation of isocitrate to α-keto-gluterate (α-KG). Mutations in genes 
encoding IDH1 and IDH2 are reported in genomic sequencing of AML (Parsons 
et al. 2008; Mardis et al. 2009; Gross et al. 2010). Heterozygous IDH1/2 
mutations occur due to missense in the ORF region and are reported in 12%-
22% of AML (Boissel et al. 2010; Gross et al. 2010). The mutated IDH1 has 
been shown to catalyse α-KG to 2-hydroxygluterate (2-HG) (Boissel et al. 
2010; Gross et al. 2010). The abnormal levels of 2-HG were reported in AML 
cells and sera from patients with IDH mutations (Boissel et al. 2010; Gross et 
al. 2010). The hypermethylation of various promoter sites that are specific 
to myeloid differentiation and leukaemogenesis has been associated with 
IDH mutations (Figueroa et al. 2010). Further evidence reported that the 
altered levels of 2-HG/α-KG in IDH1/2 mutant cells disrupted the expression 
of jumonji histone lysine demethylases (JHDM), which regulates the 
expression of Mdm2 and p53 (Xu et al. 2011). Hence, epigenetic mutations, 
such as IDH1/2, are being extensively studied to understand the mechanisms 
regulating AML generation.   
1.6.1.5.3 TET2 
TET2 mutations were reported in 24% of patients with secondary AML 
(Delhommeau et al. 2009; Abdel-Wahab et al. 2010). DNA analysis showed 
that TET2 mutations frequently occurred following transformation of 
myeloproliferative neoplasms (MPN) to AML (Delhommeau et al. 2009; 
Abdel-Wahab et al. 2010). The majority of TET2 mutations were found in 
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the precursor cells of AML patients with mutations in CD34+ progenitor cells 
(Langemeijer et al. 2009). Furthermore, mutations in TET2 resulted in the 
defective demethylation of DNA and impaired conversion of 5-
methylcytosine to 5-hydroxymethylcytosine (5-hmC) (Ko et al. 2010). 
However, a rare co-occurrence of TET2 mutation and IDH1/2 mutation 
suggested the existence of a common mechanism that guides the 
leukaemogenic potential (Metzeler et al. 2011; Xu et al. 2011). 
Figure 1. 12: Frequency of cytogenetic aberrations in AML. 
Comparison of frequency of occurrence of cytogenetic aberrations in childhood and adult AML, 
NK – normal karyotype and CK – complex karyotypes.   
1.6.1.6 AML-associated translocations: the paradigm of fusion proteins 
AML associated with non-random translocations often results in the 
generation of a chimeric gene that encodes a novel fusion protein (Scandura 
et al. 2002; Cozzio et al. 2003; So et al. 2003; Somervaille and Cleary 2006). 
The fusion proteins retain the DNA-binding motifs and guide the interaction 
of the co-repressor complex with the active transcription locus, thus 
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altering the expression of the target genes that are essential for myeloid 
development and causing leukaemic transformation (Scandura et al. 2002). 
However, other abnormalities or ‘second hits’ appear to be necessary for 
full leukaemic development (Scandura et al. 2002). There are 749 recurrent 
aberrations reported in AML. Bearing in mind the enormity of oncogenic 
fusions identified in AML, I will be restricting the discussion to oncogenes 
(Meis1 and Hoxa9) and fusion proteins (AML1-ETO and MLL-fusions) studied 
in this thesis. 
1.6.1.6.1  AML1-ETO; t(8;21) 
1.6.1.6.1.1 Cytogenetic and clinical characteristics of AML1-ETO translocations 
The t(8;21) translocation contributes to approximately 10% of AML cases 
(Martens and Stunnenberg 2010) that are associated strongly with childhood 
leukaemia and are classified as FAB M2 subtype of leukaemia with 
maturation (Mrozek et al. 2001). The chimeric oncofusion is produced by 
aberrant translocation of the AML1 gene on chromosome 21q22 with the 
ETO (Eight Twenty One) gene on chromosome 8q22, generating a fusion 
protein AML1-ETO (Peterson and Zhang 2004). The AML1-ETO protein 
contains the N-terminal of AML1 with DNA binding and core binding factor β 
(CBFβ)-binding runt homology domain (RHD), while the C-terminal is 
replaced by almost the entire ETO protein (Wotton et al. 1994; Mao et al. 
1999). 
AML1 is a DNA-binding TF and plays a vital role in haemopoiesis (de Bruijn 
and Speck 2004). AML1 is a component of the CBF complex with a central 
RHD domain that binds to DNA and interacts with various TFs, such as CBFβ, 
Ets proteins, smads and C/EBPα (Wotton et al. 1994; Mao et al. 1999; 
Scandura et al. 2002). AML1 interacts with CBP/p300 and activates 
transcription of IL-3, M-CSFR (macrophage colony-stimulating factor 
receptor), T- and B-cell receptors, as well as functions as a co-repressor of 
CD4, Sin3 and N-CoR, along with various other nuclear proteins that play a 
key role in chromatin remodelling (Wotton et al. 1994; Wang et al. 1998; 
Mao et al. 1999; Scandura et al. 2002). ETO is a member of the nuclear 
protein family (Feinstein et al. 1995) and functions as a transcriptional 
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repressor by interacting with promyelocytic leukaemia zinc finger (PLZF) 
and Gfi-1 that regulate haemopoiesis (Melnick et al. 2000; Davis et al. 
2003). Further, ETO has been shown to be involved in the recruitment of 
histone deacetylase (HDAC) proteins in the multi-protein complexes, such as 
N-CoR, SMRT or Sin3 (Jakubowiak et al. 2000).  
1.6.1.6.1.2 AML1-ETO fusion protein 
AML1-ETO fusion protein dominantly perturbs the normal function of AML1 
as the truncated AML1 of AML1-ETO lacks the transcriptional-activating 
domain and CBP/p300 binding domain, hence inhibiting AML1-dependent 
transactivation (Okuda et al. 1998; Davis et al. 2003). It has been suggested 
that AML1-ETO fusion protein functions as a dominant negative regulator of 
wild type (WT) AML1 and as a transcriptional repressor, by recruiting co-
repressor NCoR/SMRT/HDAC complexes to DNA, through its ETO portion 
(Frank et al. 1995; Meyers et al. 1995; Uchida et al. 1997). AML1-ETO fusion 
protein functions as an activator of transcription by influencing the 
expression of genes controlled by AML1 protein. AML1-ETO fusion protein 
activates AML1 target genes, such as jagged1 (a notch-ligand that maintains 
proliferation of stem cells), ß-Catenin and Plakoglobin (involved in Wnt-
signalling) and anti-apoptotic gene BCL-2 (Klampfer et al. 1996; Alcalay et 
al. 2003; Muller-Tidow et al. 2004). Previous studies demonstrated that 
AML1-ETO protein was a suppressor of cell differentiation and inhibited key 
TFs involved in haemopoietic differentiation, like PU.1, C/EBPα and GATA-1 
(Petrovick et al. 1998; Mao et al. 1999). Also, AML1-ETO has been shown to 
physically interact and silence the E-protein family, particularly, 
HEB/TCF12, hence targeting DNA through E-box motifs (Zhang et al. 2004; 
Gardini et al. 2008). AML1-ETO has also been involved in the formation of 
pre-leukaemic cells with primitive cell-characteristics (expression of c-Kit) 
and defective differentiation potential (Beghini et al. 2000). Hence, AML1-
ETO is a multifunctional protein affecting various cell programs, such as 
differentiation, proliferation, apoptosis and self-renewal. However, 
additional mutations along with the formation of AML1-ETO are essential for 
the development of AML (Scandura et al. 2002).     
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1.6.1.6.2 MLL-ENL, t(11;19)(q23;p13.3) 
1.6.1.6.2.1 Cytogenetic and clinical characteristics of MLL translocations 
MLL has been associated with a chromosomal rearrangement at 11q23 and 
has been reported in both adult and paediatric AML and ALL patients 
(Djabali et al. 1992; Tkachuk et al. 1992). MLL translocations result in 
binding of N-terminal of MLL with DNA and its methytransferase domain with 
the C-terminal portion of its translocation partner (Yano et al. 1997). MLL 
translocation accounts for 10% of human acute leukaemia and has poor 
prognosis (Eguchi et al. 2005). The MLL has more than 60 translocation 
partner genes and has been involved in more than 100 recurrent 
translocations (Meyer et al. 2009). The most frequent MLL rearrangements 
include AF4, AF9, ENL, ELL and AF10. MLL-ENL fusion protein with t(11;19) 
translocation is frequently reported in infants and results in a medial 
survival of less than 1 year (Meyer et al. 2009; Muntean and Hess 2012). 
MLL protein is a member of the trithorax group family of proteins that is 
evolutionarily conserved (Ringrose and Paro 2004). It is a positive regulator 
of Hox gene expression through histone H3 lysine 4(H3K4)-methytransferase 
activity (Ringrose and Paro 2004). PHD (plant homeodomain) zinc-fingers 
located centrally in the MLL protein mediate homodimerisation and it’s 
binding to other nuclear proteins (Chang et al. 2010b; Milne et al. 2010). 
The C-terminal of MLL protein, called the SET domain, is involved in 
homodimerisation of the MLL protein, which is necessary for the interaction 
with mammalian ATP-dependent chromatin remodelling SWI/SNF complex 
(Milne et al. 2002; Nakamura et al. 2002). 
1.6.1.6.2.2 MLL-ENL fusion protein 
The MLL-ENL fusion protein is capable of initiating an aberrant self-renewal 
program in the targeted HSPCs, leading to transformation of both HSCs and 
myeloid progenitors, like CMPs and GMPs, to form LSCs (Horton et al. 2013; 
Krivtsov et al. 2013). The MLL-ENL fusion protein contains the N-terminal 
transactivating domain retained in the MLL gene portion and the C-terminal 
is replaced by the fusion partner i.e. ENL (Muntean et al. 2008; Yokoyama et 
al. 2010). Hence, both PHD zinc fingers and SET domain are lost from the 
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fusion protein. A previous publication showed that the conserved 
transcriptional activation domain of ENL was both necessary and sufficient 
to immortalise murine myeloid cells in vitro (Zeisig et al. 2005). ENL is a 
nuclear protein and evidence suggests that ENL, as a fusion partner, forms a 
higher-order super elongation complex (SEP), which is recruited to MLL-
target loci for transcriptional activation and elongation in MLL-ENL 
transformed cells (Lin et al. 2010). Further, studies demonstrated that 
DOT1L, a histone methyltransferase, is involved in MLL-ENL mediated 
oncogeneic transformation (Chang et al. 2010a; Jo et al. 2011). Evidence 
gathered from previous studies showed that the MLL-ENL fusion protein acts 
as a transcriptional regulator and induces aberrant expression of 
downstream targets of MLL, such as Hoxa7, Hoxa9, EPHA7, Meis1 and Pbx 
(Nakamura et al. 1996; Armstrong et al. 2002; Muntean and Hess 2012). 
Also, MLL-ENL has been shown to interact with c-Myc and to block cell 
differentiation (Schreiner et al. 2001). However, further research is 
essential to understand the precise mechanism for this aberrant 
transcriptional activity. 
1.6.1.6.3  Meis1 and Hoxa9 induced AML 
Hox family members represent TF with DNA binding domains consisting of 60 
amino acids, termed homeodomains (Boncinelli et al. 1989; Pearson et al. 
2005). Hox genes are important for embryonic development and are key 
regulators of haemopoiesis (Pearson et al. 2005). Among Hox genes, Hoxa9 
is highly expressed in haemopoietic progenitors and is linked with various 
forms of leukaemia (Argiropoulos and Humphries 2007). Elevated expression 
of Hoxa9 and Meis1 gene expression is often observed in AML patients and 
Hoxa9 is a highly correlated gene for poor prognosis in AML (Golub et al. 
1999; Lawrence et al. 1999; Afonja et al. 2000). Studies involving retroviral 
gene transfer models of AML showed that enforced overexpression of Hox 
genes, like Hoxa9, enhanced proliferation, causing leukaemia with long 
latency (Kroon et al. 1998). However, co-expression of Meis1 with Hoxa9 
accelerated the onset of AML suggesting an inevitable role of Hox pathways 
in leukaemic transformation (Kroon et al. 1998; Thorsteinsdottir et al. 
2001). 
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Meis1, a proto-oncogene, was identified as a common viral integration site 
in myeloid leukaemic cells of BXH-2 mice (Nakamura et al. 1996). Several 
studies have demonstrated that overexpression of Meis1, together with Hox 
gene or NUP98-Hox fusion gene, induced rapid onset of AML in murine BM 
transplantable models (Shen et al. 1997; Kroon et al. 1998; Lawrence et al. 
1999; Afonja et al. 2000; Kroon et al. 2001; Thorsteinsdottir et al. 2001; 
Pineault et al. 2002). Hoxa9 protein binds with TALE (3-amino-acid-loop-
extension) protein family members, like Meis and Pbx (Pre-B cell leukaemia 
homeobox), to form heterodimers that define the binding affinity and 
specificity of Hoxa9 (Shen et al. 1997). The molecular mechanism of 
interaction between Meis1 and Hox genes in leukaemic transformation is not 
fully understood. However, studies in Hoxa9 and NUP98-Hox models of AML 
demonstrated that Meis1 upregulated Flt3, suggesting Flt3 as a possible 
downstream target of Hoxa9 and Meis1 (Wang et al. 2005; Palmqvist et al. 
2006; Wang et al. 2006). This is further supported by the elevated Flt3 
levels reported in AML samples that correlate with high levels of Hoxa9 and 
Meis1 expression (Ozeki et al. 2004; Quentmeier et al. 2004). Nevertheless, 
characterisation of Meis1-Hoxa9 regulated pathways controlling AML 
development is essential.     
1.6.1.7 Retroviral transduction/ transplantation model 
Retroviral transduction of AML oncogenes or oncogenic fusions into murine 
primitive haemopoietic cells successfully generated the pathological AML 
(Lavau et al. 1997; Kroon et al. 1998; Zeisig et al. 2003). The retroviral 
transduction and transformation assay (RTTA) involves oncogenes and 
oncogenic fusions that are cloned into a retroviral expression vector, MSCV 
and transduced into primitive murine BM cells in vitro cultured in cytokines 
(IL-3, IL-6 and) substituted media (Lavau et al. 1997; Kroon et al. 1998; 
Lavau et al. 2000). Transduced cells are selected by reporter genes and 
transplanted into lethally irradiated recipients and are tracked for AML 
development (Lavau et al. 1997; Kroon et al. 1998; Lavau et al. 2000).  
RTTA mouse models have provided an insight into the clonality of AML and 
reinforced the need for more than one mutation to cause AML (Kroon et al. 
2001; Kelly et al. 2002a; Grisolano et al. 2003). RTTA of Flt3-ITD or 
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NUP98/HoxA9 resulted in myeloproliferative disorder (Yuan et al. 2001; 
Kelly et al. 2002b). However, genetic mutations in receptor tyrosine kinase 
such as Flt3 and TEL/PDGFβR coupled with transduction of oncogenic fusions 
(including PML-RARα or AML1-ETO) led to AML development in transplanted 
recipients (Kroon et al. 2001; Kelly et al. 2002a; Grisolano et al. 2003). The 
retroviral gene transfer system also shed light on the cell of origin of AML 
(Westervelt and Ley 1999). This model allowed investigators to test the 
oncogenic transformation potential of haemopoietic cells, including HSCs 
and cells along their differentiation hierarchy (Kroon et al. 2001; Huntly et 
al. 2004). RTTA studies of NUP98/HoxA9 generated oligoclonal AML in 
secondary recipients, suggesting HSCs as the target cells hit by the 
oncogenic fusions (Kroon et al. 2001). Retroviral introduction of oncogenes 
or oncogenic fusions is a great tool to explore the molecular pathways 
underlying AML (Wong et al. 2007; Yeung et al. 2010; Smith et al. 2011). 
Also, the transduction/transplantation could be taken forward to human 
cells and immunocompromised NOD/SCID mice that will provide a more 
relevant model for human AML and also serves as a novel model for 
preclinical therapeutic studies such as administration of small molecule 
tyrosine kinase inhibitors (Stover et al. 2005).  
Despite the merits of RTTA model, drawbacks include the influence of 
genetic background of the mice on the outcome of type and latency of 
leukaemia (Zhang et al. 1998; Kelly et al. 2002a). Additionally, retroviral 
transduction resulted in the dysregulated transgene expression controlled by 
the long terminal repeat (LTR) promoter (Westervelt et al. 2003; Ren 2004). 
Hence, the irregulated expressions of oncogenes or oncogenic fusions are 
toxic or are associated with increased disease penetration (Westervelt et al. 
2003; Ren 2004). Also, the lack of control over proviral integration site in 
the genome leads to insertional mutagenesis and MSCV retroviral vector by 
itself is associated with leukaemogenesis (Kohn et al. 2003; Du et al. 2005).   
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1.6.2 Hypothesis: 
The main goal of my PhD is to test the hypothesis that hypoxia-signalling 
pathways regulate HSC fate decisions and under certain pathological 
conditions facilitate leukaemogenesis. I focused on the following objectives: 
a. To study the role of Hif-α in normal haemopoiesis and HSC functions.
b. To explore and validate the role of the Cited2-Mcl-1 pathway in
leukaemogenesis.
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 Mouse genetics 2.1
2.1.1 Mouse husbandry 
All the experiments were approved by the Home Office under the project 
licence 60/4076 and personal licence (60/12879). Mice were housed in the 
dedicated facility that meets the “Code of practice for the housing and care 
of animals used in scientific procedures”. Vigilant measures were followed 
to comply the 3Rs principles. Special care was taken to provide pathogen 
free environment. Mice that were 6-8 weeks old were used for breeding. 
Breeders were housed as pairs or trios. Pups were weaned at 3-4 weeks of 
age. At weaning, the pups were ear notched to give each one a unique 
identity and the ear-notches were collected for genotyping.  
2.1.2 Generation of CKO transgenic mice 
Hif-1α
fl/fl
 and Hif-2α
fl/fl
 mice were provided by Professor Sir Peter Ratcliffe
on a collaborative basis. CKO for Hif-1α were generated using the Cre-loxP 
technology (Gu et al. 1994) by Ryan et al (Ryan et al. 2000). A conditional 
allele of Hif-1α was generated by introducing a loxP site at intron 1 and a 
loxP flanked neo-cassette at intron 2. The target vector was introduced by 
electroporation into F1-derived R1 embryonic stem cells. The homologous 
recombination of the target vector resulted in modified Hif-1α allele with a 
loxP site 59 and loxP-flanked neo-cassette 39,both at exon 2. Transient 
expression of cre recombinase in the targeted ES cells, excised neomycin 
resistant gene. Clones containing loxP-flanked exon 2 and deleted neo-
cassette, as confirmed by PCR were injected into the blastocysts of 
recipient C57BL/6. This generated Hif-1α
fl/fl
 chimeric mice with normal
levels of HIF-1α expression (Figure 2.1). Crossing Hif-1α
fl/fl mice with cre
recombinase mice resulted in excision of exon 2, producing modified Hif-1α 
mRNA transcript with non-functional protein. Hif-1α
fl/fl mice imported from
Prof. Ratcliffe’s lab were then crossed to C57BL/6 mice carrying cre under 
the Mx-1 promoter (HIf-1α
+/+
 Mx-1 Cre) (Table 2.1). This generated Hif-1α 
CKO mice in which the deletion of Hif-1α  is induced by administration of 
immuno-stimulant pIpC.  
Chapter 2 
91 
Hif-2αfl/fl mice were generated by Gruber et al (Gruber et al. 2007). In order 
to generate conditional allele for Hif-2α, loxP sites were introduced at 0.5 
Kbp upstream and downstream (with PGK-neo cassette) of exon 2. The 
construct with loxP sites was transfected into the 129X1/SvJ derived RW-4 
embryonic stem cells. ES cell clones with correct 3-loxP allele were injected 
to the recipient blastocysts for germ line transfer of targeted allele. The 
offspring with heterozygous 3-loxP allele was crossed to E2A-cre to remove 
loxP flanked PGK neomycin cassette (Figure 2.1). Mice with exon 2-flanked 
loxP sites were crossed with C57BL/6 WT mice to separate E2A-Cre. Cre- 
mediated recombination lead to the loss of loxP-flanked exon2 and 
produced mutant Hif-2α transcript. The Hif-2αfl/fl mice obtained from Prof. 
Ratcliffe’s lab were crossed to C57BL/6 mice carrying cre under the Mx-1 
promoter. This generates Hif-2α CKO mice in which the deletion of Hif-2α is 
induced by administration of immuno-stimulant pIpC(Table 2.1). 
Figure 2. 1: Targeting strategy for generation of Hif-loxP alleles. 	  Structure of WT allele of Hif-1α or Hif-2α, targeting vector, 3-loxP allele and conditional 2- 
allele for Hif-1α or Hif-2α is generated.  LoxP sites are introduced at intron 1 and 2 with frt-
PGK::NeoR-frt (FNF) cassette sites at intron 2 flanked by loxP site. – loxP sites.
Cited2fl/fl transgenic mice were generated by MacDonald et al (MacDonald et 
al. 2008). The mice were given to us by Professor Shoumo Bhattacharya 
(University of Oxford) on a collaborative basis. The targeting vector was 
constructed by introducing  sites in the intron 1 followed by frt-PGK::NeoR-
frt (FNF) cassette downstream of exon 2 and second  site as well as splice-
acceptor-internal-ribosome-entry-site-lacZ cassette (IRES-Lacz) and a 
thymidine kinase (TK) cassette was introduced. The targeting vector 
Exon 2 
neo Exon 2 
Wt Hif-1α allele/ 
Wt Hif-2α allele  
neo Exon 2 
Exon 2 
Targeting vector 
3-loxP allele 
2-loxP allele 
X 
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linearised by NotI and electroporated into 129Sv derived ES cells. The ES 
cells were selected for right target by PCR and injected in to blastocysts of 
CD57BL/6J and crossed to C57BL/6J females (Figure 2.2). Heterozygous 
mice generated were crossed to FLPeR mice to remove the FNF selection 
cassette and generated Cited2+/fl mice. These mice were intercrossed to 
obtain Cited2fl/fl mice. The Cited2fl/fl mice from Prof. Bhattacharya were 
crossed to C57BL/6 mice carrying cre under the Mx1 promoter or Vav 
promoter to generate CKO mice (Table 2.1).  
Figure 2. 2: Targeting stratergy for the generation of Cited2 2-loxP allele. 
Structure of WT allele of Cited2, targeting vector, targeted allele and conditional loxP allele for 
Cited2 is shown. LoxP sites are introduced at introns and frt-PGK::Neo-frt (FNF) cassette 
downstream of exon2, followed by a second loxP site, a splice-acceptor-internal ribosome entry 
site-lacZ cassete, and a thymidine kinase (TK) cassette. –loxP site and block square-ORF.
Mcl-1 transgenic mice were generated by Campbell et al that express a 
FLAG-tagged mouse Mcl-1 cDNA in a vector bearing transcriptional 
regulatory sequences from the vav gene (Campbell et al. 2010b). Transgenic 
vector with murine Mcl-1 cDNA was introduced with to N-terminal FLAG 
epitope and inserted into Vav transgenic vector (Ogilvy et al. 1998). The 
transgene was excised by digesting with HindIII and into C57/BL6 mice by 
pronuclear injection as described above. Successful expression of transgene 
was confirmed by PCR using specific primers to the SV40 pA region 
(Campbell et al. 2010a) (Figure 2.3).  
FNF 
Targeting vector 
Targeted allele 
2-loxP allele 
X 
Exon 1 Exon 2 
Cited2 Wt allele 
Exon 2 Exon 1 
lacZ TK 
Exon 2 Exon 1 
lacZ 
Exon 2 Exon 1 
FNF lacZ 
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Figure 2. 3 Schematic representation of vector overexpressing murine Mcl-1. 
 Transgenic mice were generated that express a FLAG-tagged mouse Mcl-1 cDNA in a vector 
bearing transcriptional regulatory sequences from the vav gene. 
Desired genotype Crosses 
Hif-1α+/+: Hif-2αfl/fl 
Hif-1α+/+: Hif-2αfl/fl Mx1 
Cre 
Hif-1α+/+: Hif-2α+/fl X Hif-1α+/+: Hif-2α+/fl
Hif-1α+/+: Hif-2αfl/fl  X Hif-1α+/+: Hif-2αfl/fl 
Hif-1α+/+: Hif-2αfl/fl Mx1Cre X Hif-1α+/+: Hif-2αfl/fl 
Hif-1α+/fl: Hif-2αfl/fl 
Hif-1α+/fl: Hif-2αfl/fl Mx1 
Cre 
Hif-1α+/+: Hif-2α+/fl X Hif-1α+/fl: Hif-2α+/fl
Hif-1α+/fl: Hif-2αfl/fl X Hif-1α+/fl: Hif-2αfl/fl 
Hif-1α+/fl: Hif-2αfl/fl Mx1Cre X Hif-1α+/fl: Hif-2αfl/fl 
Hif-1αfl/fl: Hif-2αfl/fl 
Hif-1αfl/fl: Hif-2αfl/fl Mx1 Cre 
Hif-1α+/fl: Hif-2α+/fl X Hif-1α+/fl: Hif-2α+/fl
Hif-1αfl/fl: Hif-2αfl/fl X Hif-1αfl/fl: Hif-2αfl/fl 
Hif-1αfl/fl: Hif-2αfl/fl Mx1Cre X Hif-1αfl/fl: Hif-2αfl/fl 
Cited2fl/fl 
Cited2fl/fl Vav-iCre 
Cited2+/fl: Cited2+/fl
Cited2fl/fl: Cited2fl/fl 
Cited2fl/fl Vav-iCre: Cited2fl/fl 
Cited2fl/fl Vav-iCre 
Cited2fl/fl Vav-iCre Mcl-1 
Cited2fl/fl Vav-iCre: Cited2fl/fl
Cited2fl/fl Vav-iCre: Cited2fl/fl Mcl-1 
Table 2. 1: Strategy used to generate CKO mouse models for Hif-1α , Hif-2α  and Cited2. 
Transgenic mice with codon improved cre (iCre), with reduced epigenetic 
silencing in mammals) (Shimshek et al. 2002) transgene expression regulated 
by the haemopoietic specific Vav promoter element were generated by de 
Boer et al (de Boer et al. 2003a). The endogenous murine Vav gene is 
expressed in all the haemopoietic cells and Vav promoter element drives the 
expression of transgene efficiently and exclusively in all haemopoietic 
system (Ogilvy et al. 1998). Tissue restricted expression of iCre driven by 
Vav promoter was confirmed in all the haemopoietic system including 
spleen, thymus, lymph nodes with an exception in the testis (de Boer et al. 
2003a) (Figure 2.4).    
F Mcl-1 
Vav Exon  1 
Vav Intron 1 
Elements 
Vav 5’ 
ATG 
     Intron 1 
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Figure 2. 4: Model of Vav iCre mediated gene deletion. 
Conditional deletion of Cited2 floxed allele in haemopoietic tissues is mediated by expression 
of iCre driven by the Vav promoter. Once recombined, the excision of floxed Cited2 exon 2 
results in expression of lacZ cassette driven by Cited2 promoter confirming the gene 
deletion.  – loxP site, block square – ORF.  
Mx1-Cre inducible gene deletion system in mice provides an advantage of 
gene deletion at given time during ontogeny (Kuhn et al. 1995). The 
expression of Cre recombinase is regulated by promoter element of Mx1 
gene. Endogenous Mx1 gene is silenced in the healthy mice and expressed as 
a defense to viral infection (Hug et al. 1988). The expression of Mx1 
promoter can be transiently activated to high levels by administration of 
interferon α (INF-α), interferon β (INF-β) or an IFN inducer like pIpC, a 
synthetic double-stranded RNA (Kuhn et al. 1995). pIpC is a analog of ds-RNA 
that mimic the molecular pattern associated with viral infection (GE 
Healthcare, Cat No: 27-4732-01) . pIpC is recognised by Toll-like receptor 3 
(TEL3) resulting in production of type-I IFN-β, inflammatory cytokines and 
chemokines (including IL-6, TNF-α, Cxcl-10) and activate NF-kB TF 
X 
Cited2fl/fl 
lacZ 
Exon 2 
iCreVav 
Cited2fl/fl Vav iCre
lacZ 
Exon 2 
iCreVav F2 generation 
lacZ iCre 
Cited2fl/fl Vav iCre
F2 
generation 
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(Alexopoulou et al. 2001; Matsumoto et al. 2002). The mice harboring a 
floxed target gene and Mx1-Cre transgene when treated with pIpC results in 
the activation of Mx1 promoter, drives the Cre expression that recognises 
the loxP sites and by homologous recombination generates inactivating 
mutation of the target gene (Kuhn et al. 1995) (Figure 2.5). 
Figure 2. 5: Model of Mx1 Cre mediated gene deletion. 
Conditional deletion of Hif-α floxed allele is mediated by expression of Cre driven by the Mx1 
promoter. pIpC administration activates the Mx1 promoter leading to Cre expression. The Cre 
mediated recombination at the loxP site of exon 2 results in the excision of floxed Hif-α allele. 
Supplier details of all the reagents used in this thesis is summarised with the 
catalogue numbers in appendix Supplementary table. 
Hif-αfl/fl
CreMx1 
Exon 2 
Hif-αfl/fl Mx1 Cre
Exon 2 
pIpC pIpC 
CreMx1 
Hif-αΔ/Δ Mx1 Cre
Hif-αfl/fl
CreMx1 
Hif-αΔ/Δ Mx1 Cre
Exon 2 
Exon 2 
Hif-αfl/fl
Exon 2 
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2.1.3 Preparation and administration of pIpC 
pIpC is a synthetic double stranded RNA. It induces interferon response in 
the mice activating the Mx1 promoter. Thus inducing the deletion of floxed 
allele in the Mx1 driven cre mice (Kuhn et al. 1995). To prepare 1mg/ml of 
pIpC solution, 100ml of sterile PBS was added to 265mg of lyophilised pIpC 
and dissolved at 50oC for 2-3 hours. 165ml of pre-warmed PBS was added to 
pIpC solution to make up the volume to 265ml. The solution was placed at 
50oC for additional 1hour until pIpC was fully dissolved. The solution was 
allowed to cool overnight at room temperature and 1ml aliquots of 1mg/ml 
concentration were prepared and stored at -20oC.  
Mice with 8-12 weeks of age received 6 doses of pIpC (300mg/dose) via 
intra-peritoneal (IP) injections every alternate day. Injected mice were 
monitored for the health status. The mice were sacrificed at day 11 after 
the last injection. Deletion of the floxed gene was confirmed by PCR of 
genomic DNA. Transplanted recipients with floxed allele of Hif-1α and/or 
Hif-2α received 5 doses of pIpC (250mg) via IP injections following 8 weeks 
after transplant every alternate day.   
2.1.4 Genotyping 
2.1.4.1 Extraction of genomic DNA 
Genomic DNA was extracted from ear notch samples and haemopoietic cells 
using the ISOLATE II Genomic DNA Kit. The tissue samples or cell pellets 
were lysed in lysis buffer and proteinase K solution at 56°C, for 4 hours. 
Ethanol was then added to provide optimal DNA binding condition. The 
lysate was passed through spin column with silica membrane enabling 
binding of DNA. Remnant salts, cellular components and other impurities 
were removed in two wash steps by centrifugation. Genomic DNA was eluted 
from the silica membrane using preheated ddH20. DNA concentration was 
measured by nanodrop spectrometer (Nanodrop ND1000 Spectrophotometer; 
Labtech International Ltd, East Sussex, UK) by recording the absorbance at 
wavelength 260nm. The purity of DNA was assessed by the ratio of 
absorbance at 260nm and 280nm. DNA with A260/A280 ratio of 1.7-1.9 was 
considered pure. 
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2.1.4.2 Polymerase chain reaction (PCR) 
The genomic DNA extracted was used to determine the genotypes of the 
chimeric mice. Primers for the PCR reactions are summarised in Table 2.2. 
Each PCR reaction with final volume of 25µl contained 2ng – 200ng of DNA 
template, 10µM of each of the primers, 2mM of MgCl2, 1X coloured buffer 
solution, 0.2mM of each of the dNTPs and 1 unit of Mango Taq (Bioline) 
(Table 2.3-2.7). The PCR product was loaded on to the Agarose gel directly 
and analysed by electrophoresis.  
Gene Primer Band length 
Cited2 
WT 
5'-AAA GGC GCT AAG GAT AGA CAC-3' 
5'-ATA CTG AGG TCC CTG GCA C-3' 
300bp 
Floxed 
5’-ATA ATA ATA ACC GGG CAG G-3’ 
5’-ATA CTG AGG TCC CTG GCA C-3’ 
280bp 
Hif-1α WT 
5'-GCA GTT AAG AGC ACT AGT TG-3' 
5'-GGA GCT ATC TCT CTA GAC C-3' 
200bp 
Floxed 
5'-TTGGGGATGAAAACATCTGC-3' 
5'-GGA GCT ATC TCT CTA GAC C-3' 
2-loxP-250bp 
1-loxP-280bp 
Hif-2α WT 
5'-CAG GCA GTA TGC CTG GCT AAT TCC AGT T-3' 
5'-CTT CTT CCA TCA TCT GGG ATC TGG GAC T-3' 
430bp 
Floxed 
5'-CAG GCA GTA TGC CTG GCT AAT TCC AGT T-3' 
5'-GCT AAC ACT GTA CTG TCT GAA AGA GTA GC-3' 
2-loxP– 460bp 
1-loxP– 360bp 
Vav-iCre 
5'-CCG AGG GGC CAA GTG AGA GG-3' 
5'-GGA GGG CAG GCA GGT TTT GGT G-3' 
380bp 
Mx1-Cre 
5'-CGT TTT CTG AGC ATA CCT GGA-3' 
5'-ATT CTC CCA CCG TCA GTA CG-3' 
400bp 
Mcl-1 
5’-GGACTACAAAGACGATGACG-3’ 
5’-GGTATAGGTCGTCCTCTTCC-3’ 
500bp 
Table 2. 2: Allele specific primers used for genotyping of Cited2, Hif-1α and Hif-2α mutant mice.
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Temperature Time 
1 95ºC 5 min 
2 95ºC 30 sec 
3 67.5ºC 30 sec (-0.7ºC / cycle) 
4 72ºC 40 sec 
From step 2 repeat 12 cycles 
5 95ºC 30 sec 
6 60ºC 30 sec 
7 72ºC 40 sec 
From step 5 repeat 22 cycles 
8 72ºC 5 min 
9 10ºC Forever 
Table 2. 3: Touchdown PCR programme used for genotyping Cited2 mutant mice tant mice.
Step Temperature Time 
1 94ºC 5 min 
2 94ºC 30 sec 
3 57ºC 45 sec 
4 72ºC 60 sec 
From step 2, repeat 35 cycles 
5 72ºC 5 min 
6 10ºC Forever 
Table 2. 4: PCR programme used for genotyping Hif-1α and Hif-2α mutant mice ant mice.
Step Temperature Time 
1 94ºC 15 min 
2 95ºC 40 sec 
3 50ºC 30 sec 
4 72ºC 60 sec 
From step 2, repeat 33 cycles 
5 72ºC 10 min 
6 14ºC Forever 
Table 2. 5: PCR programme used for genotyping Mcl-1 mutant mice. 
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Step Temperature Time 
1 95ºC 5 min 
2 94ºC 40 sec 
3 58C 40 sec 
4 72ºC 30 sec 
From step 2, repeat 30 cycles 
5 72ºC 5 min 
6 10ºC Forever 
Table 2. 6: PCR programme used for genotyping Vav-iCre mice. 
Step Temperature Time 
1 95ºC 5 mn 
2 95ºC 30 sec 
3 67ºC 45 sec 
4 72ºC 1 min 
From step 2, repeat 39 cycles 
5 72ºC 5 min 
6 10ºC Forever 
Table 2. 7: PCR programme used for genotyping Mx1-Cre mice 
2.1.4.3 Gel electrophoresis 
Agarose gel of required concentration was prepared by dissolving agarose in 
1X TAE buffer (40 mM Tris acetate, pH approx. 8.3, containing 1 mM EDTA). 
Sybr safe, a substitute for ethidium bromide was added to the gel at 
0.0001X concentration. The gel was run at 100V in 1X TAE buffer and the 
band length was measured against a standard DNA ladder (Bioloine easy 
ladder I).   
 Molecular and cell biology 2.2
2.2.1 Cultural conditions of cell lines and primary murine cells 
Platinum E cells are the retroviral packaging cell lines derived from 293T 
cells. These were kindly gifted by Dr. Peter Laslo (Leeds Univeristy). The 
cells have EF1alpha promoter region and high expression of gag, pol and 
ecotropic env structural proteins. IRES drive the expression of selectable 
markers puromycin and blasticidin resistance. The cells are cultured in 
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Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 2.0 mM L-glutamine, 100 units/ml 
penicillin and 100 units/ml streptomycin. The efficiency of cells to produce 
stable retrovirus was maintained by selection against puromycin (1µg/ml) 
and blasticidin (10µg/ml), every 2 months. The cells were split when they 
were 70%-80% confluent (Morita et al. 2000).  
HEK 293 cells are transformed human embryonic kidney cell with sheared 
adenovirus 5 DNA (Graham et al. 1977). The cells lines were used to produce 
lentivirus. Cells were cultured in DMEM, supplemented with 10% heat-
inactivated FBS, 2.0 mM L-glutamine, 100 units/ml penicillin, and 100 
units/ml streptomycin.   
NIH 3T3 cells are immortalised murine embryonic fibroblasts. They were 
generated from outbred NIH Swiss mice using 3T3 protocol (Jainchill et al. 
1969). NIH 3T3 cells were cultured in DMEM, supplemented with 10% heat-
inactivated FBS, 2.0 mM L-glutamine, 100units/ml penicillin, and 
100units/ml streptomycin. These cells were used for retroviral and lentiviral 
titration experiments. 
Adherent cells were passaged when they were 70% -80% confluent. Cells 
were washed with PBS, trypsinised and cell pellet was re-suspend in 
complete DMEM medium. Cell viability was calculated by trypan blue 
staining and haemocytometer.  
To freeze harvested cells (cell lines and primary murine cells), cell pellet 
was re-suspended in freezing solution (FBS and 10% DMSO) and aliquoted to 
pre-chilled 2ml cryovials. Each vial contained about 0.5E6-3E6 cells. These 
cryovials were transferred to Mr.Frosty (allows slow cooling at the rate of -
10°C/min) and placed overnight at -80°C. The cells were then moved to 
liquid nitrogen for long-term preservation. In order to culture cells from 
liquid nitrogen, cells in the cryovials were thawed rapidly at 37°C and were 
swiftly re-suspended in 10ml of FBS, pre-warmed at 37°C. The centrifuge at 
450xg for 5min and cells were plated at respective densities based on the 
cell viability.  
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HSPCs were grown in Iscove's Modified Dulbecco's Media (IMDM) 
supplemented with cytokines including 40ng/ml SCF, 20ng/ml Interlukine-3 
(IL-3), 20ng/ml Interluekine-6 (IL-6) along with 10% heat-inactivated FBS 
(Invitrogen), 2.0 mM L-glutamine, 100 units/ml penicillin and 100 units/ml 
streptomycin. Cells were plated at density of 0.3E6-1E6 cells/ml.  
2.2.2 Retroviral/lentiviral gene transfer and expression 
2.2.2.1 Design and production of retroviral/lentiviral constructs 
The retroviral vector with oncogenic fusions pMSCVneo MLL-ENL, pMSCVneo 
AML1-ETO, pMSCVpuro Meis1a pMSCVneo Hoxa9 and Control vector 
pMSCVneo, pMSCVpuro were kindly gifted by Dr. Tim Somervaille 
(Manchester University) and Prof. Eric So (King’s College London).  
Murine Stem Cell Virus (pMSCV) vector was employed for the consistent 
high-level expression of gene of interest in haemopoetic system (Hawley et 
al. 1996). A 6kb fragment encoding MLL-ENL fusion transcript was inserted 
using the EcoRI site downstream of proviral LTR region of pMSCV vector. LTR 
region drives the transcription of the inserted cDNA. The murine PGK-1 
internal promoter encodes the puromycin resistant gene and enables the 
selection of infected haemopoetic cells by making them resistant to 
antibiotics (Lavau C et al 1997) (Figure 2.6). 
cDNA encoding Meis1a was cloned into the EcoRI and HpaI site of MSCVPGK-
PAC vector. The PGK promotor controls the expression of puromycin 
resistance cassette. The LTR region regulates the expression of Meis1a gene 
expression. The complete length of murine Hoxa9 fragment was inserted at 
BamHI-XhoI site in the pMSCV vector. The LTR region drives the expression 
of Hoxa9 gene while the PGK promoter encodes the neomycin resistance 
gene. The cells infected with both Meis1a and Hoxa9 were selected by 
double resistance against puromycin and neomycin (Kroon et al. 1998) 
(Figure 2.6). 
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Figure 2. 6: Schematic representation of the retroviral vectors employed for 
transformation of murine HSPCs. 
A CSI lentiviral vector (obtained from Professor Tariq Enver, UCL) was used 
for the expression of Cited2 and Mcl-1 genes in the haemopoietic cells. The 
vector consists EF-1alpha promoter that drives the expression of gene of 
interest and an IRES region that regulates the expression of reporter GFP. 
Human CITED2 or MCL-1 cDNA was inserted at the BamHI site, downstream 
of the promoter region (Personal communication with Prof. Kamil Kranc). 
Cells incorporated with gene of interest were sorted based on the 
expression of GFP. 
2.2.2.2 Transformation and preparation of plasmid DNA 
The plasmids were transformed into a competent bacterial cell. 2µl of 
plasmid was mixed with 25µl of competence bacteria in an ependoff tube. 
After 15 min of incubation on ice, the tube was placed in water bath at 42°C 
for 30 seconds followed by 5 min of incubation on ice. The mix was streaked 
on the LB agar plate containing 100µg/ml of ampicillin and incubated 
overnight at 37°C. An individual colony from the LB agar plate was selected 
LTR PGk-neo LTR 
MLL ENL 
LTR PGk-neo LTR 
AML1 ETO9a 
LTR PGk-puro LTR 
Meis 1 
LTR PGk-neo LTR 
Hoxa9 
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and cultured in 250ml of LB broth with ampicillin (100ug/ml) for 14-16 hours 
at 37°C in the bacterial shaker. Large volume of plasmid DNA was prepared 
using maxi-prep kit (Qiagen) using manufacturer’s instructions. DNA was 
eluted in pre-warmed ddH2O, quantified and quality tested by nanodrop as 
described in section 2.1.3.1. 
2.2.2.3 Retrovirus/lentivirus production 
Platinum-E cells and HEK 293 cells were used to transfect pMSCV constructs 
and lentivectors, respectively. 60mm tissue culture dishes were coated with 
0.1% sterile gelatine for 20 minutes at room temperature. The cells were 
trypsinised with extra care to obtain single cell suspension. 2E6 cells 
suspended in 10ml of substituted DMEM were plated into each 60mm dish 
and incubated at 37°C, 5% CO2 for 24 hours. For transfection, 10µg of 
plasmid DNA and 3µg of VSV-G packaging plasmid (encodes for viral envelop 
protein) was diluted in sterile H2O to make up the volume to 420ml in sterile 
Bijou tubes. For lentiviral transfection, additional packaging plasmid p8.91 
that encodes for viral capsid (gal, pol, REE sequence) was used. 60µl of 2M 
CaCl2 was added to the above mix, gentle finger flicked and incubated at 
room temperature for 10 min. 500µl of 2X HBS solution (NaCl, KCL, Glucose, 
HEPES, Na2HPO4, pH 7.1) in the bijou tube was bubbled using 1ml pipette 
while simultaneously adding the plasmid and CaCl2 solution drop wise into 
the 2X HBS solution. The transfection mix was incubated at room 
temperature for 20 minutes; added drop wise into the packaging cells and 
returned back to the incubator. 
 After 12-16 hours of incubation, the cells were fed with fresh DMEM without 
any substitution and cultured for 24-48 hours. The virus supernatant was 
collected at periods of 24 and 48 hours, filtered using 0.45µm filters and 
snap frozen as 1ml aliquots using dry ice. These aliquots were stored at -
80°C for future use.  
NIH3T3 cells were used to test the infection efficiency. 3T3 cells were 
plated at 0.1-0.3E5 cells/ml in 6 well plates in complete DMEM and 
incubated for 6-8hours. Once the cells were adherent, DMEM was replaced 
by infection cocktail (virus supernatant and 4ug/ml polybrene). After 12-16 
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hours of infection, the cells were washed and substituted with fresh media. 
The infection efficiency for retrovirus was tested by culturing the infected 
cells and uninfected cells in substituted DMEM along with antibiotics 
puromycin (1.5mg/ml) and neomycin (1mg/ml) for 48 hours. The infection 
efficiency was recorded by comparing the percentage of live cells in 
infected and uninfected cells. To test the lentivirus infection efficiency, 
infected cells were examined for GFP expression by flow cytometry. 
2.2.2.4 Isolation and transduction protocol of murine HSPCs 
Cells were extracted from the BM as described in section 1.42. The cells 
were pelleted by centrifugation (450g for 5minutes) and re-suspended in 
RBC lysis buffer (NH4Cl) for 1 minute at room temperature. The cells were 
washed in sterile wash buffer (PBS with 2% FBS). Up to 100E6 cells were re-
suspended in 100µl of wash buffer and 2.5µl of CD117 (c-Kit) magnetic 
beads. The cells were incubated in dark rotor at 4°C for 20 minutes, washed 
and re-suspend in 3 ml of wash buffer. A MS column was placed in the MACS 
separation unit attached to the MACS multi-stand. To equilibrate the MS 
column, 3 ml of wash buffer was passed through the column via gravity. The 
cells were added through the 0.45µm filter into the MS column and allowed 
to flow through. To ensure the clear separation of c-Kit positive cells, the 
MS column was washed 3 times using a wash buffer (PBS/2% FBS) via gravity. 
The flow through from the MS column was collected to compare the purity 
of isolated of CD117 cells. 5ml of wash buffer was added to the MS column 
and immediately removed from the MACS separation unit. Using the plunger, 
the cells attached to the column via magnetic beads were flushed into the 
15ml falcon tube. This step was repeated to ensure all the cells were 
extracted from the column. The c-Kit positive cells (HSPCs) were counted 
and checked for purity of c-Kit positive cells by staining with c-Kit antibody 
and flow cytometry.  
For each infection, 0.5E6 HSPCs were plated in 500µl of IMDM with 40ng 
SCF, 20ng IL-3, 20ng IL-6, 10%FBS, 2mM L-glutamine, 100U/ml of penicillin 
and streptomycin (supplemented IMDM) and incubated overnight. Cells along 
with the media were transferred into 50ml falcon tubes with 1ml of virus 
supernatant and 4µg/ml of polybrene. The falcon tubes were placed in 
Chapter 2 
106 
centrifuge pre-warmed to 32°C and spun for 2 hours at 800g. After 
spinoculation, the cells were re-suspended in 500ul of fresh supplemented 
IMDM and returned to the incubator for 6-8 hours. For second run of 
infection, 500ul of virus with polybrene (4mg/ml final concentration) were 
added drop wise into the cells and returned to the incubator for overnight 
infection. Spinoculation procedure was repeated as mentioned before. 
Retrovirus transduced cells were cultured in supplemented IMDM for 24-36 
hours, later transferred to antibiotic medium for selection of puromycin 
and/or neomycin resistance. Lentivirus transduced cells were cultured for 
24 hours and checked for infection efficiency by expression of GFP using 
flow cytometry.  
2.2.3 Serial re-plating transformation assay 
HSPCs, retrovirally transduced with proto-oncogenes are selected for 
antibiotic resistance for 36 hours. The viable cells positively selected for 
antibiotic resistance were counted by tryphan blue staining. Methylcellulose 
(M3231, Stem cell technologies) was thawed at 37oC and supplemented with 
20ml IMDM, 20 ng/ml SCF, 10 ng/ml, IL-3, 10 ng/ml IL-6, 10 ng/ml GM-CSF, 
100Units/ml penicillin, and 100mg/ml streptomycin. Contents of 
methylcellulose were mixed by vigorous shaking and aliquoted into 15 ml 
falcons as 2.25ml aliquots, stored at -20oC. HSPCs are re-suspended in IMDM 
and appropriate antibiotics [puromycin (1.5µg/ml) and/or neomycin 
(1mg/ml)] making up the final volume to 250µl. Cell suspension was 
immediately added to the pre-warmed methylcellulose aliquot and vortex 
for even mixing of cells. 1ml of methylcellulose with 10E3 cells was plated 
into each well of 6 well plates using 18g blunt needle attached to 3ml 
syringe. The plates were humidified and incubated for 6 days at 37oC, 5% 
CO2.  
At day 6, colonies were counted and the morphology of the colonies was 
examined. To re-plate CFCs, methylcellulose wells were washed using IMDM 
with 2% FBS using 10ml syringe. The process was repeated to extract all the 
colonies from the well into the 50ml falcon. Cells were centrifuged a 450xg 
for 10minutes and the step was repeated with fresh IMDM (2% FBS) to get rid 
of any remnant methylcellulose. Cell pellets were re-suspended in 1 ml of 
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IMDM and counted for viable cells using tryphan blue. Cells were plated onto 
methylcellulose at density of 10E3 cells/well as mentioned above with 
appropriate antibiotics and incubated for 6 days at 37oC, 5% CO2. An aliquot 
of cells were used for immunostaining and the rest was frozen in multiple 
aliquots. The process is repeated until CFC-3 to produce pre-LSCs (Figure 
2.7). 
Figure 2. 7: Schematic representation of RTTA.  
BM cells from donor mice are enriched for haemopoietic stem and progenitor cells (HSPCs), 
transduced with retrovirus expressing fusion genes AML1-ETO9a, MLL-ENL or co-expression of 
Meis1 and Hoxa9 are serially re-plated to form pre-LSCs. At CFC-3, pre-LSCs are injected in to 
lethally irradiated mice that generate LSCs and transplantable AML.  
 Isolation and flow cytometry for haemopoietic 2.3
cells from the BM, Spleen, PB and Thymus 
Dissected tibias and femurs were crushed and the cells were collected in 
PBS (2% FBS) by filtering through 70µM filters. Spleen and thymi were 
dissected and crushed using in 2ml PBS (2% FBS) with 5ml pluger. Isolated 
cells were collected in PBS (2% FBS). Peripheral blood (PB) was incubated in 
RBS lysis buffer (NH4Cl, Sigma) for 20 min at room temperature and washed 
with PBS/2% FBS. 
BM, spleen and PB cells (10,000,000) were incubated in CD16/CD32 antibody 
in 100µl of cold PBS/2% FBS for 5 minutes on ice and were stained with 
conjugated antibody for immunophenotypic analysis by flow cytometry 
(FACS). For slam staining, cell surface markers with rat anti-lineage (CD2, 
CD3, CD5, CD4, CD8a, Gr-1, CD19, B220, Ter119) with biotin (BD 
biosciences), Streptavidin-PE or streptavidin-PB, c-Kit-APC/APC-Cy7, Sca-1-
APC-Cy7/PECy7, CD150 APC/PE-Cy7, CD48-PE (BD Biosciences, Biolegend) 
HSPCs Pre- LSCs Pre- LSCs     LSCs 
Healthy recipient  
mice 
Leukemic 
mice Donor mice 
MLL-ENL 
AML1-ETO9a 
Meis1-Hoxa9 
1st 2nd 3rd 
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was used. For lineage staining, antibodies Gr-1-APC/Pe-Cy7, CD11b-PE/PE-
Cy7 (myeloid cells), CD19-APC-Cy7, B220-PE (B-cells), CD4-APC/PE, Ter119-
FITC (erythroid) and CD8a-APC/PE (T-cells) (Table 2.8) were used. Cells 
were incubated with antibody cocktail in cold PBS/2% FBS for 20 minutes in 
dark on ice. Washed with PBS/2% FBS and re-suspended in 500µl of PBS/2% 
with viability dye DAPI. FACS analysis was performed using FACSCanto II flow 
cytometer (BD Biosciences) and the data acquired through BD FACSDiva (BD 
Biosciences) was analysed by Flowjo software (Tree Star Inc., USA).   
Conjugated 
fluorochrome Antigen Host Clone Concn Supplier Cat # 
Biotin CD2 Rat IgG2b, λ RM2-5 1/800 BioLegend 100103 
Biotin CD3 Hamster IgG1, K 145-2C11 1/800 BD Biosciences 553060 
PE CD4 rat IgG2a,κ H129.19 1/200 BioLegend 130310 
Biotin CD4 rat IgG2a,κ H129.19 1/1600 BD Biosciences 553649 
APC CD4 (L3T4) rat IgG2a,κ RM4-5 1/200 BD Biosciences 553051 
Biotin CD5 rat IgG2a,κ 53-7.3 1/800 BD Biosciences 553019 
PE CD8a rat IgG2a,κ 53-6.7 1/200 BioLegend 100708 
Biotin CD8a rat IgG2a,κ 53-6.7 1/800 BD Biosciences 553029 
APC CD8a rat IgG2a,κ 53-6.7 1/200 BioLegend 100712 
PE-Cy7 CD11b rat IgG2b,κ M1/70 1/1500 BioLegend 101215 
APC CD11b rat IgG2b,κ M1/70 1/1500 BioLegend 101211 
Biotin CD19 rat IgG2a,κ 1D3 1/200 BD Biosciences 553784 
APC-Cy7 CD19 rat IgG2a,κ 6D5 1/200 BioLegend 115530 
APC CD31 rat IgG2a,κ MEC13.3 1/200 BioLegend 102510 
FITC CD45.1 mouse IgG2a, k A20 1/200 BioLegend 110706 
Pacific Blue CD45.2 mouse IgG2a,κ 104 1/200 BioLegend 109820 
Biotin CD45R / B220 rat IgG2a,κ RA3-6B2 1/200 BD Biosciences 553086 
APC CD45R / B220 rat IgG2a,κ RA3-6B2 1/2000 BioLegend 103212 
PE CD48 Hamster IgG HM48-1 1/400 BioLegend 103406 
APC CD48 Hamster IgG HM48-1 1/400 BioLegend 103411 
AF 488 CD48 Hamster IgG HM48-1 1/400 BioLegend 103414 
APC-Cy7 CD117 / c-Kit rat IgG2b,κ 2B8 1/200 BioLegend 105826 
APC CD117 / c-Kit rat IgG2b,κ 2B8 1/200 BioLegend 105812 
PE-Cy7 CD150 / SLAM rat IgG2a,κ TC15-12F12.2 1/200 BioLegend 115914 
APC rat IgG2a,κ TC15-12F12.2 1/200 BioLegend 115910
PE CD166 / ALCAM rat IgG2a,κ ALC48 1/200 eBioscience 12-1661-81
PE-Cy7 Gr-1 / Ly-6G/C rat IgG2b,κ RB6-8C5 1/1500 BioLegend 108416
CD150 / SLAM
Biotin Gr-1 / Ly-6G/C rat IgG2b,κ RB6-8C5 1/200 BD Biosciences 553125 
APC Gr-1 / Ly-6G/C rat IgG2b,κ RB6-8C5 1/1500 BioLegend 108412 
FITC Sca-1 / Ly-6A/E rat IgG2a,κ E13-161.7 1/200 BioLegend 122506 
APC-Cy7 Sca-1 / Ly-6A/E rat IgG2a,κ E13-161.7 1/200 BioLegend 122506 
PE-Cy7 Sca-1 / Ly6-A/E rat IgG2a,κ E13-161.7 1/200 BioLegend 122514 
FITC Ter119 rat IgG2b,κ TER-119 1/100 BioLegend 116206 
Biotin Ter119 rat IgG2b,κ TER-119 1/50 BD Biosciences 553672 
PE Streptavidin 1/200 BD Biosciences 554061 
Pacific Blue Streptavidin 1/100 Molecular probes invitrogen S11222 
PE Annexin V 1/50 BD Biosciences 556422 
Table 2. 8: List of antibodies used for flow cytometric analysis.
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 Isolation and flow cytometry for HSC niche cells 2.4
from the BM 
Briefly crushed bones (tibia and femur) were washed with PBS/2% FBS to 
remove haemopoietic cells. The bones fragments were digested in 3mg/ml 
collagenase VIII (Sigma) dissolved in HBSS/2% FBS for 2 hours at 37oC by 
constant agitation at 11rpm. The released cells were washed with PBS/2% 
FBS and filtered using 70µM filters. Cells were stained with flourochrome-
conjugated antibodies (CD45, Ter119, CD31, CD166 (ALCAM), Sca-1) and 
were analysed by FACS as mentioned above. 
 Detection of apoptosis using Annexin V 2.5
 The 1,000,000 cells from the BM was re-suspended in 100µl PBS/2 % FBS 
containing 5µl of Annexin V APC and incubated for 20 minutes at RT in dark. 
500µl of PBS/2% FBS was added to stop the reaction. DAPI, viability dye was 
added prior to acquisition and immediately analysed using FACS as described 
in the section 2.3.  
 Analysis of LacZ expression using FDG 2.6
(Fluorescein di[β-D-galactopyranoside) 
FACS based detection of LacZ+ cells by using fluorogenic substrate of 
galactosidase, FDG. Glactosidase based FDG cleavage releases flourescene 
product FITC that can be detected by FACS (Guo and Wu 2008). Cells were 
re-suspended in 50µl of PBS/2% FBS and warmed for 10 min at 37oC in water 
bath. 50 ul of pre-warmed (37oC) FDG was added with rapid mixing and 
incubated in 37oC water bath for 1 min. To stop the reaction, 1 ml of cold 
PBS/2% FBS (frozen pipettes tips) was added and centrifuged in pre-cooled 
4oC micro-centrifuge 3200 rpm for 4 min. cells were re-suspended in cold 
0.5 ml of PBS/2% FBS and transferred into cold FACS tubes and analysed for 
FITC using flow cytometer.  
 Cell sorting 2.7
 Cells were isolated from the BM and PB as mentioned in section 2.3. 
Isolated BM cells were enriched for c-Kit+ cells using magnetic beads and 
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MACS column as described in section 2.2.2.4. The cells were re-suspended in 
100µl of cold PBS/2% FBS with antibodies and incubated for 200 minutes on 
ice in dark. The cells were washed with PBS/2% FBS and re-suspended in 
500µl of PBS/2% FBS filtering through 70µM filters. The sorting was 
performed using BD FACSAria (BD Biosciences).  
 In vivo serial transplantation 2.8
Competitive BM transplantation assay was performed using B6.SJL mice with 
CD45.1 isoform as recipients. Mice were lethally irradiated (9Gy) using 
cobalt source irradiator. They were maintained in sterile conditions within 
IVC (individually ventilated cages) cages and treated with antibiotic (Baytril- 
0.15mg/ml) for 2 weeks after irradiation. The health status was monitored 
throughout the experiment period and scored according to project license 
60/4076 CD45.2+ donor BM cells were isolated as mention above (section 
2.3) and were mixed with 500,000 CD45.1+ competitor BM cells in a 1:1 
ratio and injected intravenously (IV) into lethally irradiated recipients at 
200µl volume/mice. For secondary and tertiary transplantation, BM cells 
were sorted for LSK as mentioned in the section 2.6 and together with 
200,000 CD45.1+ support BM cells, 2000 LSKs were injected into the lethally 
irradiated recipients.   
 Gene expression assay 2.9
2.9.1 Extraction of RNA 
RNA was extracted and purified using RNeasy micro Kit (Qiagen) according 
to manufacturers protocol. Equal number of cells was sorted directly in to 
lysis buffer (RNeasy micro kit) using FACSAria as described in section 2.6. 
RNA was extracted in 15µl of RNase-free water. 
2.9.2 Quantitative PCR- total RNA 
cDNA was prepared from total RNA using high capacity cDNA reverse 
transcription kit (Applied Biosystems) according to manufacturers protocol. 
13µl of total RNA extracted from equal number of cells was used as 
template as the RNA obtained was below the quantification level due to 
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sample restrictions. Quantitative reverse transcription PCR (RT-PCR) was 
performed using universal probe library assay (UPL) for Hif-1α and Hif-2α 
and housekeeping gene (TATA-binding protein –TBP) (Table 2.9). Reactions 
were run on a LightCycler 480 System. 4.8µl of 10 times diluted cDNA was 
used per 10µl reaction of Primers (100µM), LAN-based probe (locked-nucleic 
acid) and Light-cycler 480 probes master (2X) programmed for 40 cycles 
(Table 2.10). All experiments were performed in technical triplicate. 
Differences in input cDNA were normalised using TBP expression and the 
mRNA expression levels were determined using comparative CT method 
(Schmittgen and Livak 2008).   
Table 2. 9: Primers used for quantitative RT-PCR 
Step	   Temperature Time 
1 95oC 10	  min	  
2 95oC 10	  sec	  
3 60oC 30	  sec	  
Repeat	  from	  step	  2	  for	  40	  cycles	  
4 72oC 1	  sec	  
5 40oC 30	  sec	  
Table 2. 10: PCR programme for quantitative analysis of Hif-1α  and Hif-2α  using 
LightCycler 480 system
Genes Primers 
TBP 
5’-GGCGGTTTGGCTAGGTTT-3’ 
5’-GGGTTATCTTCACACACCATGA-3’ 
Hif-1α 
5’-TTACGTGTGAGAAAACTTCTGGAT-3’ 
5’-GCCATCTAGGGCTTTCAGATAA-3’ 
Hif-2α 
5’-TGACAGCTGACAAGGAGAAAAA-3’ 
5’-CAACTCATAGAAGACCTCCGTCTC-3’ 
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 Introduction 3.1
Previous studies have suggested that HSCs are localised in the special 
microenvironment of the BM, called the haemopoietic niche (Schofield 1978; 
Calvi et al. 2003; Zhang et al. 2003; Kiel et al. 2005; Scadden 2006; Morrison 
and Spradling 2008; Wang and Wagers 2011). BM is believed to be hypoxic 
compared to other tissues and HSCs reside in the most hypoxic region of the 
BM (Cipolleschi et al. 1993; Levesque et al. 2007; Parmar et al. 2007; 
Kubota et al. 2008; Eliasson and Jonsson 2010; Eliasson et al. 2010; Simsek 
et al. 2010; Takubo et al. 2010). The two isoforms of HIFs, HIF-1α and HIF-
2α are key elements of cellular and systemic hypoxia responses and regulate 
gene expression to adapt to a hypoxic environment (Semenza 1999; Coleman 
and Ratcliffe 2007; Gruber et al. 2007; Kaelin and Ratcliffe 2008). Several 
studies have reported the hypoxic nature of HSCs (Danet et al. 2003; 
Hermitte et al. 2006; Shima et al. 2009; Shima et al. 2010; Takubo et al. 
2010). Analysis of BM HSCs in mice with the hypoxia probe Pimo showed that 
HSCs retained the dye highly demonstrating that they were hypoxic (Danet 
et al. 2003; Takubo et al. 2010). Transplantation experiments revealed that 
human HSCs acquired hypoxic status when transplanted into irradiated mice 
and entered the quiescent phase (Shima et al. 2010). Human HSCs that were 
cultured ex vivo under hypoxia retained the reconstitution potential when 
transplanted into immunodeficient mice (Danet et al. 2003; Hermitte et al. 
2006). Human HSCs and primitive progenitors when cultured under hypoxia 
in vitro, stabilised Hif-1α protein, retained the primitive phenotype and 
induced cell cycle quiescence (Danet et al. 2003; Hermitte et al. 2006; 
Shima et al. 2009). Therefore, the hypoxic nature of HSCs and the HSC 
niches is conserved across species.  
Hifs were proven to be critical during embryogenesis and early 
development, as deletion of Hif-1α and Hif-2α in mice was embryonic lethal 
(Maltepe et al. 1997; Iyer et al. 1998; Ryan et al. 1998; Tian et al. 1998; 
Adelman et al. 1999; Adelman et al. 2000; Peng et al. 2000; Compernolle et 
al. 2002; Scortegagna et al. 2003a; Ramirez-Bergeron et al. 2006; Gruber et 
al. 2007). Hif-1α null embryos showed defective neural tubes, 
cardiovascular defects, including hyperplasia and reduced viable 
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mesenchymal cells in the cranial region with enhanced hypoxia (Iyer et al. 
1998; Ryan et al. 1998). Deletion of Hif-1ß subunit in mouse embryos 
resulted in decreased Vegf expression, leading to haemopoietic defects with 
decreased numbers of haemopoietic progenitors and mature cells due to 
increased apoptosis (Adelman et al. 1999; Ramirez-Bergeron et al. 2006). In 
adult mice, Takubo et al used a CKO approach using Mx1-Cre transgene and 
showed that acute deletion of Hif-1α resulted in loss of the cell cycle 
quiescence of HSCs and progressive loss of long-term repopulating capability 
of HSCs in chemotherapeutic 5-FU treated mice following serial 
transplantation (Takubo et al. 2010). Deletion of Hif-1α resulted in elevated 
expression of p16Ink4a and p19Arf, products of Ink4a that regulate cellular 
senescence (Takubo et al. 2010). Transplantation assay showed that the 
decrease in HSCs and primitive progenitor cells (LSKs) was regulated by Hif-
1α in an Ink4 dependent manner and suppression of p16Ink4a and p19Arf in 
Hif-1α-deficient HSCs restored their repopulation potential (Takubo et al. 
2010). During aging, Hif-1α deletion resulted in loss of the hypoxic nature of 
HSCs, decreased HSC number and resulted in extra medullary haemopoiesis 
(Takubo et al. 2010). It is noteworthy that HSC lacking Hif-1α maintained 
normal haemopoiesis under steady state and successfully reconstituted 
primary recipients when transplanted into lethally irradiated recipients 
(Takubo et al. 2010). Loss of repopulation potential of HSCs lacking Hif-1α 
was observed in secondary transplantation (Takubo et al. 2010). 
Stabilisation of Hif-1α protein by deletion of one or both alleles of Vhl 
enhanced the quiescent state in HSCs. However, over stabilisation of Hif-1α 
by deletion of both alleles of Vhl in HSCs led to loss of their reconstitution 
ability (Takubo et al. 2010). Additionally, it was shown that conditional 
deletion of Hif-1α resulted in dysregulated mitochondrial respiration 
(Simsek et al. 2010). Meis1 regulates the transcription of Hif-1α in LT-HSCs 
thereby contributing to HSC metabolism and enhanced glycolytic respiration 
in HSCs (Simsek et al. 2010). In conclusion, genetic studies, mostly from Prof 
Suda’s laboratory, indicated an important role for Hif-1α in HSC 
maintenance under stressful conditions.  
Investigations using murine models have stressed the importance of Hif-2α 
during embryogenesis (Tian et al. 1998; Peng et al. 2000; Compernolle et al. 
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2002; Scortegagna et al. 2003a; Gruber et al. 2007). Mouse embryos lacking 
Hif-2α exhibited variable phenotypes, including embryonic lethality (Peng et 
al. 2000), mid-gestation lethality (Tian et al. 1998) and perinatal death 
(Compernolle et al. 2002).  Scrotegagna et al. generated congenic mixed 
strain F1 hybrids (Estill and Garcia 2000) with germ-line knockout of Hif-2α 
by interbreeding C57BL/6 and 129S6/SvEvTac (sub-strain of 129 strain called 
“steel”) background Hif-2α heterozygotes (Simpson et al. 1997; Scortegagna 
et al. 2003a). These unique mixed strain background mice lacking Hif-2α 
survived until adulthood, developed pancytopenia and multiple organ 
pathologies (in the eyes, heart, liver, testis and BM) involving mitochondrial 
dysfunction, sensitive to high oxidative stress (Scortegagna et al. 2003a). To 
further investigate the role of Hif-2α in adult mice, Gruber et al took a CKO 
approach using the ubiquitously expressed Cre transgene (Ubc-CreERT2), 
where Hif-2α deletion in Hif-2αfl/fl Ubc-CreERT2 was induced by tamoxifen 
in widespread tissues, including brain, intestine, liver, heart, kidney, BM, 
spleen, thymus (Gruber et al. 2007; Ruzankina et al. 2007). Postnatal 
deletion of Hif-2α generated anaemia with reduced RBC, haematocrit and 
haemoglobin values (Gruber et al. 2007). Reduced erythroid colony forming 
potential of haemopoietic progenitors and reduced circulating Epo in the 
serum at steady state and under stress conditions were also reported 
(Gruber et al. 2007). Previous studies indicated that the downstream target 
genes of Hif-1α and Hif-2α, such as Cited2, Vegfα and Foxo3a, were 
essential for HSC maintenance (Gerber et al., 2002; Kranc et al., 2009; 
Miyamoto et al., 2007; Rehn et al., 2011). Together these results suggested 
that Hif-1α and Hif-2α were required for normal haemopoiesis. However, 
the cell-autonomous requirement of Hif-2α in regulating haemopoiesis is not 
known.  
Hif-1α and Hif-2α share similar domain structure and undergo the same 
proteolytic degradation (Wang et al. 1995). The expression of Hif-1α is 
ubiquitous while Hif-2α expression is restricted to certain cell types, such as 
vascular endothelial cells, hepatocytes, kidney fibroblasts, glial cells, 
pancreas, epithelial cells lining intestinal lumen, neural crest cell 
derivatives, and lung type II pneumocytes and in HSCs and haemopoietic 
progenitor cells (Tian et al. 1997; Jain et al. 1998; Wiesener et al. 2003). 
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While Hif-1α is essential for maintenance of LSCs (Zhang et al. 2012), Hif-2α 
expression is associated with various cancers, such as breast cancer, 
squamous cell carcinoma, lung cancer and Vhl associated renal clear cell 
carcinoma (RCC) and hemangiomas (Maxwell et al. 1999; Harris 2002; 
Covello et al. 2005; Hu et al. 2006). In addition, specific expression of Hif-
2α and not Hif-1α in RCC patient samples has been reported (Maxwell et al. 
1999). Hif-1α and Hif-2α share overlapping as well as opposing roles in 
different cell types. In RCC cells, VEGF, GLUT-1 and IL-6 were regulated by 
both Hif-1α and Hif-2α (Hu et al. 2003), but in mouse ESCs Vegf was 
regulated by Hif-1α alone (Iyer et al. 1998; Ryan et al. 1998; Hu et al. 
2003). However, Hif-1α played a key role in glycolysis and controlled the 
expression of key genes, including HK1, HK2, PGK1 and LDHA in RCC and 
mouse ES cells (Iyer et al. 1998; Ryan et al. 1998). Hif-2α, on the other 
hand had unique target genes like Epo in kidney (Scortegagna et al. 2003a; 
Gruber et al. 2007; Rankin et al. 2007) and liver (Kapitsinou et al. 2010), 
CCND1 (Raval et al. 2005) in RCC cells and Oct4 in mouse ES cells (Covello et 
al. 2006). Therefore, Hif-1α and Hif-2α have similar and distinct functions 
in different cell types and their functions are cell context-specific. 
However, the interplay between Hif-1α and Hif-2α in the HSCs remains 
unknown. 
 Outline of experiments described in Chapter 3 3.2
Very little is known about the role of Hif-2α in adult haemopoiesis. Specific 
functions of Hif-2α and its role within HSCs remain unexplored. 
Furthermore, the genetic requirement for and functional overlap between 
both Hif-1α and Hif-2α in the HSC functions remain to be investigated. 
Therefore, in this Chapter, I have focused on investigating the cell-
autonomous roles of Hif-1α and Hif-2α in HSC survival and function. I 
conducted transplantation experiments where BM cells from mice carrying a 
floxed allele of Hif-2α or Hif-1α and Hif-2α with inducible Mx1-Cre and 
Control mice were transplanted to syngeneic recipients. Upon inducible 
gene deletion, the floxed alleles were deleted specifically in the donor 
derived haemopoietic cells and the haemopoietic organs were analysed. 
There was no difference in the number of HSCs or primitive progenitors 
Chapter 3 
119 
lacking Hif-1α and Hif-2α or Hif-2α alone, suggesting that Hif-2α is 
dispensable for adult haemopoiesis and additional deletion of Hif-1α did not 
affect HSC functions. I also aged the transplanted mice harbouring the 
haemopoietic system lacking Hif-2α alone or both Hif-1α and Hif-2α and 
showed that Hif-2α or both Hif-1α and Hif-2α were dispensable for stress 
induced haemopoiesis. Furthermore, I conducted serial transplantation 
experiments that determined the self-renewal properties of HSCs lacking 
Hif-2α or Hif-1α and Hif-2α. HSCs of all genotypes retained self-renewal 
ability equivalent to Control HSCs and repopulated the donor mice through 
successive transplantations. Taken together these experiments imply that 
Hif-2α is not essential for cell-autonomous maintenance of HSC functions 
under steady state and stressful conditions of serial transplantation and 
aging. It is also evident that HSCs lacking Hif-2α together with Hif-1α 
efficiently sustain normal haemopoiesis (Guitart, Subramani et al, Blood, 
2013). 
 Result 3.3
3.3.1 The lack of requirement of Hif-2α in cell-autonomous 
HSC maintenance 
To study the requirement of Hif-2α specifically within the haemopoietic 
system, I employed a competitive BM transplantation assay. I generated Hif-
2α CKO mice, by crossing Hif-2αfl/fl mice to Hif-2α+/+ Mx1-Cre mice. This 
cross subsequently generated Hif-2αfl/fl Mx1-Cre (in which floxed Hif-2α 
allele can be deleted upon administration of pIpC) and Hif-2αfl/fl without 
Mx1-Cre (hereafter referred to as Control). I transplanted 500,000 CD45.2+ 
BM cells taken from untreated Hif-2αfl/fl Mx1-Cre mice and Hif-2αfl/fl Control 
mice, along with 500,000 CD45.1+ support BM cells into lethally irradiated 
congenic CD45.1+ recipients (Figure 3.1A). Having confirmed the 
engraftment of donor cells (Figure 3.1B) 8 weeks after transplantation the 
recipient mice were injected with 5-6 doses of pIpC (250ug per injection) on 
alternate days. Two weeks after the last pIpC injection, deletion of the 
floxed Hif-2α alleles in donor derived CD45.2+ sorted cells from PB was 
confirmed by PCR (Figure 3.1C). Mice were sacrificed at 2 weeks and 4 
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weeks after last pIpC injection and haemopoietic organs were analysed for 
contribution of donor-derived cells. In the recipients, there was equal 
reconstitution of donor-derived CD45.2+ cells in PB, BM and spleen from pIpC 
treated Hif-2αfl/fl Mx1-Cre (hereafter referred to as Hif-2αΔ/Δ) and Control 
mice (Figure 3.2A). There was equal contribution of Hif-2αΔ/Δ -derived and 
Control-derived CD45.2+ Lin-, LK (Lin- c-Kit+), LSK (Lin-Sca-1+c-Kit+), LMMPs 
(LSK CD150-CD48+ and LSK CD150+CD48+), HSC (LSK CD150+CD48-) and ST-HSC 
(LSK CD150-CD48-) cells in the BM of recipient mice (Figure 3.2B-H and 3.3). 
In mice sacrificed 2 weeks after the last pIpC injection the frequency of 
CD45.2+ derived myeloid (Gr-1+ and Mac-1+) cells and erythroid (Ter119+) 
cells in the PB, BM and spleens was similar in both groups of recipients (Fig 
3.4A, 3.4B and 3.4C). The same frequencies of CD45.2+ T-cells (CD4+, CD8+) 
in the PB, spleen and thymus (CD4+and CD8+) (Figure 3.4) were observed. 
However, there was an increase in the frequency of CD45.2+ derived B-cells 
(CD19+B220+ cells) in the spleens of Hif-2αΔ/Δ recipients compared to 
Controls (Figure 3.4C). The contribution of donor-derived cells to 
multilineage haemopoiesis in mice sacrificed 4 weeks after last pIpC 
injection showed a decrease in CD45.2+ myeloid cells in PB, BM and spleens 
of Hif-2αΔ/Δ recipients and an increase in B-cells in the BM of Hif-2αΔ/Δ 
recipients compared to Control recipients (Figure 3.5). The above results 
showed that HSCs lacking Hif-2α efficiently repopulated primary recipient 
mice and therefore Hif-2α was not absolutely essential for cell-autonomous 
HSC functions. The decrease in myeloid cells in the PB, BM and spleens and 
an increase in B-cells in the BM of Hif-2αΔ/Δ recipients observed in primary 
transplant recipients suggested that Hif-2α might play a role in the 
differentiation of myeloid and B-cells. However, more research is required 
to fully understand the importance of Hif-2α in myeloid and lymphoid 
differentiation.  
3.3.2 The requirement for Hif-1α  and Hif-2α  in cell-
autonomous HSC maintenance 
Hif-1α is expressed at higher levels in HSCs compared to progenitor cells 
(Takubo et al. 2010). Loss of Hif-1α has been shown to lead to reduced 
numbers of HSCs and loss of HSC quiescence under stressful conditions, such 
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as aging, serial transplantation and 5-FU treatment (Takubo et al. 2010). 
Meis1, a transcriptional regulator of Hif-1α and Hif-2α, was shown to be 
necessary for HSC quiescence and HSCs lacking Hif-1α expression failed to 
repopulate BM upon secondary transplantation (Simsek et al. 2010; Kocabas 
et al. 2012). The expression of Hif-2α in HSCs was higher than in the 
downstream progenitor cells (Takubo et al. 2010). However, the relationship 
between Hif-1α and Hif-2α and the ability of Hif-2α to compensate for the 
loss of Hif-1α in cell-autonomous HSC maintenance remains to be 
investigated. To dissect the role of Hif-1α and Hif-2α in cell-autonomous 
HSC maintenance and to uncover possible functional compensatory 
mechanism between Hif-1α and Hif-2α, I performed competitive BM 
transplantation experiments. 500,000 CD45.2+ BM cells from untreated Hif-
1αfl/fl Hif-2αfl/fl Mx1-Cre mice (double knockout, DKO) and Control mice 
were transplanted into lethally irradiated CD45.1+ recipients along with 
500,000 CD45.1+ support BM (Figure 3.6A). Mice were treated with 5-6 doses 
of pIpC (250ug/injection) on alternate days and analysed after 2 weeks and 
4 weeks of the last pIpC treatment. Deletion of floxed alleles in the sorted 
CD45.2+ haemopoietic cells was confirmed by PCR (Figure 3.6B). Analysis of 
BM after 2 weeks and 4 weeks post pIpC injection showed no difference in 
the reconstitution of donor-derived HSCs, LMPPs, LSKs, LK or Lin- cells in 
DKO and Control recipients (Figure 3.7 and 3.8). The frequencies of donor-
derived mature blood lineages of DKO recipients were equal to Control 
recipients (Figure 3.9A-3.9D and 3.10A-3.10D). These experiments showed 
that deletion of Hif-1α and Hif-2α within HSCs had no effect on short-term 
and long-term reconstitution of primary recipients. Taken together these 
data indicate that HSCs lacking both Hif-1α and Hif-2α efficiently 
repopulate primary recipients and sustain multilineage haemopoiesis.     
3.3.3 The requirement for Hif-1α  and Hif-2α  in the 
maintenance of HSC self-renewal capacity in serial 
transplantation  
Takubo et al reported that HSCs lacking Hif-1α displayed reduced self-
renewal potential and progressive HSC loss when transplanted into lethally 
irradiated secondary recipients (Takubo et al. 2010). In primary recipients, 
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cells lacking Hif-1α exhibited successful haemopoietic reconstitution, but 
displayed reduced LSKs and failed to repopulate secondary recipients 
(Takubo et al. 2010). Serial transplantation is the most stringent measure of 
self-renewal potential of HSCs (Siminovitch et al. 1964; Harrison 1972; 
Harrison et al. 1978; Harrison and Astle 1982; Iscove and Nawa 1997; Sudo 
et al. 2000; Kondo et al. 2003; Ito et al. 2006; Janzen et al. 2006; Purton 
and Scadden 2007; Liu et al. 2009; Takubo et al. 2010; Kocabas et al. 2012). 
HSCs have self-renewal potential and efficiently sustain multilineage 
haemopoiesis during serial transplantation (Rosendaal et al. 1979; 
Lemischka et al. 1986; Purton et al. 2006). HSC population from the donor 
mice is transplanted into sequential irradiated recipients and their ability to 
repopulate recipients and sustain haemopoiesis is determined. I conducted 
serial transplantation experiments to test the self-renewal properties and 
long-term repopulation potential of HSCs deficient of Hif-2α or both Hif-1α 
and Hif-2α. After 4 weeks of last pIpC treatment (14 weeks post transplant) 
of primary recipients, 3000 CD45.2+ LSK cells were sorted from primary 
recipients of Hif-2αΔ/Δ, DKO and Control cells. LSK cells were then 
transplanted into lethally irradiated secondary recipients along with 200,000 
CD45.1+ support BM (Figure 3.11A). Analysis of PB, BM and spleens showed 
equal reconstitution of donor-derived CD45.2+ cells of Hif-2αΔ/Δ, DKO and 
Control recipients (Figure 3.11B and 3.11C). Analysis of Hif-2αΔ/Δ and DKO 
with respective Control recipients at 24 weeks and 28 weeks after 
transplantation showed comparable frequencies of donor-derived HSCs, 
primitive progenitors (Figure 3.12 and 3.13) and equal reconstitution of 
mature blood lineages irrespective of the genotype (Figure 3.14). Further, I 
transplanted 3000 donor-derived LSKs from secondary recipients of Hif-
2αΔ/Δ, DKO and Control into lethally irradiated tertiary recipients (Figure 
3.15A). The analysis of PB, BM and spleens of the recipients at 16 weeks 
post transplantation indicated that Hif-2αΔ/Δ, DKO and Control donor-
derived HSCs equally efficiently reconstituted the recipient mice (Figure 
3.15B and 3.15C). There were no significant differences in HSCs or primitive 
progenitors (Figure 3.16 and 3.17), which successfully formed all the mature 
lineages irrespective of the genotype (Figure 3.18). However, the cells from 
DKO recipients seemed to have an advantage in reconstitution potential in 
comparison with Control recipients, but this did not reach statistical 
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significance (Figure 3.15C and 3.17). This might be due to the low 
engraftment of cells derived from Control mice in contrast to cells from DKO 
mice. Nevertheless, DKO HSCs efficiently repopulated lethally irradiated 
secondary and tertiary recipients. These experiments suggested that HSCs 
lacking Hif-2α alone or both Hif-1α and Hif-2α maintained the 
reconstitution potential during serial transplantation and Hif-α−dependent 
signalling is dispensable for cell-autonomous HSC function.  
3.3.4 The requirement for Hif-1α  and Hif-2α  in normal 
haemopoiesis in aged mice 
Several studies involving murine models have investigated the age-related 
modulations of HSC functions (de Haan et al. 1997; Sudo et al. 2000; Rossi 
et al. 2005; Chambers et al. 2007). Studies in aged mice reported an 
increase in the number of HSCs accompanied by decreased self-renewal 
potential and myeloid-biased defective differentiation (de Haan et al. 1997; 
Sudo et al. 2000; Rossi et al. 2005; Chambers et al. 2007). HSCs display 
defective homing ability and increased stress induced apoptosis with age 
(Morrison et al. 1996; Liang et al. 2005). Expression of cyclin-dependent 
inhibitor, p16Ink4a was increased with age in HSCs from mice as well as in 
human CD34+ cells and deletion of p16In4a reinstated the self-renewal and 
apoptotic defects (Janzen et al. 2006; de Jonge et al. 2009). Notably, 
according to Takubo et al, aged Hif-1α CKO mice exhibited decreased HSC 
number compared to Control (Takubo et al. 2010). Defective transplantation 
phenotype of Hif-1α-deficient HSCs was Ink4a-dependent as suppression of 
p16Ink4a and p19Arf restored the transplantation defects (Takubo et al. 
2010). Hence, it was interesting to see the effect of aging on HSCs lacking 
both Hif-1α and Hif-2α. To examine the effect of deletion of Hif-2α or Hif-
1α and Hif-2α in aged mice, Hif-2αΔ/Δ, DKO and Control primary recipients 
were aged for 37 weeks after transplantation and the Hif-2αΔ/Δ secondary 
recipients were aged for 32 weeks post transplantation while DKO secondary 
recipients were aged for 35 weeks. Details of recipient’s age, pIpC 
treatment and analysis are summarised in the table3.1. Aged mice were 
sacrificed and analysed for donor-derived cell contribution using flow 
cytometry. The analysis of PB, BM and spleens of aged Hif-2αΔ/Δ and DKO 
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primary recipients at week 27 after last pIpC injection showed an equal 
contribution of donor-derived HSCs, primitive progenitors (Figure 3.19) and 
multilineage re-constitution compared to Control recipients (Figure 3.20). 
Secondary recipients transplanted with Hif-2αΔ/Δ and DKO cells analysed at 
week 24 and week 27 after last pIpC displayed no significant difference 
between donor-derived HSCs, LMPPs, LSKs or Lin- cells from Hif-2αΔ/Δ, DKO 
and Control recipients (Figure 3.21). There were equal frequencies of donor-
derived mature blood lineages in the PB, BM and Spleen (Figure 3.22). These 
experiments further showed that HSCs lacking both Hif-1α and Hif-2α 
retained reconstitution capacity during serial transplantation and 
maintenance of multilineage haemopoiesis during the course of aging.   
Analysis	  
Donor	   Cell	  type	   pIpC	  administration	  
Weeks	  after	  last	  pIpC	  
injection	  
Weeks	  after	  
transplantation	  
Primary	  
Transplant	  
Hif-­‐2αfl/fl	  Mx1-­‐Cre,	  
Hif-­‐1αfl/fl:Hif-­‐2αfl/fl	  Mx1-­‐Cre	  and	  
Control	  
500000	  BM	  cells	  
8	  weeks	  after	  
transplant	  
2	  weeks	   12	  weeks	  
4	  weeks	   14	  weeks	  
27	  weeks	   37	  weeks	  
Secondary	  
Transplant	  
Primary	  recipient	  (Hif-­‐2αΔ/Δ	  and	  
Control)	   3000	  LSK	  
-­‐	   -­‐	   24	  weeks	  
-­‐	   -­‐	   32	  weeks	  
Primary	  recipient	  (DKO	  and	  Control)	   3000	  LSK	  
-­‐	   -­‐	   28	  weeks	  
-­‐	   -­‐	   35	  weeks	  
Tertiary	  
Transplant	  
Secondary	  recipient	  (Hif-­‐2αΔ/Δ	  and	  
Control)	   3000	  LSK	   -­‐	   -­‐	   16	  weeks	  
Secondary	  recipient	  (DKO	  and	  
Control)	   3000	  LSK	   -­‐	   -­‐	   16	  weeks	  
Table 3. 1: Details of time frame between transplantation, pIpC treatment and analyses of transplantation recipients.
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 Discussion 3.4
3.4.1 Hif-2α  is dispensable for cell-autonomous HSC 
maintenance in stressful conditions of transplantation 
Hypoxia is believed to be important in regulating HSC fate decisions of 
quiescence, self-renewal, apoptosis and differentiation (Miyamoto et al. 
2007; Kranc et al. 2009; Simsek et al. 2010; Takubo et al. 2010; Suda et al. 
2011). Hif-1α−deficient HSCs displayed functional defects with progressive 
loss of self-renewal potential and increased apoptosis (Takubo et al. 2010; 
Kocabas et al. 2012). Scortegagna and collegues studied congenic mixed 
breed Hif-2α knockout mice (C57BL/6 Hif-2α heterozygote:129S6/SvEvTac 
Hif-2α heterozygote) with global deletion of Hif-2α (Scortegagna et al. 
2003a). These Hif-2α null mice showed increased perinatal lethality and a 
small number of Hif-2α null mice survived till adulthood, developed multiple 
organ pathologies, impaired mitochondrial metabolism, elevated oxidative 
stress and pancytopenia (Scortegagna et al. 2003a). Conditional postnatal 
ablation of Hif-2α in mice using ubiquitously expressed Ubc-Cre activated by 
tamoxifen treatment developed anaemia and defective erythropoiesis 
(Gruber et al. 2007). Acute deletion of Hif-2α in mice resulted in decreased 
RBC number, haematocrit and haemoglobin levels with reduced Epo 
production (Gruber et al. 2007). Lack of Hif-2α expression led to a decrease 
in erythroid progenitors in the BM, while in the spleen deletion of Hif-2α led 
to increase in erythroid colony forming potential activating potential 
compensatory mechanism (Gruber et al. 2007). However, specific role of 
Hif-2α in the regulation of cell-autonomous HSC functions remained to be 
investigated.  
In this study, I have analysed the cell-autonomous effects of Hif-2α 
deficiency on HSC functions. The results in this Chapter demonstrate that 
HSCs lacking Hif-2α sustained normal haemopoiesis under stressful 
conditions of transplantation. Serial transplantation experiments showed 
that Hif-2α-deficient HSCs repopulated the secondary and tertiary 
recipients and maintained multilineage haemopoiesis. In the study by 
Takubo et al, the authors conditionally deleted Hif-1α in mice using Mx1-Cre 
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(Takubo et al. 2010). PIpC treated Hif-1αfl/fl Mx1-Cre mice showed that the 
frequency of LSKs, HSCs, differentiation capacity and their short-term 
reconstitution potential were identical to the Controls. Primary recipients 
transplanted with Hif-1αfl/fl Mx1-Cre displayed efficient haemopoietic 
reconstitution upon Hif-1α deletion. However, a decrease in number of LSK 
cells and a progressive loss of quiescent HSCs was observed in cells lacking 
Hif-1α (Takubo et al. 2010). Hif-1α deficiency ultimately resulted in the loss 
of long-term reconstitution capacity of HSCs in the PB and BM upon 
transplantation to secondary recipients (Takubo et al. 2010).  
My data suggest that unlike Hif-1α (Takubo et al. 2010), Hif-2α is not 
essential for maintenance of self-renewal properties of HSCs. The results in 
this Chapter imply that regardless of the fact that HSC and progenitors 
inherently express high levels of Hif-2α (Takubo et al. 2010), HSCs in which 
Hif-2α was deleted were capable of regulating multilineage haemopoiesis, 
demonstrating conclusively that Hif-2α was dispensable for maintenance of 
HSC functions. Analysis of aged primary and secondary recipients with Hif-
2αΔ/Δ and Control HSCs showed equal reconstitution of HSCs, primitive 
progenitors and mature blood lineages. These observations are in agreement 
with results from Prof. Kranc’s laboratory showing that conditional deletion 
of Hif-2α specifically in the haemopoietic system using Vav-iCre (efficiently 
deletes the floxed gene during early haemopoietic development in the 
embryos) did not perturb normal haemopoiesis. HSCs lacking Hif-2α were 
capable of normal multilineage haemopoiesis under steady state conditions 
and upon serial transplantation (Guitart, Subramani et al, Blood, 2013). In 
conclusion, my data taken together with other observations from our 
laboratory indicate that Hif-2α is dispensable for cell-autonomous HSC 
maintenance in stressful conditions of transplantation and aging.  
3.4.2 Additional deletion of Hif-1α  has no impact on self-
renewal capacity of Hif-2α-deficient HSCs 
To examine the interplay between Hif-1α and Hif-2α and to address the 
hypothesis that additional deletion of Hif-2α exacerbates the phenotypes 
observed in Hif-1α-deficient mice (Takubo et al. 2010), I conducted serial 
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transplantation assays using BM cells lacking Hif-1α/Hif-2α and Control BM 
cells. HSCs from DKO mice exhibited equal engraftment and repopulation 
potential as the Control HSCs. DKO HSCs sustained normal multilineage 
haemopoiesis in the primary recipient mice. Furthermore, surprisingly, HSCs 
lacking Hif-1α and Hif-2α sorted from primary recipients were capable of 
repopulating the secondary and tertiary recipients. While, according to the 
published data (Takubo et al. 2010), Hif-1α-deficient HSCs can repopulate 
primary, but not secondary recipients, HSCs lacking both Hif-1α and Hif-2α 
were able to repopulate primary and secondary recipients and sustained 
long-term multilineage haemopoiesis. These results are further supported by 
data from Prof. Kranc’s laboratory that show primary recipients lacking Hif-
1α and Hif-2α mediated by Vav-iCre had equal reconstitution in PB and BM 
with similar number of LSK and HSCs compared to Control (Unpublished 
data, Prof. Kranc lab). Mice lacking Hif-1α under stressful conditions of 
aging showed reduced numbers of HSCs and extra-medullary haemopoiesis in 
the spleen (Takubo et al. 2010). Data from the experiments in this thesis 
showed that aged primary and secondary recipients of recipients of DKO and 
Hif-2αΔ/Δ HSCs had normal donor-derived multilineage haemopoiesis 
compared to respective Controls. Although, Hif-1α was shown to be critical 
for maintenance of HSC functions under various stress conditions, such as 
aging, 5-FU treatment and serial transplantation, Hif-1α-deficient HSCs 
were able to sustain steady state haemopoiesis (Takubo et al. 2010). 
Additionally, a recent publication reported a prominent increase in Hif-2α 
mRNA levels in Hif-1α-deficient HSCs (Kocabas et al. 2012). I have shown 
that HSCs lacking Hif-1α, with additional deletion of Hif-2α, sustained self-
renewal properties and long-term reconstitution. Hence, it is possible that 
the HSC phenotype described in the Hif-1α-deficient mice (Takubo et al. 
2010) was caused by overexpression of Hif-2α and that in our system co-
deletion of Hif-2α rectified the defective HSC phenotype in a cell-
autonomous manner. However, further studies need to be conducted to 
understand the underlying mechanism. Collectively, these results imply that 
Hif-2α is not required for cell-autonomous HSC maintenance and additional 
deletion of Hif-2α along with Hif-1α in HSCs does not enhance the 
phenotype reported in Hif-1α-deficient HSCs.  
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Previous studies have shown that hypoxia signalling pathways might play an 
important role in development and in the regulation of differentiated cells, 
including, functions of myeloid, B-cells and T-cells (Walmsley et al. 2005; 
Cramer et al. 2003; Kojima et al. 2002; Walmsley et al. 2005; Kojima et al. 
2010). In this Chapter, analysis of primary recipients for mature blood 
lineages revealed a decrease in donor-derived myeloid cells in PB, BM and 
spleen of Hif-2αΔ/Δ recipients and an increase in B-cells in the BM and spleen 
of Hif-2αΔ/Δ recipients compared to Control. A previous publication showed 
that deletion of Hif-1α specifically in the myeloid lineages resulted in 
increased apoptosis and reduced neutrophils (Walmsley et al. 2005). Also 
another study illustrated that deletion of Hif-1α in myeloid cells led to a 
drastic reduction in cellular ATP pool, resulting in impaired survival and 
functional defects in myeloid cell infiltration, mobilisation and aggregation 
(Cramer et al. 2003). Hif-1α−deficient mice exhibit impaired maturation of 
B-cells (Kojima et al. 2002; Walmsley et al. 2005; Kojima et al. 2010).  
Taken together these studies along with the results in this Chapter imply 
that Hif-1α and Hif-2α play a role in the maintenance of myeloid cell 
proliferation and functions. It might be possible that Hif-1α and Hif-2α play 
antagonistic roles in the maintenance of B-cells. However, more detailed 
study to understand the contributions of Hif-1α and  Hif-2α in the 
development and maintenance of myeloid and lymphoid cell functions is 
necessary to explain the differences in myeloid lineages observed in this 
study. 
Hypoxia has been shown to regulate angiogenesis and other organs apart 
from BM are hypoxic, including thymus, retina, liver and kidney (Moss 1968; 
Vanderkooi et al. 1991; Linsenmeier and Braun 1992; Hale et al. 2002; Biju 
et al. 2004). Thymocytes from mice showed decreased apoptosis during in 
vitro hypoxic culture (Hale et al. 2002). Analysis of thymi from the Hif-2αΔ/Δ 
mice and DKO showed no difference in the number of CD4+, CD8+ or 
CD4+CD8+ cells compared to Controls. Contrastingly, studies of murine 
models with deletion of pVhl in the thymocytes resulting in enhanced 
stabilisation of the Hif-1α protein have shown reduced CD4+CD8+ thymocytes 
due to increased apoptosis (Biju et al. 2004). Further, inactivation of Hif-1α 
in pVhl deficient thymocytes restored their number and reduced apoptosis, 
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both in vivo and in vitro (Biju et al. 2004). Taking these results into 
account, though increased expression of Hif-1α via pVhl affected thymocyte 
development, deletion of Hif-1α and Hif-2α did not affect thymocyte 
numbers. Hence the defective phenotype displayed in thymus (Biju et al. 
2004) might be due to toxic effects of Hif-1α accumulation. However, 
further studies focusing on the functions of thymi need to be determined to 
understand the variable phenotype in the thymus with defective Hif-1α and 
Hif-2α expression.      
Several publications have demonstrated that Hif target genes, such as Vegf, 
Foxo3a, Cited2 and Cripto were essential for cell-autonomous HSC 
maintenance (Chen et al. 2007; Miyamoto et al. 2007; Kranc et al. 2009; 
Miharada et al. 2011; Rehn et al. 2011). Deletion of Cited2, a downstream 
target of Hif-1α and Hif-2α (Schodel et al. 2011), led to loss of HSCs via 
apoptosis and resulted in multilineage BM failure (Chen et al. 2007; Kranc et 
al. 2009). Foxo3a gene transcription was active in hypoxic conditions and 
regulated the transcription of Cited2 in both normoxia and hypoxia (Bakker 
et al. 2007; Miyamoto et al. 2007). In hypoxic conditions, Foxo3a knockdown 
studies in MEFs, NIH3T3 cells and breast cancer cells, resulted in decreased 
survival rates (Bakker et al. 2007). Foxo3a was shown to inhibit Hif-1α-
induced apoptosis by inducing Cited2 expression (Bakker et al. 2007). 
Stabilised Hif-1α is known to bind the HRE element in the Cripto promoter 
region (Miharada et al. 2011). Hif-1αfl/fl Mx1-Cre mice displayed reduced 
number of HSCs and decreased expression of Cripto in the endosteal niche 
(Miharada et al. 2011). Hence, under hypoxia heat shock protein GRP78 and 
its ligand Cripto regulated Hif-1α-mediated HSC quiescence and 
maintenance in the BM niche (Miharada et al. 2011). Vegfα expression is 
regulated by Hif by binding to the HRE region under hypoxic conditions 
(Rehn et al. 2011). Deletion of the HRE element prevented Hif-1α binding 
and thereby prevented Vegfα activation (Rehn et al. 2011). This resulted in 
increased HSC number with impaired reconstitution ability and defective 
differentiation potential (Rehn et al. 2011). Although Hif target genes were 
shown to be important in regulating HSC functions, it is possible that other 
Hif-independent pathways might be additionally regulating the Hif target 
genes to Control HSC functions (Figure 3.23).  
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Meis1 is a member of homeobox genes that was shown to be highly 
expressed in primitive HSCs (Krumlauf 1994; Wong et al. 2007). Meis1 
regulates transcription of Hif-1α and Hif-2α in vitro (Simsek et al. 2010). A 
recent publication reports that loss of Meis1 in the HSCs led to down-
regulation of Hif-1α and Hif-2α (Simsek et al. 2010). The authors suggested 
that this decreased expression of Hifs resulted in defective HSC metabolism, 
loss of HSCs via apoptosis and impaired HSC long-term reconstitution 
(Kocabas et al. 2012). Considering the evidence from my experiments 
indicating that deletion of Hif-2α or both Hif-1α and Hif-2α within the HSCs 
did not perturb HSC functions, the phenotype observed in Meis1 deficient 
HSCs might be due to the influence of other HSC regulators (e.g. ROS 
modulators) controlled by Meis1. In conclusion, down-regulation of Hif-1α 
and Hif-2α alone are unlikely to explain the phenotype observed in Meis1-
deficient HSCs.  
While several studies have suggested that HSCs are localised in special 
hypoxic niches and contribute to the maintenance of HSC functions 
(Cipolleschi et al. 1993; Scadden 2006; Levesque et al. 2007; Parmar et al. 
2007; Suda et al. 2011), a recent publication by Nombela-Arrieta suggested 
that the hypoxic profile of HSCs was independent of the hypoxic state of the 
microenvironment (Nombela-Arrieta et al. 2013). Studies in mice using 
imaging techniques showed that HSPCs that retained the hypoxia marker, 
Pimo, at high levels and expressed Hif-1α were distributed throughout the 
BM which argued that localisation of HSCs was not restricted to the hypoxic 
niche (Nombela-Arrieta et al. 2013).  HSPCs in Go and G1 of cell cycle phase 
retained similar levels of pimo and showed no change in the Hif-1α 
expression (Nombela-Arrieta et al. 2013). Opposed to what is published in 
the literature, Nombela-Arrieta et al. showed that post-treatment with the 
cytotoxic agent 5-FU, highly proliferating HSPCs displayed an increase in 
Hif-1α expression and high levels of Pimo (Nombela-Arrieta et al. 2013). 
This study reported that stabilisation Hif-1α in HSPCs was a cell-intrinsic 
phenomenon and not influenced by the possible different oxygen tension 
within the BM (Nombela-Arrieta et al. 2013). These results suggested that 
cell-intrinsic expression of Hif-1α with in the HSCs governs the glycolytic 
metabolism (Simsek et al. 2010) thereby regulating HSC functions and 
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revealed a surprising discovery that HSCs do not require expression of Hifs in 
the BM microenvironment for their normal functioning (Nombela-Arrieta et 
al. 2013).  They also showed that the hypoxic profile of quiescent HSCs with 
high expression of Hif-1α and high levels of pimo incorporation were 
retained by cycling and proliferating HSCs (Nombela-Arrieta et al. 2013). 
These findings provide novel insights into the molecular and cellular 
mechanisms governing HSC functions and their fate choices. This study 
provides an interesting approach to further dissect the complex Hif-
regulated molecular pathways in HSCs. 
 Conclusion 3.5
The results presented in this Chapter indicate that Hif-2α is not essential for 
cell-autonomous maintenance of HSC functions under steady state and 
stressful conditions of serial transplantation and aging. HSCs lacking both 
Hif-1α and Hif-2α successfully engraft and sustain long-term serial 
transplantation.  Additional deletion of Hif-2α does not exacerbate the 
phenotype published in mice lacking expression of Hif-1α. In conclusion, my 
data reveal unexpected findings indicating that regardless of the oxygen 
tension in anatomically different BM niches, HSCs functions, including self-
renewal, long-term multilineage haemopoiesis and survival, do not critically 
require intrinsic Hif-1α- and Hif-2α-dependent signalling. 
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Figure 3. 1: Primary transplantation of Hif-2α fl/fl and Control BM cells  
(A) Experimental design - 500,000 CD45.2+ donor-derived BM cells from untreated Hif-2αfl/fl 
Mx1-Cre mice and Hif-2αfl/fl Control mice along with 500,000 CD45.1+ support BM cells were 
injected into lethally irradiated B6.SJL (CD45.1) recipients, (B) Percentage of CD45.2+ donor-
derived cells at 8 weeks post-transplantation from PB of primary recipients transplanted with BM 
cells from untreated Hif-2αfl/fl Mx1-Cre mice (red, n=28) and Hif-2αfl/fl Control mice (green, 
n=25) showing successful engraftment of donor derived cells, (C) Gene deletion confirmed by 
genomic PCR: Deletion of Hif-2α in donor derived CD45.2+ cells from the PB at 2 weeks after 
last pIpC injection. 1: Control cells, 2: Hif-2αΔ/Δ cells, PB- Peripheral blood. 
       500,000 BM + 
 500,000 support BM 8 weeks 
Lethally irradiated 
WT recipient 
Analysis 
pIpC 
Hif-2α fl/fl Mx1-Cre 
Hif-2α fl/fl  
2 weeks 
A 
1"""""2"
Hif'2α"
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Figure 3. 2: Analysis of chimerism in primary recipients transplanted with Hif-2α fl/fl 
Mx1-Cre and Control BM, 2 weeks after last pIpC injection  
(A) Percentage of CD45.2+ donor-derived cells in PB, BM and spleen of primary recipients. 
Percentage of CD45.2+ (B) Lin-, (C) LK, (D) LSK, (E) and (F) LMPPs, (G) HSCs and (H) ST-
HSCs in the BM of primary recipients from Hif-2αΔ/Δ  (red, n=7) and Control (green, n=8) cells. 
Results are represented as mean ± SD and statistical analysis was performed by two-tailed 
student's t tests assuming unequal variance. The data are obtained from two independent 
experiments. 
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Figure 3. 3: Analysis of primary recipients transplanted with Hif-2αΔ/Δ and Control BM 4 
weeks after last pIpC injection.  
Percentage of CD45.2+ donor-derived cells (A) Lin-, (B) LK, (C) LSK, (D) and (E) LMPPs, (F) 
HSCs and (G) ST-HSCs in the BM of primary recipients from Hif-2αΔ/Δ (n=9) and Control (n=9) 
cells. Results are represented as mean ± SD and statistical analysis was performed by two-tailed 
student's t tests assuming unequal variance. 
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Figure 3. 4: Percentage of donor– derived CD45.2+ myeloid (Gr-1+ Mac-1+), B-cells 
(CD19+ B220+), erythroid (Ter119+) and T-cells (CD4+ CD8+)   
(A) PB, (B) BM, (C) Spleen and (D) Thymus analysed 2 weeks after last pIpC injection. 
Recipients transplanted with Control cells (green, n=8) and Hif-2αΔ/Δ cells (Red, n=7). Results are 
represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance, p value = ≤ 0.05 (*). 
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Figure 3. 5: Percentage of donor –derived CD45.2+ myeloid (Gr-1+ Mac-1+), B-cells 
(CD19+ B220+), erythroid (Ter119+) and T-cells (CD4+ CD8+)    
  (A) PB, (B) BM, (C) Spleen and (D) Thymus analysed 4 weeks after last pIpC injection. 
Recipients transplanted with Control cells (green, n=7) and Hif-2αΔ/Δ cells (red, n=7). Results are 
represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance, p value ≤ 0.05 (*), p ≤ 0.005 (**) and p ≤ 0.0005 (***). 
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Figure 3. 6: Primary transplantation of Hif-1α fl/fl Hif-2α fl/fl Mx1-Cre and Control BM cells  
(A) Experimental design - 500,000 donor-derived CD45.2+ BM cells from untreated Hif-1αfl/fl 
Hif-2αfl/fl Mx1-Cre mice and Control mice together with 500,000 CD45.1+ support BM were 
injected into lethally irradiated B6.SJL CD45.1 recipients. 8 weeks post transplantation, mice 
were injected with 5 doses of pIpC to induce gene deletion, (B) Gene deletion shown by genomic 
PCR: Deletion of Hif-1α and Hif-2α in donor derived CD45.2+ cells from the PB at 2 weeks after 
last pIpC injection. 1: Control cells and 2: DKO cells. 
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Figure 3. 7: Analysis of primary recipients transplanted with Hif-1α fl/fl Hif-2α fl/fl Mx1-Cre 
and Control BM 2 weeks after last pIpC injection  
(A) Percentage of CD45.2+ donor-derived cells in PB, BM and spleen of primary recipients. 
Percentage of CD45.2+ in (B) Lin-, (C) LK, (D) LSK, (E) and (F) LMPPs, (G) HSCs and (H) ST-
HSCs in the BM of primary recipients transplanted with Control cells (green, n=5) and DKO cells 
(blue, n=7). Results are represented as mean ± SD and statistical analysis was performed by two-
tailed student's t tests assuming unequal variance. 
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Figure 3. 8: Analysis of primary recipients transplanted with Hif-1α fl/fl Hif-2α fl/fl Mx1-Cre 
and Control BM 4 weeks after last pIpC injection.  
Percentage of CD45.2+ donor-derived CD45.2+ (A) Lin-, (B) LK, (C) LSK, (D) and (E) LMPPs, 
(F) HSCs and (G) ST-HSCs in the BM of primary recipients transplanted with Control cells 
(green, n=9) and DKO cells (Blue, n=5). Results are represented as mean ± SD and statistical 
analysis was performed by two-tailed student's t tests assuming unequal variance. 
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Figure 3. 9: Percentage of donor –derived CD45.2+ myeloid, B-cells, erythroid and T-
cells  
(A) PB, (B) BM, (C) Spleen and (D) Thymus, analysed 2 weeks after last pIpC injection. 
Recipients transplanted with Control cells (green, n=5) and DKO cells (blue, n=8). Results are 
represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
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Figure 3. 10: Percentage of donor –derived CD45.2+ myeloid, B-cells and T-cells  
in (A) PB, together with erythroid cells in (B) BM, (C) Spleen and T-cells in (D) Thymus, in 
recipients transplanted with Control cells (green, n=9) and DKO cells (blue, n=5) analysed 4 
weeks after last pIpC injection. Results are represented as mean ± SD and statistical analysis was 
performed by two-tailed student's t tests assuming unequal variance. 
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Figure 3. 11: Secondary transplantation 
(A) Experimental design – 14 weeks post transplantation (4 weeks after last pIpC injection), 3000 
donor-derived LSKs were sorted from primary recipients transplanted with Hif-2αΔ/Δ, DKO and 
Control cells, Analysis of engraftment of donor-derived LSKs in the PB, BM and spleen of 
secondary recipients transplanted with (B) Hif-2αΔ/Δ (red) and (C) DKO (blue) with Control cells 
transplanted after 24 weeks and 28 weeks of transplant respectively. Results are represented as mean 
± SD and statistical analysis was performed by two-tailed student's t tests assuming unequal 
variance (n=3). 
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Figure 3. 12: Analysis of BM from secondary recipients transplanted with Hif-2αΔ/Δ and 
Control LSKs at 24 weeks post transplantation.  
Percentage of donor-derived CD45.2+ (A) Lin-, (B) LSK, (C) and (D) LMPPs, (E) HSCs and (F) 
ST-HSCs in secondary recipients transplanted with Hif-2αΔ/Δ (n=3) and Control cells (n=3). Results 
are represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
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Figure 3. 13: Analysis of BM from secondary recipients transplanted with DKO and 
Control LSKs at 28 weeks post transplantation.  
Percentage of donor-derived CD45.2+ (A) Lin-, (B) LSK, (C-D) LMPPs, (E) HSCs and (F) ST-
HSCs in secondary recipients transplanted with DKO (n=3) and Control cells (n=3). Results are 
represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
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Figure 3. 14: Analysis of contribution of donor-derived CD45.2+ LSKs from primary 
recipients towards mature blood lineages in secondary recipients.  
Percentage of CD45.2+ myeloid (Gr-1, Mac-1), B-cells (CD19, B220), erythroid (Ter119) in (A) 
BM along with T-cells (CD4 and CD8) in the (B) Spleen and (C) Thymus from Hif-2αΔ/Δ (red)
and (D) BM, (E) spleen and (F) thymus from DKO-derived (blue) cells with respective Controls 
(green), n=3. Results are represented as mean ± SD. 
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Figure 3. 15: Tertiary transplantation  
(A) Experimental design, Engraftment of donor-derived LSKs in PB, BM and spleen of tertiary 
recipients transplanted with (B) Hif-2αΔ/Δ (red) (C) DKO (blue) LSKs from secondary recipients 
with respective Controls (green), n=3. 
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Figure 3. 16: Analysis of BM from tertiary recipients for reconstitution potential of Hif-
2αΔ/Δ LSKs with respective Control at 16 weeks post transplant.  
Percentage of CD45.2+-derived (A) Lin-, (B) LK, (C) LSK, (D) and (E) LMPPs, (F) HSCs and 
(G) ST-HSCs in tertiary recipients transplanted with Hif-2αΔ/Δ (n=4) and Control cells (n=10). 
Results are represented as mean ± SD and statistical analysis was performed by two-tailed 
student's t tests assuming unequal variance. 
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Figure 3. 17: Analysis of BM from tertiary recipients for reconstitution potential of DKO
LSKs with respective Control at 16 weeks post transplant.  
Percentage of CD45.2+-derived (A) Lin-, (B) LK, (C) LSK, (D) and (E) LMPPs, (F) HSCs and 
(G) ST-HSCs in tertiary recipients transplanted with DKO (n=4) and Control cells (n=10). Results 
are represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
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Figure 3. 18: Analysis of PB, BM, spleen and thymus from tertiary recipients for Hif-2α
Δ/Δ and DKO LSK-derived mature blood lineages at 16 weeks post transplant.  
Percentage of CD45.2+-derived myeloid, B-cell, erythroid and T-cells in (A) BM and (B) spleen 
from Hif-2αΔ/Δ (red, n=4) and (C) BM, (D) spleen from DKO derived LSKs (blue, n=4) with 
Controls (green, n= 10). Results are represented as mean ± SD and statistical analysis was 
performed by two-tailed student's t tests assuming unequal variance, ns - not significant (p≥ 0.05). 
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Figure 3. 19: Analysis of aged primary recipients. 
Percentage of CD45.2-derived (A) Lin-, (B) LSKs, (C) and (D) LMPPs, (E) HSCs and (F) ST-
HSCs in the BM of primary recipients transplanted with Hif-2αΔ/Δ (red, n=5), DKO (blue, n=4) and 
Control (green, n=8) cells, analysed at 28 weeks after last pIpC injection. Results are represented as 
mean ± SD and statistical analysis was performed by two-tailed student's t tests assuming unequal 
variance. 
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Figure 3. 20: Analysis of mature blood lineages in aged primary recipients. 
Percentage of CD45.2-derived myeloid, B-cells, erythroid and T-cells in (A) PB, (B) BM, (C) 
spleen in primary recipients transplanted with Hif-2αΔ/Δ (red, n=5), (E) PB, (F) BM and (G) spleen 
in DKO (blue, n=4) recipients, analysed at 28 weeks after last pIpC injection. Results are represented 
as mean ± SD and statistical analysis was performed by two-tailed student's t tests assuming 
unequal variance. 
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Figure 3. 21: Analysis of aged secondary recipients. 
Percentage of CD45.2-derived (A) Lin-, (B) LSKs, (C) and (D) LMPPs, (E) HSCs and (F) ST-
HSCs in the BM of secondary recipients transplanted with Hif-2αΔ/Δ (red, n=3), DKO (blue, n=3) 
and Control (green, n=5) cells, analysed at 24-27 weeks after transplantation. Results are represented 
as mean ± SD and statistical analysis was performed by two-tailed student's t tests assuming 
unequal variance. 
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Figure 3. 22: Analysis of mature blood lineages in aged secondary recipients. 
Percentage of CD45.2-derived myeloid, B-cells, erythroid and T-cells in (A) PB, (B) BM, (C) 
spleen in secondary recipients transplanted with Hif-2αΔ/Δ (red, n=3), (E) PB, (F) BM and (G) 
spleen in DKO (blue, n=3) recipients, analysed at 24-27 weeks after transplantation. Results are 
represented as mean ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
Figure 3.23: Schematic representation of Hif-dependent and independent regulatory 
pathway for maintenance of HSC functions. 
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 Introduction 4.1
Adult haemopoiesis involves interaction between multipotent HSCs and their 
microenvironment (Schofield 1978; Scadden 2006; Jones and Wagers 2008; 
Suda et al. 2011). Various studies suggested that HSCs reside in the 
specialised BM microenvironment defined as the “HSC niche” that plays 
crucial roles in the maintenance of HSC properties and functions (Kiel et al. 
2005; Sugiyama et al. 2006; Parmar et al. 2007; Sacchetti et al. 2007; 
Simsek et al. 2010; Takubo et al. 2010). Also, studies showed that HSCs are 
located in the endosteal zone of the BM characterised by a low partial 
pressure of oxygen (Draenert and Draenert 1980; Calvi et al. 2003; Zhang et 
al. 2003; Arai et al. 2004). Parmer et al, using Ho DNA dye demonstrated 
that HSCs were enriched in the region of BM, which exhibits very low 
perfusion of the dye (Parmar et al. 2007). Further studies showed that HSCs 
were positive for Pimo and displayed low metabolic activity (Parmar et al. 
2007; Simsek et al. 2010; Takubo et al. 2010). These findings implied that 
the hypoxic profile of HSCs was determined by their position in the BM 
niche. In contrast, a recent study using quantitative imaging of femoral BM 
revealed a widespread distribution of HSCs in the BM, with no special 
preference for localisation (Nombela-Arrieta et al. 2013). The results also 
showed that hypoxic profile of HSC, with high expression of Hif-1α was 
dependent on intercellular glycolytic metabolism and not on the oxygen 
gradient or proximity to vasculature in the BM microenvironment (Nombela-
Arrieta et al. 2013). This result was supported by in vitro BM assay in which 
hypoxic culture of BM cells enhanced colony formation and transplantation 
capacity  (Cipolleschi et al., 1993; Goodell et al 1993; Danet et al., 2003; 
Ivanovic et al., 2004). In human CD34+ cells, hypoxia was shown to induce 
quiescence under culture conditions (Hermitte et al. 2006; Shima et al. 
2010). Also, studies of human HSCs reported stabilisation of Hif-1α in the 
circulating HSCs (Piccoli et al. 2007). Taking into account the discrepancies 
in previous studies describing HSC localisation in the BM niche and the role 
of hypoxia in regulating HSC fate, more studies dissecting the complex 
interplay between HSC, hypoxia and the BM niche and their influences in 
regulating HSC functions are essential.  
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Various studies have shown that the niche contributes to the maintenance of 
various HSC functions, including self-renewal, quiescence and 
differentiation (Blanpain et al. 2004; Parmar et al. 2007; Kubota et al. 
2008). The cellular components of the HSC niche contributing towards 
regulation of these fates are debated. However, studies have shown that 
both the endosteal and vascular niches represent major components of the 
HSC niche. While some publications have supported the idea that endosteal 
niches are enriched with HSCs and are in close proximity to OBs during 
steady state and also after BM transplantation (Gong 1978; Zhang et al. 
2003; Ellis et al. 2011), other publications have suggested that HSCs localise 
adjacent to the BM sinusoidal endothelial cells, which support the 
perivascular and endothelial niches harbouring HSCs (Duncan et al. 2005; 
Ding et al. 2012; Kiel et al. 2005).  
Pervious publications have provided evidence that factors regulating 
endosteal niche cells influenced the HSC number and function (Calvi et al. 
2003; Suda et al. 2011). Ex vivo real-time imaging of trabecular BM from 
irradiated mice showed that transplanted HSCs were in close proximity to 
the endosteum (Xie et al. 2009). Experimental evidence from the 3D live-
imaging of calvarium BM of mice showed that after transplantation HSC-
enriched cells gradually made their way into the osteoblastic region of the 
BM away from the vasculature (Lo Celso et al. 2009). This study revealed 
that HSCs in the murine calvarium BM resides in close proximity to 
endosteum and OBs (Lo Celso et al. 2009). Analysis of transgenic mice with 
activated parathyroid hormone peptide receptor showed an increase in OB 
numbers that was mediated by Notch ligand, Jagged 1 and in-turn led to an 
increase in HSCs (Calvi et al. 2003). OBs express molecules such as 
angioepoietin-1 (Ang-1), Tpo and osteopoietin (OPN), which are reported to 
influence HSC maintenance (Arai et al. 2004; Nilsson et al. 2005; Qian et al. 
2007). The interaction of Ang-1 in Tie2-enriched HSCs resulted in prolonged 
long-term reconstitution and enhanced their quiescence (Arai et al. 2004). 
Tpo-deficient mice displayed a drastic loss of HSCs in the postnatal period 
(Qian et al. 2007) and OPN played a role in localisation of HSCs in the 
endosteal niche and enhanced their quiescent phenotype (Nilsson et al. 
2005). Hence, OBs contribute to molecules that regulate HSC maintenance 
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in their niche. Additional cells, such as OCs and macrophages, have also 
been reported to influence HSC-niche interactions (Christopher et al. 2011; 
Miyamoto et al. 2011). These studies together suggest the localisation of 
HSCs in the endosteal niche and the influence of factors secreted by the OBs 
on HSC functions. 
On the other hand, several studies suggest the existence of vascular and 
perivascular HSC niche that consists of endothelial cells, BM sinusoidal 
endothelial cells, CAR cells and MSCs (Kiel et al. 2005; Mendez-Ferrer et al. 
2010; Omatsu et al. 2010; Suda et al. 2011). It has been shown that HSCs 
are localised adjacent to BM sinusoidal endothelial cells (Kiel et al. 2005). 
Further, transgenic mice studies showed that the interaction of endothelial 
cells and HSCs was mediated by Notch signalling (Duncan et al. 2005). 
Deletion of Scf secreted by endothelial cells led to a reduced frequency of 
HSCs and resulted in their defective reconstitution potential in congenic 
recipients (Ding et al. 2012). CAR cells in the perivascular niche were shown 
to secrete Scf and Cxcl12 essential for HSC maintenance (Omatsu et al. 
2010). Additionally, depletion of CAR cells was reported to affect HSC 
proliferation capability (Omatsu et al. 2010). Perivascular MSCs were shown 
to express high levels of various genes mediating HSC functions, such as 
Cxcl12, Ang-1, IL-7, Scf and OPN (Chow et al. 2011). Selective depletion of 
Nestin+ mesenchymal stem cells in mice resulted in decreased primitive 
progenitor cells and defective repopulating ability of HSCs in lethally 
irradiated recipients (Mendez-Ferrer et al. 2010). A recent publication 
reported the identification of non-myelinating Schwann cells in the 
perivascular niche as the source of TGF-β activation, thereby playing a 
critical role in TGF-β/Smad signalling in HSC maintenance (Yamazaki et al. 
2011). Furthermore, live imaging of murine calvarial BM reported a highly 
vascularised endosteal niche contributing to the co-existence of endosteal 
and vascular niche (Lo Celso et al. 2009). This was further supported by a 
recent publication where quantitative imaging of femoral BM displayed a 
micro-vascular network in the endosteal niche (Nombela-Arrieta et al. 
2013).  Taken together, it is evident that the BM niche is dynamic and 
consists of diverse cell types regulating HSC functions and fate decisions.  
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A recent publication showed that Scf, a key HSC niche factor, was expressed 
exclusively by perivascular cells and that specific deletion of Scf from 
endothelial and leptin receptor (Lepr)-expressing perivascular cells led to 
loss of HSCs (Ding et al. 2012). Additionally, conditional deletion of Scf from 
OBs or HSCs did not affect the HSC functions (Ding et al. 2012). Further, cell 
type specific conditional deletion of the chemokine, Cxcl12 from the BM 
niche showed that HSC mainly reside in the perivascular niche as deletion of 
Cxcl12 from the endothelial and perivascular stromal cells depleted HSCs 
(Ding and Morrison 2013). Deletion of Cxcl12 from OBs decreased early 
lymphoid progenitors without affecting HSCs or myeloerythroid progenitors, 
suggesting primitive lymphoid progenitors reside in the endosteal niche 
(Ding and Morrison 2013). These papers together revealed that HSCs and 
progenitor cells reside in distinct cellular niches in the BM with HSCs 
choosing the perivascular niche and early lymphoid progenitors in the 
endosteal niche (Ding et al. 2012; Ding and Morrison 2013). Hence a detailed 
characterisation of the BM niche and their roles in regulating HSC functions 
by unfolding their cellular and molecular complexities is necessary to 
provide a more detailed understanding of the BM microenvironment. 
The importance of Hifs in maintaining cell-autonomous HSC functions is 
under extensive study, however the importance of Hifs in the HSC niche is 
poorly understood. Hif signalling is known to play a vital role in maintaining 
the functional microenvironment of the BM (Chan et al. 2009; Nishida et al. 
2012; Rankin et al. 2012). Takubo et al showed that lethally irradiated Hif-
1αΔ/Δ mice (lacking Hif-1α in the BM microenvironment) transplanted with 
BM mononuclear cells expressing WT levels of Hif-1α successfully 
maintained long-term reconstitution potential suggesting that Hif-1α 
expression in the BM niche is not essential for HSC functions (Takubo et al. 
2010). Vegf, regulated by hypoxia has been reported as highly expressed in 
perichondrial cells and chondrocytes, thus influencing HSC niche activity 
(Chan et al. 2009). A previous study showed that impaired expression of 
Vegfα (a hypoxia regulated angiogenic factor) led to increased HSC 
numbers, while affecting their self-renewal and differentiation properties 
(Rehn et al 2011). It was demonstrated that stabilisation of Hifs by Vhl 
deletion specifically in the OBs resulted in accumulation of trabecular OBs 
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and increased expression of Vegf and Epo in turn leading to expansion of 
HSCs (Rankin et al. 2012). Deletion of Vhl in OBs resulted in elevated Epo 
production in the BM and increased primitive erythroid progenitors and 
matured erythroid cells (Rankin et al. 2012). However, Hifs were proposed 
to mediate the haemopoietic defects, such as increased LSKs in Vhl-
deficient mice as co-deletion of Hif-1α and Hif-2α reverted the defective 
phenotype (Rankin et al. 2012). A genetic knockout approach of membrane-
type 1 matrix metalloproteinase (MT1-MMP) in mice caused severe 
pancytopenia and resulted in a defective HSC pool (Nishida et al. 2012). 
Also, several factors secreted by BM niche cells, such as SDF-1, IL-7, Scf and 
Epo were reduced in MT1-MMP-deficient mice (Nishida et al. 2012). Further, 
expression of SDF-1 or Scf reversed the pancytopenia and bypassed the HSC 
proliferation defects (Nishida et al. 2012). This study also revealed that in 
Nestin+ mesenchymal stem cells, MT1-MMP induced Hif-1α expression and 
thereby regulated postnatal haemopoiesis (Nishida et al. 2012).     
Scortegagna et al studied the effect of global deletion of Hif-2α on the HSC 
microenvironment using a small number of congenic Hif-2α null mice that 
survived 1 month into adulthood generated by crossing two different inbred 
strains, C57BL/6 and 129S6/SvEvTac that are Hif-2α heterozygotes 
(Scortegagna et al. 2003b). These Hif-2α null mice showed decreased 
haematocrit, RBC and renal Epo production (Scortegagna et al. 2003b; 
Scortegagna et al. 2005). Transplantation of WT BM cells into lethally 
irradiated mice lacking global Hif-2α expression showed reduced 
haematocrit levels and PB cell counts with low numbers of WBC, RBC and 
platelets as opposed to Controls when analysed after short-term 
engraftment (Scortegagna et al. 2003b). The donor cells in the Hif-2α null 
mice were decreased but repopulated the irradiated recipients and were 
capable of inducing normal haemopoiesis (Scortegagna et al. 2003b). This 
study suggested that haemopoietic defects in transplanted Hif-2α null mice 
might be due to an altered BM microenvironment (Scortegagna et al. 
2003b). However, the phenotype described above might represent a unique 
strain specific phenotype caused by systemic deletion of Hif-2α. Although 
this study attempted to explain the potential role of Hif-2α in the BM niche 
and its influence on HSC engraftment, the overall role of Hif-2α in the HSC 
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niche and its effect on HSC functions remained unclear. In this Chapter, I 
have therefore studied the effect of deletion of Hif-1α and Hif-2α in the 
niche and their importance in maintenance of HSC functions.  
 Outline of experiments described in Chapter 4 4.2
The aim of the experiments in this Chapter was to dissect out the role of 
Hif-2α alone, and Hif-1α and Hif-2α in combination, in non-cell-autonomous 
HSC maintenance. I generated inducible mouse models where acute deletion 
of the floxed Hif-1α and/or Hif-2α allele was achieved by induction of Mx1-
Cre expression by pIpC. Upon confirmation of successful Hif-1α and/or Hif-
2α deletion in the BM microenvironment, I performed immunophenotypic 
analyses of BM, spleens, thymi, PB and found a decrease in absolute 
numbers of HSCs and primitive progenitors in the Hif-2αΔ/Δ mice compared 
to the Control mice. However, the numbers of primitive progenitors and 
HSCs were reverted back to the Control levels with additional deletion of 
one or both alleles of Hif-1α respectively. These results indicate that Hif-2α 
is essential for non-cell-autonomous maintenance of HSC functions and also 
indicate the previously unappreciated interplay between Hif-1α and Hif-2α.   
 Results 4.3
4.3.1 The analysis of mature haemopoietic cells in pIpC-
treated Hif-2α fl/fl Mx1-Cre mice. 
To examine the role of Hif-2α in the maintenance of the haemopoietic 
system, I employed the loss of function approach. Hif-2α is essential for 
embryogenesis (Tian et al. 1998; Peng et al. 2000; Compernolle et al. 2002; 
Scortegagna et al. 2003a; Gruber et al. 2007), however the role of Hif-2α in 
adult haemopoiesis has not been fully explored. As the Hif-2α null mice are 
embryonic lethal (Tian et al. 1998; Peng et al. 2000; Compernolle et al. 
2002), to investigate the function of Hif-2α in adult haemopoiesis I used the 
inducible gene deletion strategy using the Mx1-Cre system. Mx1-Cre is shown 
to efficiently delete floxed alleles in both haemopoietic cells and the 
surrounding BM microenvironment, but to a lesser extent also within non-
haemopoietic organs, such as heart, liver, kidney and urinary bladder (Kuhn 
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et al. 1995; Schneider et al. 2003; Walkley and Orkin 2006; Walkley et al. 
2007). I generated Hif-2αfl/fl Mx1-Cre mice and Hif-2αfl/fl without Mx1-Cre 
(Control) in which the deletion of the floxed Hif-2α allele within the 
haemopoietic system and BM microenvironment is induced by activation of 
Mx1-Cre by administration of pIpC (Section 2.1.2) (Figure 4.1A). Hif-2αfl/fl 
Mx1-Cre and Hif-2αfl/fl males that were 8-12 weeks old were treated IP with 
6 doses of 300ug of pIpC on alternate days. Efficient deletion of the Hif-2α 
allele in the Hif-2αfl/fl Mx1-Cre mice (here after referred to as Hif-2αΔ/Δ) in 
the BM haemopoietic cells and in the CD45- non-haemopoietic cell 
components of the BM was confirmed by PCR using genomic DNA as a 
template (Figure 4.1B). Mice were sacrificed at day 11 from the last pIpC 
injection. Immunophenotypic analyses of differentiated cells in BM and 
spleens of Hif-2αΔ/Δ mice and Control mice revealed equal frequencies and 
total numbers of myeloid cells (Gr-1+ Mac-1+) and erythroid cells (Ter119+) 
(Figure 4.2A, 4.2C-4.2D and 4.2F-4.2H). In the BM of Hif-2αΔ/Δ mice, there 
was a decrease in B-cells (CD19+ B220+) however, spleen had equal number 
of B-cells in the Hif-2αΔ/Δ mice and Control mice (4.2B and 4.2E). There was 
no difference in the total number of T-cells (CD4+ or CD8+) in the spleen or 
T-cells (CD4+, CD8+ and double positive) in the thymus between Hif-2αΔ/Δ 
mice and Control mice (Figure 4.2I-4.2K). These results showed that acute 
deletion of Hif-2α had no impact on multilineage differentiation potential of 
HSCs/progenitors and that Hif-2α was dispensable for the maintenance of 
mature blood lineages in mice (at least within the first 11 days after Hif-2α 
deletion). 
4.3.2 The requirement for Hif-2α  in non-cell-autonomous HSC 
maintenance 
The requirement of Hif-2α in the non-cell-autonomous maintenance of HSC 
functions and its functions in the BM niche cells remained to be 
investigated. Hence, I looked into the effects of Hif-2α deletion on HSCs and 
also in the BM microenvironment. To address this, I used the Mx1-Cre 
inducible gene deletion model that excises the floxed Hif-2α allele in the 
BM microenvironment and in the haemopoietic system upon pIpC treatment.  
Hif-2αfl/fl Mx1-Cre mice and Control mice that were between 8-12 weeks of 
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age were treated with sequential pIpC (6 doses, 300ug per dose).  After pIpC 
treatment, the Hif-2α floxed allele was deleted efficiently within both the 
haemopoietic system and in non-haemopoietic CD45- cell components of the 
BM microenvironment (Figure 4.1B). Mice were analysed 11 days after the 
last pIpC injection. Immunophenotypic analyses of the BM revealed that Hif-
2αΔ/Δ mice had reduced frequencies and absolute numbers of LSKs, HSCs 
(LSK CD150+CD48-) and primitive progenitors within the LSK compartment 
(LSK CD150+CD48+ and LSK CD150-CD48+) compared to Control mice (Figure 
4.3C–4.3F). However, there was no difference in the numbers of myeloid 
progenitors (Lin-c-Kit+, LK cells), Lin- cells (comprising HSCs and different 
progenitors at different stages of the differentiation hierarchy) or LSK 
CD150-CD48- (ST-HSCs) between Hif-2αΔ/Δ mice and Control mice (Figure 
4.3A-4.3B and 4.3G). Deletion of Hif-2α led to a decrease in numbers of 
HSCs and primitive progenitors compared to Controls. Taking into account 
that deletion of Hif-2α within HSCs does not perturb normal haemopoiesis 
along with the above results, my data indicated that Hif-2α is required for 
maintenance of HSCs in a non-cell-autonomous manner. The results in this 
thesis suggested that although Hif-2α within the HSCs alone may be 
dispensable for normal haemopoiesis, Hif-2α in the BM microenvironment is 
essential for normal maintenance of HSCs and primitive progenitors. 
4.3.3  The lack of extra-medullary haemopoiesis in Hif-2αΔ/Δ 
mice 
The above experiments showed the decrease in numbers of HSCs and 
primitive progenitors in the Hif-2αΔ/Δ mice compared to the Control mice. 
This decrease could be due to mobilisation of HSCs or primitive progenitors 
from BM to PB and their migration to other haemopoietic organs such as the 
spleen. To address this, I performed immunophenotypic analyses to detect 
the presence of primitive progenitors in the blood and spleens of Hif-2αΔ/Δ 
mice and Control mice. Hif-2αfl/fl Mx1-Cre and Control mice were treated 
with 6 doses of pIpC on alternate days and 11 days after the last pIpC 
injection mice were sacrificed and tested for extra-medullary haemopoiesis 
in the spleen and the PB. FACS analyses revealed that there was no 
difference in the percentage of LSKs in the spleen or PB of Hif-2αΔ/Δ mice 
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and in the Control (Figure 4.4). This confirmed that there was no 
mobilisation of the HSCs or primitive progenitors from the BM to the spleen 
or PB in the Hif-2αΔ/Δ mice.  
Next, to test if the loss of HSCs and primitive progenitor cells in the Hif-
2αΔ/Δ mice was due to apoptosis, I carried out a cell viability assay using 
Annexin V and DAPI. I performed the immunostaining of the LSKs from the 
BM with Annexin V and DAPI. There was no difference in the percentage of 
Annexin-/DAPI- (alive cells), Annexin V+/DAPI- (early apoptotic cells), 
Annexin V+/DAPI+ (late apoptotic cells) or AnnexinV-/DAPI+ (dead cells) in 
the BM from Hif-2αΔ/Δ mice and the Control mice (Figure 4.5). This cell 
viability assay showed no difference in the frequency of cell death in the 
LSK cells in Hif-2αΔ/Δ and Control mice. 
4.3.4 The analysis of HSCs in pIpC-treated Hif-2α fl/fl mice, Hif-
1α+/fl Hif-2α fl/fl mice and Hif-1α fl/fl Hif-2α fl/fl mice 
It is widely accepted that Hif-1α and Hif-2α have high sequence homology, 
but vary widely in their mRNA expression pattern (Gruber et al. 2007; 
Takubo et al. 2010). While Hif-1α is expressed ubiquitously and expressed at 
higher levels in the HSCs compared to haemopoietic progenitor and mature 
cells, Hif-2α expression is restricted to organs like the endothelium, lung, 
brain, neural crest derivatives and Hif-2α is expressed in HSCs and 
haemopoietic progenitors (Gruber et al. 2007; Takubo et al. 2010; Kocabas 
et al. 2012). Hif-1α and Hif-2α have common target genes, including Vegf 
and Glut-1, (Hu et al. 2003) but may also regulate the expression of distinct 
genes; e.g. Hif-1α regulates hexokinase, PGK-1 (Hu et al. 2003) while Hif-2α 
regulates renal Epo (Rankin et al. 2007). The interplay between Hif-1α and 
Hif-2α in the HSC and BM microenvironment has yet to be fully understood. 
To address this, I generated Hif-1α+/fl Hif2αfl/fl Mx1-Cre, Hif-1αfl/fl Hif-2αfl/fl 
Mx1-Cre and Hif-1αfl/fl Hif-2αfl/fl (Control) mice. Upon induction of Cre by 
pIpC, the floxed alleles are excised resulting in acute deletion of Hif-1α and 
Hif-2α in the adult haemopoietic organs and BM microenvironment (Figure 
4.6A and 4.6B). In my previous experiment (Chapter 4 Section 4.2.2), 
deletion of Hif-2α resulted in decreased HSCs and primitive progenitors in 
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the LSK compartment (LSK CD150+CD48+ and LSK CD150-CD48+, LSK CD150-
CD48-). To investigate if additional deletion of Hif-1α would exacerbate the 
Hif-2αΔ/Δ phenotype, Hif2αfl/fl Mx1-Cre, Hif-1α+/fl Hif2αfl/fl Mx1-Cre, Hif-1αfl/fl 
Hif-2αfl/fl Mx1-Cre and Hif-1αfl/fl Hif-2αfl/fl (Control) mice were treated with 
6 doses of pIpC injections and monitored on a daily basis. Gene deletion was 
confirmed in Hif-1α+/fl Hif-2αfl/fl Mx1-Cre mice (Hif-1α+/Δ Hif-2αΔ/Δ) and Hif-
1αfl/fl Hif-2αfl/fl Mx1-Cre (DKO) BM cells (Figure 4.6A). There were no survival 
defects observed and the WBC count was normal in PB, BM and spleens in 
Hif-1α and Hif-2α deficient mice compared to Control irrespective of the 
genotypes (Figure 4.6C-4.6D). Mice were sacrificed at day 11 after the last 
pIpC injection and the haemopoietic organs were characterised 
immunophenotypically.  
Surprisingly, unlike Hif-2αΔ/Δ mice, Hif-1α+/Δ Hif-2αΔ/Δ mice showed similar 
number of LSKs and primitive progenitors (LSK CD150-CD48+, LSK 
CD150+CD48+) to the Control mice (Figure 4.7C, 4,7E and 4.7F). However, 
the number of HSCs in Hif-1α+/Δ Hif-2αΔ/Δ mice (i.e. mice lacking one allele 
of Hif-1α and both alleles of Hif−2α) was reduced compared to the Control 
mice (Figure 4.7D). With deletion of both alleles of Hif-1α and Hif-2α, in 
DKO mice there was a similar number of HSCs to Control mice compared to 
decreased HSCs in the Hif-2αΔ/Δ (Figure 4.7D). However, DKO mice showed 
reduced numbers of primitive progenitors in the LSK compartment (LSK 
CD150-CD48+, LSK CD150+CD48+) compared to Control mice with WT levels of 
Hif-1α and Hif-2α (Figure 4.7E-F). The number of ST-HSCs did not show any 
significant changes in any of the genotypes (Figure 4.7G). There was no 
difference in the Lin-, LK and mature blood lineages in the spleen or thymus 
in Hif-1α+/Δ Hif-2αΔ/Δ, DKO, and Control mice (Figure 4.7A-4.7B and 4.8). 
However, in the BM of DKO mice there was an increase in the number of 
myeloid cells (Gr-1 Mac-1) and erythroid cells (Ter119+) compared to the 
Control mice (Figure 4.8A and 4.8C). The total number of B-cells (CD19+ 
B220+) was equal to Control mice in all the genotypes (Figure 4.8B and J). 
These results illustrate the dose dependent interplay between Hif-1α and 
Hif-2α between different cell types (Table 4.1). 
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4.3.5 The analysis of HSCs in males and females of pIpC-
treated Hif-2α fl/fl mice, Hif-1α+/fl Hif-2α fl/fl mice and Hif-
1α fl/fl Hif-2α fl/fl mice 
Previous studies have shown the influence of sex hormones in regulating 
bone mass (Manolagas 2010). Studies have shown that Hif target genes, Vegf 
and Angiopoietins (Ang1 and Ang2), were regulated by oestrogen and 
progesterone in human endometrial stromal cells (Tsuzuki et al. 2013). Also, 
various publications have demonstrated that sex steroid hormones, 
oestrogen and androgen, regulated HIF-1α, HIF-2α and VEGF expression in 
various cancer models, such as human endothelial cancer, prostrate cancer 
and in murine breast cancer cells (Mabjeesh et al. 2003; Boddy et al. 2005; 
Kazi and Koos 2007; George et al. 2012). Pregnancy or exogenous 
administration of oestrogen was shown to decrease haemopoietic colony 
forming cells and mature B-lymphocytes (Fried et al. 1974; Medina et al. 
1993). A recent publication showed that estradiol treatment increased the 
number of HSCs in the vascular niche (Illing et al. 2012). In the previous 
section I have shown that Hif-2α deletion in the HSCs and BM 
microenvironment resulted in decreased number of HSCs and primitive 
progenitor cells compared to Control and co-deletion of both alleles of Hif-
1α rectified the defective HSC phenotype (Section 4.3.2 and 4.3.4). 
Immunophenotypic analysis of sex-matched BM by multicolour flow 
cytometry showed that Hif-2αΔ/Δ males displayed decreased absolute 
numbers of HSCs (LSK CD150+CD48-) and primitive progenitors within the LSK 
compartment (LSK CD150+CD48+ and LSK CD150-CD48+, LSK CD150-CD48-) 
compared to the Control males analysed 11 days after last pIpC 
administration (Figure 4.9). Further, analysis of Hif-2αΔ/Δ females showed 
equal number of HSCs (LSK CD150+CD48-) and primitive progenitors within 
the LSK compartment (LSK CD150+CD48+ and LSK CD150-CD48+) compared to 
the Control (Figure 4.9). However, analysis of Hif-1α+/Δ Hif-2αΔ/Δ males and 
females along with Controls for respective gender showed comparable 
numbers of HSCs (LSK CD150+CD48-) and primitive progenitors within the LSK 
compartment (LSK CD150+CD48+ and LSK CD150-CD48+, LSK CD150-CD48-) 
(Figure 4.10). The DKO males and females had similar number of HSCs (LSK 
CD150+CD48-) compared to respective Controls (Figure 4.10B). The absolute 
number of primitive progenitors within the LSK compartment (LSK 
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CD150+CD48+ and LSK CD150-CD48+) were decreased in DKO males compared 
to Control mice whereas DKO and Control females showed no difference in 
absolute number of primitive progenitors within the LSK compartment (LSK 
CD150+CD48+ and LSK CD150-CD48+) (Figure 4.10D-E). These surprising 
results imply that the role of Hifs in HSC maintenance is dependent on 
gender. 
4.3.6 Immunophenotypic analysis of HSC niche cells lacking 
Hif-2α   
It has been shown that OBs-specific Vhl deletion (most likely via 
upregulation of HIFs in the OBs) resulted in expansion of the HSC niche and 
increased numbers of HSCs (Rankin et al. 2012). However, there is no direct 
evidence of specific functions of Hif-1α and Hif-2α in the maintenance of 
adult HSC niche. I have shown that Hif-2α is essential for the maintenance 
of functional HSCs in a non-cell-autonomous manner specifically in males 
(Section 4.3.6). Also, deletion of Hif-1α together with Hif-2α rescued the 
HSC loss observed in Hif-2αΔ/Δ males. To further dissect the role of Hif-2α in 
maintaining the BM niche and in turn number of functional HSCs, I used the 
CKO mouse model.  
I analysed the expression of Hif-1α and Hif-2α in different populations of 
niche cells sorted based on the expression of immunophenotypic markers by 
flow cytometry (Nakamura et al 2010). Hif-1α expression in endothelial and 
endosteal cells that were ALCAM+Sca-1- was higher compared to immature 
mesenchymal enriched ALCAM-Sca-1+ cells and endosteal cells that were 
ALCAM-Sca-1- (Figure 4.11A). Hif-2α expression was highest in endothelial 
cells (10 folds higher) followed by similar expression levels in immature 
mesenchymal enriched ALCAM-Sca-1+ cells and endosteal cells that were 
ALCAM+Sca-1-, with lowest levels of expression in the endosteal cells that 
were ALCAM-Sca-1- (Figure 4.11B). To investigate the effect of deletion of 
Hif-2α on the HSC niche in males, I analysed sex-matched Hif-2αfl/fl Mx1-Cre 
and Control males. The deletion of the floxed allele was induced by pIpC 
administration. Mice between 8 weeks and 12 weeks of age received 6 doses 
of pIpC and were sacrificed at 11 days after the last pIpC injection. To 
isolate the BM niche cells, bone fragments from Hif-2αΔ/Δ and Control mice 
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were treated with crude collagenase VIII. Efficient deletion of Hif-2α in the 
BM microenvironmental cells was confirmed by PCR (Figure 4.6B). The 
isolated cells were analysed for the expression of cell surface markers using 
flow cytometry to distinguish different subpopulations of the endothelial 
and endosteal niche (Nakamura et al 2010). There was no difference in the 
number of endothelial cells (CD45-Ter119-CD31+) cells between Hif-2αΔ/Δ and 
Control mice (Figure 4.12A). There was no difference in the number of 
immature mesenchymal enriched ALCAM-Sca-1+ cells (Figure 4.12B) or 
endosteal cells that were ALCAM-Sca-1- and ALCAM+Sca-1-, classed as OB-
enriched cells (Figure 4.12C-D), between Hif-2αΔ/Δ and Control mice. 
Collectively, the immunophenotypic analysis of the male BM niche showed 
no difference in the number of endothelial, endosteal and mesenchymal 
niche cells in Hif-2αΔ/Δ or Control mice.  
4.3.7 The analysis of Hif-2α  deficient BM niche in regulating 
HSC reconstitution potential 
To test the effect of Hif-2α deletion on the functionality of the HSC niche, I 
performed a transplantation experiment. 500,000 WT CD45.1+ BM cells were 
transplanted into lethally irradiated Hif-2αfl/fl Mx1-Cre and Control mice. 
After 8 weeks of transplantation following multilineage engraftment (Figure 
4.13B) mice were injected with 6 doses of pIpC on alternate days to induce 
the deletion of Hif-2α. BM was analysed 4 weeks after the last dose of pIpC 
(Figure 4.13A). The result suggested an equal number of HSCs and primitive 
progenitor cells in the Hif-2αΔ/Δ and Control recipient mice (Figure 4.14). I 
also analysed the number of endosteal and endothelial cells in the BM niche. 
Consistent with the previous data shown in figure 4.13, there was no 
difference in the number of endothelial cells, immature mesenchymal cells 
or OBs in the Hif-2αΔ/Δ mice or Controls (Figure 4.15). The results suggest 
that Hif-2α deletion in the HSC niche alone might not be critical for HSC 
maintenance and that deletion from the HSC niche together with HSCs might 
affect their functions. However, this experiment had insufficient numbers of 
Hif-2αΔ/Δ males to perform statistical tests.  
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 Discussion 4.4
4.4.1 Hif-2α  is essential for non-cell-autonomous maintenance 
of HSCs specifically in males, but not females 
The above experiments shed light on our current understanding of the 
contribution of Hifs to the non-cell-autonomous maintenance of HSCs. 
Analysis of different populations of BM niche cells in WT mice revealed that 
Hif-2α was expressed in all cell populations analysed with highest expression 
in endothelial cells (Figure 4.10B). The results described in this Chapter 
showed that acute deletion of Hif-2α in the haemopoietic system and 
surrounding BM microenvironment resulted in a decrease of LSKs, 
particularly in males and not in females. The results discussed hereafter 
pertain to the studies observed specifically in males unless otherwise 
mentioned. Analysis of Hif-2αΔ/Δ mice after 11 days of pIpC was chosen as 
the optimum time point to overcome the interferon responsive phenotype 
and to analyse the effect of acute Hif-α deletion on HSCs. Hif-2αΔ/Δ mice 
showed a reduced number of primitive progenitors (LSK CD48+CD150+, LSK 
CD48-CD150+). The frequency and total number of HSCs was reduced in mice 
lacking Hif-2α compared to Control mice. Immunophenotypic analyses of 
spleens and PB of Hif-2αΔ/Δ mice showed no evidence of mobilised HSCs or 
primitive progenitors in Hif-2αΔ/Δ mice compared to Control mice. Together, 
these results imply that Hif-2α signalling within the BM microenvironment 
contributed to the maintenance of the HSC pool and primitive progenitors. 
There was no difference in cell viability in primitive progenitors between 
Hif-2αΔ/Δ and Control mice as revealed by Annexin V staining. The mature 
cells in the haemopoietic organs including BM, spleen and thymus were 
unaffected upon the deletion of Hif-2α. Hif-2αΔ/Δ mice displayed normal 
haemopoiesis, which successfully differentiated into mature blood lineages. 
Hence, the reduced number of HSCs and primitive progenitors and the lack 
of phenotype in the mature blood cells in Hif-2αΔ/Δ compared to Control 
mice additionally suggested that the effect of Hif-2α deletion was specific 
to HSC and primitive progenitor cells. This is correlated with more recent 
work by Rankin et al who showed an enhanced stabilisation of Hifs by Vhl 
deletion specifically in the endosteal niche cells, leading to expansion of 
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niche cells and an increase in HSC numbers (Rankin et al. 2012). It has been 
shown before that Hif-2α in mice is a major isoform of Hifs controlling Epo 
production in the kidney and global expression of Hif-2α is critical for 
erythropoiesis (Scortegagna et al. 2003a; Gruber et al. 2007). A previous 
publication suggested that Hif-2α in the BM microenvironment regulated 
repopulation potential of HSCs, but the importance of Hif-2α in the BM 
microenvironment was not fully understood (Scortegagna et al. 2003b). 
These results taken together with previous data showing that Hif-2α was 
dispensable for cell-autonomous HSC maintenance (Chapter 3) suggested 
that Hif-2α expression in the BM microenvironment was essential for the 
maintenance of HSC functions in a non-cell-autonomous manner and was 
gender dependent. However, since Mx1-Cre is known to recombine floxed 
alleles in non-haemopoietic organs like heart, liver, kidney and urinary 
bladder (Kuhn et al. 1995; Schneider et al. 2003; Walkley and Orkin 2006; 
Walkley et al. 2007) it might be possible that Hif-2α deletion also outside 
the BM microenvironment contributed to the phenotype in Hif-2αΔ/Δ mice. 
Nonetheless, as shown by data described in figures 4.3 and 4.6B, deletion of 
Hif-2α in the BM microenvironment cells accounted at least partially for the 
loss of HSCs and primitive progenitors.  
4.4.2 Additional deletion of Hif-1α  rescues non-cell-
autonomous HSC loss observed in Hif-2αΔ /Δ males 
Several studies have suggested that hypoxia-signalling pathways in the BM 
niche might play a vital role in regulating HSC functions (Rehn et al. 2011; 
Nishida et al. 2012; Rankin et al. 2012). Several publications showed the 
importance of Hif-1α in regulating BM niche functions (Miharada et al 2011; 
Nishida et al. 2012; Rankin et al 2012). MT1-MMP and Cripto play a major 
role in regulating HSC functions via Hif-1α-signalling (Miharada et al 2011; 
Nishida et al. 2012). MT1-MMP regulates haemopoietic Hif-dependent 
signalling in the BM niche cells by activating the Hif-1α pathway via FIH-1 
(Nishida et al. 2012). It has been reported that reduced expression of Cripto 
resulted in decreased number of HSCs that are positive for its receptor 
GRP78 in the endosteal region of Hif-1α CKO mice (Miharada et al 2011). 
Increased stabilisation of HIFs by Vhl deletion resulted in Nestin+ HSC niche 
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cell expansion and in turn increased HSCs with defective self-renewal and 
differentiation potential (Rankin et al 2012). However, the relationship 
between Hif-1α and Hif-2α signalling within the BM microenvironment 
remains unknown. It has been reported that Hif-1α deletion using Mx1-Cre 
within the HSC and BM microenvironment at steady state does not affect the 
maintenance of HSCs (Takubo et al. 2010). I have shown that deletion of 
Hif-2α specifically in males resulted in decreased numbers of HSCs and 
primitive progenitors compared to sex-matched controls. Hence, results 
from this Chapter compared to previous publications suggested that unlike 
Hif-1α,   Hif-2α expression in the BM niche is essential for the maintenance 
of HSC functions specifically in males. Alternatively, the authors might have 
missed the short-term HSC phenotype due to compensatory mechanisms 
activated in Hif-1αΔ/Δ mice analysed several weeks after pIpC (Takubo et al. 
2010). Further, I have shown that additional deletion of one allele of Hif-1α 
together with Hif-2α reverted the loss of primitive progenitors (LSK 
CD48+CD150+, LSK CD48-CD150+), but no significant rescue of reduced HSCs 
that was observed in Hif-2αΔ/Δ males. Notably, the loss of HSCs in Hif-2αΔ/Δ 
mice is bypassed only upon deletion of both alleles of Hif-1α along with Hif-
2α. Taken together, these results showed a cell type specific interplay 
between Hif-1α and Hif-2α in HSCs and primitive progenitors (Table 4.1). 
Several studies shed light on the fact that Hif-signalling pathways can be 
critically regulated in a dose-dependent manner. For example, in the study 
by Takubo et al, the authors showed that deletion of one allele of Vhl led to 
increased quiescence of HSCs and their expansion, but in contrast over-
stabilisation of Hif-1α by deletion of both alleles of Vhl resulted in defective 
HSC phenotype upon transplantation (Takubo et al. 2010). Additional studies 
showed a profound increase in Hif-2α levels in the Hif-1α-/- HSCs (Kocabas et 
al. 2012). Knockdown of Hif-2α enhanced the stabilisation and functions of 
Hif-1α protein (Carroll and Ashcroft, 2006; Raval et al., 2005; Schulz et al., 
2012). On the other hand, Vhl deletion in the endosteal niche resulted in 
increased HSC number and their reconstitution potential (Rankin et al. 
2012). These results together suggest interplay between Hif-1α and Hif-2α 
and also add to the dose-dependent effect of Hif-1α and Hif-2α in different 
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cell types. The lack of differences in the number of mature haemopoietic 
lineages observed in the BM, spleen and thymus except a decrease in 
number of B-cells (CD19+ B220+) in the spleen is in agreement with previous 
publications showing role of Hifs in B-cell regulation (Kojima et al. 2002; 
Kojima et al. 2010). Taken together, the results imply that the decrease in 
HSCs and primitive progenitor cells caused by Hif-2 α−deficiency is 
mediated by Hif-1α.  
The relationship between the BM niche and HSCs has been extensively 
studied and alterations of BM niche cell types influence the number and 
functions of HSCs (Calvi et al. 2003; Chan et al. 2009; Eliasson and Jonsson 
2010; Ding et al. 2012). Sex steroids, like oestrogen and androgen, affect 
the bone mass by regulating OBs and OCs (Samuels et al. 1999). Several 
human and murine studies have demonstrated the relationship between 
steroid hormones and hypoxia signalling pathways in several cell types, 
including HSCs, B- lymphocytes, thymocytes, BM niche cells, breast cancer, 
prostrate cancer and endocrine stromal cells (Fried et al. 1974; Medina et 
al. 1993; Thurmond et al. 2000; Tsuzuki et al. 2013). My data showed that 
acute deletion of Hif-2α reduced the number of HSCs and primitive 
progenitors in males compared to Control mice, but the females lacking Hif-
2α or Control mice had similar numbers of HSCs and primitive progenitors. 
The defective HSC phenotype was specific to males lacking Hif-2α and not 
females. This might be due to the advantage of oestrogen in the female BM 
niche compared to males. Independent from the effect of oestrogen on the 
BM niche, a recent publication showed that estradiol treated female mice 
had increased numbers of LSK and increased reconstituted potential in 
lethally irradiated mice (Tsuzuki et al. 2013). However, continued 
supplement of estradiol affected the quiescent state of HSCs and increased 
their cell cycle rate. This resulted in exhaustion of the HSCs during serial 
transplantation. In the prostrate cancer (LNCaP) cells dihydrotestosterone 
(DHT) induced Hif-1α expression and elevated Vegf production through the 
PI3/AKT pathway (Mabjeesh et al. 2003; Kimbro and Simons 2006). Hence, 
additional to my result, the publications have shown that sex steroids affect 
the BM niche and HSCs, thus playing a role in maintenance of HSCs. The 
result in this Chapter suggested that the female BM niche had an advantage 
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over the male BM niche in the absence of Hif-2α. Considering the previous 
publications showing that estradiol elevated LSK numbers and BM mass 
(Tsuzuki et al. 2013), the female BM niche might have oestrogen regulated 
HSC maintenance resistant to Hif-2α deletion. However, further studies 
need to be carried out to dissect the relationship between sex steroids and 
HSC functions and also to fully explore the mechanisms governing this 
effect. 
BM	   Hif-­‐2αΔ/Δ	  Vs	  Control	   Hif-­‐1α+/Δ:Hif-­‐2αΔ/Δ	  Vs	  Hif-­‐2αΔ/Δ	   DKO	  Vs	  Hif-­‐2αΔ/Δ	  
WBC	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
Lin-­‐	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
LK	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
LSK	   Decrease	   Increase	   No	  significant	  difference	  
LSK	  CD150-­‐CD48+	   Decrease	   Increase	   No	  significant	  difference	  
LSK	  CD150+CD48+	   Decrease	   Increase	   No	  significant	  difference	  
HSC	   Decrease	   No	  significant	  difference	   Increase	  
ST-­‐HSC	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
Myeloid	  cells	  (Gr-­‐1,	  Mac-­‐1)	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
Erythroid	  cells	  (Ter119)	   No	  significant	  difference	   No	  significant	  difference	   Decrease	  
B-­‐cells	  (CD19,	  B220)	   Decrease	   No	  significant	  difference	   No	  significant	  difference	  
T-­‐cells	  (CD4,	  CD8)	   No	  significant	  difference	   No	  significant	  difference	   No	  significant	  difference	  
Table 4. 1: Summary of phenotype observed in Hif-2αΔ/Δ, Hif-1α+/Δ	  Hif-2αΔ/Δ and DKO males. 
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4.4.3 Hif-2α  deletion does not affect absolute numbers of the 
niche cell components in the BM 
In this Chapter, I have employed immunophenotypic analysis to investigate 
the effect of Hif-2α deletion in the niche cells of the BM. Growing evidence 
indicates the importance of Hif-1α and its targets in HSC niche functions 
(Rankin et al 2012; Miharada et al 2011; Nishida et al. 2012). But, the 
importance of Hif-2α specifically in the maintenance of the HSC niche 
influencing HSC functions is unclear. The results shown in this chapter 
suggested that Hif-2α deletion did not affect total numbers of the niche cell 
components. However, the experiments are based on immunophenotypic 
analyses. The transplantation experiment provided a clue that the 
functionality of the HSC niche lacking Hif-2α was comparable to its Control. 
There was equal engraftment of HSCs in mice lacking Hif-2α in the niche 
cells as compared to the Control mice. Thus expression of Hif-2α in the 
niche cells alone might be dispensable for the maintenance of HSC pool. 
This is in contrast to the previous publication by Scrotegagna, where the 
author attributed the decrease in HSCs and reduced potential of short-term 
engraftment of WT cells in lethally irradiated Hif-2α null mice to the lack of 
Hif-2α expression in the BM niche (Scortegagna et al 2003; (Scortegagna et 
al. 2003b). However, the defective engraftment potential of WT HSCs in the 
Hif-2α−deficient BM niche might be specific to congenic mice developed by 
interbreeding two different strains and to the small experimental cohort. 
Therefore, the data from this Chapter suggested that deletion of Hif-2α in 
both HSCs and BM niche cells led to a decrease in HSCs and LMPPs. Whether 
the transplantation results indicating no difference in the number of 
engrafted HSCs between Hif-2αΔ/Δ and Control BM niche were biologically 
relevant or were a consequence of small sample size remains to be 
addressed. Further genetic studies focusing on the effect of Hif-1α and Hif-
2α deletion, singly and in combination, specifically in the niche cells will 
provide with more insights into the functions of HIFs in the maintenance of 
niche cells and HSCs.  
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 Conclusion 4.5
The experiments presented in this Chapter provide evidence that Hif-2α-
dependent signalling is essential for non-cell-autonomous HSC maintenance 
specifically in males and not in females. The results showed that the 
presence of Hif-1α is required for the generation of the phenotype in in Hif-
2αΔ/Δ males as deletion of Hif-1α rescues the HSC phenotype. My data 
showed that loss of Hif-2α expression had no effect on the number of HSC 
niche cells as revealed by immunophenotypic analysis. Transplantation 
experiment suggested that the BM niche from Hif-2αΔ/Δ males maintained 
HSC reconstitution. Hence, lack of Hif-2α  expression collectively in the HSC 
and the BM niche resulted in the decrease of HSCs and primitive progenitors 
in Hif-2αΔ/Δ males. The data also suggest the possibility of sex-steroid 
regulated Hif-pathways responsible for gender-specific HSC phenotype 
observed in Hif-2αΔ/Δ mice. Therefore, the results in this Chapter 
demonstrated that the complex interplay between Hif-1α- and Hif-2α-
dependent signalling is required for adult HSC maintenance in a non-cell-
autonomous manner. 
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Figure 4. 1: Conditional deletion of Hif-2α  induced by pIpC administration  
(A) Experimental Design- Hif-2αΔ/Δ and Control mice between 8-12 weeks of age were treated 
with 6 doses of pIpC on alternate days. The mice were sacrificed at 11 days after the last 
injection (B) Confirmation of Hif-2α deletion in the BM cells of Hif-2αΔ/Δ mice by PCR using 
genomic DNA, 1: Hif-2αΔ/Δ and 2-Control, n=5. 
pIpC 
A 
11 days 
Hif-2α fl/fl Mx1-Cre 
Hif-2α fl/fl 
300µg/injection 
 6 doses 
alternate days 
Analysis 
Hif$2α' Δ'
ﬂ'
1'''''2'B 
Mx1'Cre'
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Figure 4. 2: Analysis of mature blood lineages in Hif-2αΔ/Δ males. 
Total number of myeloid cells (Gr-1, Mac-1), erythroid cells (Ter119), B-cells (CD19, B220) and 
T-cells (CD4, CD8) in (A-C) BM, (D-H) spleen and (I-K) thymus of Hif-2αΔ/Δ (n=5) and Control 
mice (n=12) analysed 11 days after last pIpC injection. The results are presented as average 
number of cells ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance, p<0.05 (*). 
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Figure 4. 3: Conditional deletion of Hif-2α  results in defective HSCs.  
Absolute number of (A) Lin-, (B) LK, (C) LSK, (D) HSCs, (E-F) Primitive progenitors and (G) 
ST-HSCs in the BM of Hif-2αΔ/Δ (n=5) and Control males (n=12) analysed after 11 days after the 
last pIpC injection. The results are presented as average number of cells ± SD and statistical 
analysis was performed by two-tailed student's t tests assuming unequal variance, p value ≤ 0.05 
(*), p ≤ 0.005 (**) and p ≤ 0.0005 (***) and p ≥	  0.05	  (ns). 
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Figure 4. 4: Analysis of PB and spleen for extramedullary haemopoiesis.  
FACS plots representing the percentage of LSKs in the (A) PB and (B) Spleen of Hif-2αΔ/Δ 
(n=3) and control (n=4) males. The results are mean± SD. 
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Figure 4. 5: Analysis of apoptosis in the Hif-2αΔ/Δ males. 
Percentage of (A) Annexin-/DAPI- viable cells, (B) Annexin V+/DAPI- (early apoptotic cells), (C) 
Annexin V+/DAPI+ (late apoptotic cells) and (D) AnnexinV-/DAPI+ (dead cells) in the LSK cells 
from Hif-2αΔ/Δ (n=3) and Control (n=3) mice. The results are presented as average number of 
cells ± SD and statistical analysis was performed by two-tailed student’s t test assuming unequal 
variance. 
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Figure 4. 6: Conditional deletion of Hif-1α  and Hif-2α  induced by pIpC administration.  
Confirmation of Hif-1α and Hif-2α deletion in the (A) Haemopoetic cells of Hif-2αΔ/Δ and DKO 
mice (1- Control, 2-DKO and 3- Hif-2αΔ/Δ) and (B) BM microenvironment of Hif-2αΔ/Δ mice by 
PCR using genomic DNA, 1- Control, 2- Hif-2αΔ/Δ (C) Total count of WBC in the (C) BM, (D) 
Spleen and (E) Thymi of Hif-2αΔ/Δ (n=5), Hif-1α+/Δ Hif-2αΔ/Δ (n=7), DKO (n=9) and Control 
males (n=12). The results are presented as average number of cells ± SD. 
1         2       3 A 
Hif-1α Δ 
fl 
Wt 
Mx1 Cre 
Hif-2α Δ 
fl 
Hif-2α Δ 
fl 
1     2 B 
Mx1 Cre 
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Figure 4. 7: Immunophenotypic analysis of HSCs and progenitor compartments of Hif-2αΔ/Δ, 
Hif-1α+/Δ Hif-2αΔ/Δ and DKO males. 
Absolute number of (A) Lin-, (B) LK, (C) LSK, (D) HSC and (E-F) Primitive progenitors and (G) ST-
HSC in the BM of Hif-2αΔ/Δ (n=5), Hif-1α+/Δ Hif-2αΔ/Δ (n=7), DKO (n=9) and Control males (n=12) 
analysed 11 days after the last pIpC injection. The results are presented as average number of cells ± SD 
and statistical analysis was performed by two-tailed student's t tests assuming unequal variance, p value ≤ 
0.05 (*), p ≤ 0.005 (**). The results from Figure 4.3 comprising of Hif-2αΔ/Δ and control analysis is 
being used for the comparison purpose. 
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Figure 4. 8: Analysis of mature blood lineages. 
Total number of myeloid cells (Gr-1, Mac-1), erythroid cells (Ter119), B-cells (CD19, B220) and T-
cells (CD4, CD8) in (A-C) BM, (D-H) spleen and (I-K) thymus of Hif-1α+/Δ Hif-2αΔ/Δ (n=7), DKO 
(n=9) and Control males (n=12). The results are presented as average number of cells ± SD and 
statistical analysis was performed by two-tailed student's t tests assuming unequal variance, p<0.005 
(**). 
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Figure 4. 9: Gender biased effect of Hif-2α  on HSC and primitive progenitors.  
Absolute number of (A) Lin-, (B) LK, (C) LSK, (D) HSCs, (E-F) Primitive progenitors and (G) ST-HSCs in 
the BM of Hif-2αΔ/Δ and Control mice analysed after 11 days of last pIpC injection, filled circles- males, 
empty circles- females. The results are presented as average number of cells ± SD and statistical analysis was 
performed by two-tailed student's t tests assuming unequal variance, p value ≤ 0.05 (*), p ≤ 0.005 (**) and p ≤ 0.0005 (***) and p ≥	  0.05	  (ns). The data from figure 4.3 consisting of analysis of Hif-2αΔ/Δ and Control 
males are used for comparison with the Hif-2αΔ/Δ and Control females. 
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Figure 4. 10: Gender biased effect of Hif-1α+/Δ Hif-2αΔ/Δ and DKO HSC and primitive progenitors.  
Absolute number of (A) LSK, (B) HSCs, (C) ST-HSCs and (D-E) Primitive progenitors in the BM of Hif-
1α+/Δ Hif-2αΔ/Δ, DKO and Control mice analysed after 11 days of last pIpC injection, filled circles- males, 
empty circles- females. The results are presented as average number of cells ± SD and statistical analysis was 
performed by two-tailed student's t tests assuming unequal variance, p value ≤ 0.05 (*). The data from figure 
4.7 consisting of analysis of Hif-2αΔ/Δ and Control males are used for comparison with the Hif-2αΔ/Δ and 
Control females. 
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Figure 4. 11: Relative expression of Hif-1α  and Hif-2α  in the BM niche cells.  
BM niche cells were sorted based on the immunophenotypic analysis by flow cytometry. 
Relative expression of (A) Hif-1α and (B) Hif-2α in endothelial cells (CD45-Ter119-CD31+), 
immature mesenchymal enriched ALCAM-Sca-1+ cells, endosteal cells that are ALCAM-Sca-1- 
and ALCAM+Sca-1-. 
Figure 4. 12: Immunophenotypic analysis of HSC niche cells lacking Hif-2α .  
Absolute number of (A) Endothelial cells (CD45-Ter119-CD31+), (B) Immature mesenchymal 
enriched ALCAM-Sca-1+ cells, Endosteal cells that are (C) ALCAM-Sca-1- and (D) ALCAM+Sca-
1- cells in the Hif-2αΔ/Δ (n=4) and Control males (n=4). The results are presented as average 
number of cells ± SD and statistical analysis was performed by two-tailed student's t tests 
assuming unequal variance. 
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Figure 4. 13: Analysis of reconstitution potential of BM niche lacking Hif-
2α  expression.  
(A) Experimental design - Lethally irradiated Hif-2αfl/fl Mx1-Cre and Control males transplanted 
with 500,000 WT CD45.1+ BM cells after 8 weeks of transplantation were treated with 5 doses of 
pIpC and analysed 4 weeks after the last pIpC injection. (B) Percentage of CD45.1+ donor-derived 
cells at 8 weeks post-transplantation from PB of Hif-2αfl/fl Mx1-Cre (n=2) and Control recipients 
(n=2) (males) transplanted with WT BM cells showing successful engraftment of donor derived 
cells. WT- Wild type. 
    500,000  
CD45.1+ BM 
8 weeks 
Lethally irradiated 
Hif-2α fl/fl Mx1-Cre and 
Hif-2α fl/fl  
Analysis 
pIpC 
Wild type 
(CD45.1+) 
4 weeks 
A 
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Figure 4. 14: Immunophenotypic analysis of donor-derived HSCs and progenitor 
compartments in the lethally irradiated Hif-2αΔ/Δ and Control recipients.  
Percentage of donor-derived CD45.1+ (A) LSK, (B-C) Primitive progenitors and (D) HSCs in 
the BM of Hif-2αΔ/Δ (n=2) and Control males (n=2) analysed after 4 weeks of last pIpC 
injection. The results are presented as mean ± SD. 
Figure 4. 15: Analysis of BM niche cells of Hif-2αΔ/Δ and Control primary recipients 
Percentage of (A) Endothelial cells (CD45-Ter119-CD31+), (B) Immature mesenchymal enriched 
ALCAM-Sca-1+ cells, Endosteal cells that are (C) ALCAM-Sca-1- and (D) ALCAM+Sca-1- cells in 
the Hif-2αΔ/Δ (n=2) and Control male (n=2) recipients analysed 4 weeks after last pIpC injection. 
The results are presented as mean ± SD. 
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 Introduction 5.1
5.1.1 Cited2 is a hypoxia inducible transcriptional regulator 
Cited2 is a CBP/p300 interacting transactivator with glutamic acid and 
aspartic acid (ED)-rich tail 2 (Cited2). It is ubiquitously expressed nuclear 
protein and functions as a transcriptional co-activator of several DNA 
binding TFs including AP2, HNF4α, PPAR α/ϒ, and Smad2/Smad3 (Bamforth 
et al. 2001; Tien et al. 2004; Chou and Yang 2006; Qu et al. 2007). Cited2 is 
induced by hypoxia. Hif-1α and Hif-2α control the transcriptional induction 
of Cited2 by binding to HRE elements in the Cited2 promoter region 
(Bhattacharya et al. 1999). Cited2 also functions as a repressor of Hif-1α by 
competing for binding of CBP/p300 (Bhattacharya et al. 1999; Freedman et 
al. 2003; van den Beucken et al. 2007). Cited2 acts as negative regulator of 
Hif-1α-mediated signalling by high affinity binding to first Cystine-histidine-
rich (CH1) domain of p300 restricting the recruitment of CBP/p300 
(Bhattacharya et al. 1999; Freedman et al. 2003; van den Beucken et al. 
2007). Cited2 null mice died prenatally because of defective neural tube 
and cardiovascular abnormalities, in part due to abnormal transactivation by 
Tfap2 (Bamforth et al. 2001). Another publication reported abnormal 
transcriptional activity of Hif-1α in Cited2 null embryos (Yin et al. 2002). 
Mouse embryonic studies showed increased expression of Hif-1 target genes, 
such as Vegf, Glut-1 and PGK-1, in E14.5 Cited2-/- embryonic hearts and in 
MEFs under hypoxic conditions (Yin et al. 2002). However, unpublished 
results from Prof. Kranc’s lab have shown that Cited2 deletion in MEFs did 
not affect the expression of Vegf, Glut-1 or PGK-1 (Unpublished data from 
the Kranc laboratory). The myocardial defects including abnormal cardiac 
vasculature, outflow tract, inter-ventricular septum and hyposplenia in 
embryos lacking Cited2 were partially rescued by heterozygous Hif-1α 
expression (Xu et al. 2007). Cited2 was shown to inhibit induction of Hif-1α-
mediated apoptosis, regulated by Foxo3a-stimulated Cited2 expression in 
fibroblasts and breast cancer cells under hypoxic conditions (Bakker et al. 
2007). Foxo3a-induced expression of Cited2 during hypoxia led to reduced 
expression of pro-apoptotic Hif-1α target genes, such as NIX and RTP801, 
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establishing Cited2 as a negative modulator of Hif-1α transcriptional activity 
(Bakker et al. 2007) (Figure 5.1).  
5.1.2 Cited2 and its role in cancer 
The role of Cited2 in cancer is unknown. A recent study showed an increase 
in Cited2 expression in leukaemic cells from MLL-AF9 induced AML mouse 
model (Sykes et al. 2011). Experimental evidence from previous studies 
showed that Cited2 was highly expressed in lung cancer patients and in 
Engelbreth–Holm–Swarm (EHS) tumours (Futaki et al. 2003; Chou et al. 2006; 
Chou et al. 2012). An elevated expression of Cited2 was also reported in the 
F9 embryonic carcinoma (F9-PE) that produced abnormal amounts of 
extracellular matrix like collagen IV and laminins causing tumour formation 
(Futaki et al. 2003; Chou et al. 2006; Chou et al. 2012). In Rat1 cells, 
overexpression of Cited2 resulted in tumour formation in nude mice, 
thereby suggesting the oncogenic potential of Cited2 (Sun et al. 1998). In 
lung cancer patients, elevated expression of Cited2 is associated with poor 
prognosis (Chou et al. 2012). Overexpression of Cited2 enhanced growth of 
lung cancer xenografts and knockdown of Cited2 lead to tumour shrinkage 
and increased survival of nude mice (Chou et al. 2012). A study by Lau et al. 
reported an elevated expression of Cited2 in primary human breast tumours 
(Lau et al. 2010). However, the role of Cited2 in breast cancer is not clear 
(Chou et al. 2006). One study showed that knockdown of Cited2 in breast 
cancer cell lines reduced the TGF-ß-mediated tumour invasion and 
increased cell death induced by hypoxia by modulating the expression of 
MMP-9 via TGF-ß (Chou and Yang 2006). Additionally, a recent publication 
indicated that Cited2 acts as a transcriptional co-activator of the oestrogen-
receptor (ER) in breast cancer cell lines, thus resulting in oestrogen-
independent ER activation (Lau et al. 2013).  In contrast, another study 
showed that reduced expression of Cited2 mRNA in breast cancer patients 
(van Agthoven et al. 2009). However, in human colon cancer cells, Cited2 
regulated the tumour invasion and knockdown of Cited2 increased 
invasiveness of colon cancer cells in vitro (Bai and Merchant 2007). These 
findings together suggest the importance and variable role of Cited2 in 
tumourigenesis. Depending on the cell type and cancer, Cited2 appears to 
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act as a tumour suppressor or as an oncogene. The role of Cited2 in 
leukaemogenesis and LSC functions remains to be investigated.  
5.1.3 Cited2 is critical for normal haemopoiesis in foetal liver 
and adult BM 
Cited2 is essential for murine foetal liver development (Qu et al. 2007) and 
normal foetal liver haemopoiesis (Chen et al. 2007; Qu et al. 2007; Du and 
Yang 2013). Cited2 is expressed at high levels in HSCs, LSKs and in myeloid 
progenitors (LK cells) in the foetal liver (Chen et al. 2007). Chen et al 
reported that Cited2 null mouse embryos had reduced numbers of LSK and 
LK cells with compromised reconstitution ability in lethally irradiated 
recipients. The number of erythroid and myeloid cells in Cited2 null foetal 
liver was greatly decreased and an in vitro CFC assay showed reduced 
colony forming potential of foetal liver cells from Cited2-/- embryos (Chen et 
al. 2007). Cited2 null progenitor cells showed decreased expression of self-
renewal genes such as Bmi1 and Wnt signalling molecules like LEF-1 and 
Notch-1 (Chen et al. 2007). Also, Cited2-/- cells exhibited reduced levels of 
Gata2 that play an important role in HSC/progenitor cell maintenance 
(Rodrigues et al. 2005; Rodrigues et al. 2008) and primitive erythrocytes 
formation thus establishing the role of Cited2 in the molecular regulation of 
haemopoiesis during embryogenesis (Chen et al. 2007).  
Cited2 is essential for adult haemopoiesis (Kranc et al. 2009; Du et al. 
2012). Acute deletion of Cited2 in adult mice resulted in the loss of HSCs 
and fatal BM failure leading to haemopoietic specific lethality (Kranc et al. 
2009). The loss of HSC in mice lacking Cited2 was, in part, due to elevated 
levels of p19Arf and p53, leading to increased apoptosis (Kranc et al. 2009). 
Additional deletion of Ink4a/Arf or Trp53 along with Cited2 restored HSC 
functions and repopulation potential of Cited2 knockout mice, indicating the 
importance of Cited2 in HSC maintenance, at least partially via the p19Arf-
p53 pathway (Kranc et al. 2009). Haemopoiesis-specific deletion of Cited2 
resulted in defective HSC functions including reduced quiescence and 
additional deletion of Hif-1α partially rescued HSC quiescence and 
reconstitution capacity (Du et al. 2012). In contrast to these findings, 
unpublished results from Prof. Kranc’s lab showed that deletion of Hif-1α in 
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HSCs lacking Cited2 did not rescue HSC functions (Guitart et al, unpublished 
data). Therefore, the role of Cited2 and its downstream targets in 
regulating HSC functions needs further investigation. Cited2 functions as a 
regulator of primitive haemopoietic cells is conserved in humans as 
supported by in vitro knockdown studies of CITED2 in human CD34+ cells 
(Kranc et al. 2009). Cited2 is also essential for the maintenance of MEFs 
(Kranc et al. 2003). Deletion of Cited2 led to the increased expression of the 
cell-cycle inhibitors p16Ink4a and p19Arf, causing premature cellular 
senescence. Deletion of Ink4a/Arf or p53 in MEFs lacking Cited2 restored 
their proliferation (Kranc et al. 2003). Kranc et al showed that Cited2 
regulated proliferation of fibroblasts and expression of Ink4a/Arf in part via 
Bmi1 and Mel18 (Kranc et al. 2003). Therefore, Cited2 is crucial for 
physiological and pathological conditions, including tumour development.  
5.1.4 Mcl-1, an anti-apoptotic gene and its role in normal and 
malignant haemopoiesis 
Mcl-1 (Myeloid cell leukaemia-1) is an anti-apoptotic gene and a member of 
the BCL-2 family. Mcl-1 expression is induced by growth factor and cytokine 
signalling, such as by IL-7 in lymphoid progenitors (Opferman et al. 2003), 
Scf and IL-5 in murine HSPCs and human BM cell lines (Huang et al. 2000; 
Opferman et al. 2005). Mcl-1 expression is critical for embryonic 
development and deletion of Mcl-1 resulted in defective pre-implantation 
development and implantation leading to embryonic lethality (Rinkenberger 
et al. 2000). In the haemopoietic system, Mcl-1 plays crucial role in 
maintenance of HSC functions (Opferman et al. 2005; Campbell et al. 
2010b). Mcl-1 is highly expressed in mouse and human HSCs compared to 
primitive progenitors (Opferman et al. 2005; Campbell et al. 2010a). Mice 
with induced deletion of Mcl-1 were severely anaemic, had BM failure and 
were moribund (Opferman et al. 2005). They had dramatic loss of HSCs and 
progenitor cells, which failed to engraft lethally irradiated host mice 
(Opferman et al. 2005). Mcl-1 was shown to be required for the survival of 
HSPCs in vitro (Opferman et al. 2005). Analysis of expression of BCL-2 
members in de novo isolated and in vivo reconstituted human haemopoietic 
cells revealed specifically high expression of MCL-1 in primitive HSCs 
(Campbell et al. 2010a). Mice with conditional deletion of Mcl-1 in 
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neutrophils and macrophages showed survival defects and enhanced 
apoptotic granulocytes without affecting macrophage viability (Dzhagalov et 
al. 2007). 
Overexpression of Mcl-1 is associated with increased transformation 
potential (Zhou et al. 1998; Dzhagalov et al. 2008; Campbell et al. 2010a; 
Glaser et al. 2012). In vivo pharmacological targeting of BCL-2 family 
members, including MCL-1 resulted in decreased self-renewal and 
regenerative potential of human HSCs and LSCs (Campbell et al. 2010a). 
Human MCL-1 transgene expression in transgenic mice resulted in splenic 
enlargement, increased CFC colony formation from BM cells and enhanced 
survival of mature B and T cells as well as myeloid cells (Zhou et al. 1998; 
Dzhagalov et al. 2008). Under in vitro culture conditions, overexpression of 
MCL-1 transgene increased the immortalisation of myeloid cells (Zhou et al. 
1998). Among the Bcl-2 family members, specific deletion of Mcl-1 resulted 
in apoptosis of transformed murine AML cells both in vitro and in vivo, via a 
Bim-dependent apoptotic pathway (Glaser et al. 2012). Functional 
inactivation of Mcl-1 by lentiviral expression of BimS-derived BH3 variant 
ligand, BimS2A, that selectively neutralises MCL-1, showed that blockade of 
MCL-1 significantly decreased the viability of primary human AML and 
human AML-derived cell lines (Glaser et al. 2012).  
5.1.5 AML mouse model – Retroviral transformation and 
transplantation 
The RTTA mouse model is widely employed to understand the molecular 
mechanisms governing AML (Lavau et al. 1997; Kroon et al. 1998; Cozzio et 
al. 2003; Lessard and Sauvageau 2003; Yan et al. 2006; Somervaille et al. 
2009; Yan et al. 2009; Wang et al. 2010; Gibbs et al. 2012; Kamezaki et al. 
2013).  Ectopic expression of oncogenes using the retroviral expression 
vector, MSCV to infect HSPCs results in rapid development of AML (Zeisig 
and So 2009). Isolated BM cells are enriched for HSPCs by positive selection 
for c-Kit expression (Zeisig and So 2009). These cells are transduced with 
retrovirus expressing oncogenic fusions, such as AML1-ETO9a, MLL-ENL or 
Meis1 and Hoxa9 and cultured in cytokine (IL-3, IL-6 and Scf) supplemented 
media to support proliferation and survival of primitive cells (Zeisig and So 
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2009). RTTA is explained in detail in the section 2.2.3, briefly this involves 
serial re-plating of HSPCs, transduced with an oncogenic fusion and selected 
for antibiotic resistance into methylcellulose (supplemented with SCF and 
cytokines supporting myeloid differentiation) to generate pre-LSCs that are 
capable of generating LSCs and transplantable AML once transplanted into 
lethally irradiated recipients (Zeisig and So 2009). Non-transformed cells 
exhaust during initial plating in methylcellulose (CFC-1, Colony forming cell-
1), while transformed cells successfully re-plate with colonies exhibiting 
transformed morphology (Zeisig and So 2009). At CFC-3, cells are capable of 
giving rise to transplantable AML when transplanted and are termed pre-
LSCs, that eventually acquire additional mutations thus forming LSCs (Zeisig 
and So 2009).    
The AML1-ETO9a fusion transcript is reported in AML patients with the t(8; 
21) translocation (Yan et al. 2006; Yan et al. 2009; Kamezaki et al. 2013).
Previous study on murine model showed that transplantation of AML1-ETO9a 
transduced foetal liver cells into lethally irradiated recipients resulted in 
anaemia with high WBC count, elevated primitive progenitor cells and 
defective differentiation (Yan et al. 2006). Further, the study reported that 
mice transplanted with AML1-ETO9a pre-LSCs developed leukaemia with in 
16 weeks of transplantation with enlarged spleens and livers, pale femurs 
and elevated blast cells in PB (Yan et al. 2006). However, lymphnodes or 
thymi were not affected (Yan et al. 2006). Flow cytometric analysis showed 
lack of mature lineage markers with elevated LSKs resembling human AML 
without maturation (Yan et al. 2006). 
MLL-ENL fusion protein results from the chromosomal translocation t(11; 19) 
(Lavau et al. 1997). Retroviral transformation of HSPCs with MLL-ENL 
resulted in morphologically compact transformed colonies at CFC-2 and CFC-
3 that exhibited enhanced self-renewal and proliferative potential (Lavau et 
al. 1997; Cozzio et al. 2003). Mice transplanted with MLL-ENL transduced BM 
cells developed AML similar to M4 subtype (Acute myelomonocytic 
leukaemia) in human AML, with a latency of 73-118 days, with mice 
exhibiting increased WBC counts, infiltration of immature myeloid cells in 
the spleen liver, kidney and PB (Lavau et al. 1997; Cozzio et al. 2003; 
Somervaille et al. 2009). Flow cytometric analysis revealed that LSCs 
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expressed immature markers, including CD43 and c-Kit, as well as myeloid 
markers such as Mac-1 and Gr-1 (Lavau et al. 1997; Cozzio et al. 2003; 
Somervaille et al. 2009).  
 Meis1 and Hoxa9 when co-expressed in HSPCs and transplanted into mice 
resulted in the rapid onset of leukaemia with a latency of 49-70 days (Kroon 
et al. 1998). Clinical signs included infiltration into other organs, including 
spleen, lymphnodes, BM and thymus and elevated WBCs in the PB and BM 
(Kroon et al. 1998). The leukaemic cells expressed the immature c-Kit cell 
surface marker and myeloid markers, Gr-1 and Mac-1 (Kroon et al. 1998; 
Lessard and Sauvageau 2003; Wang et al. 2010; Gibbs et al. 2012). These 
murine models have given insight into the molecular factors and signalling 
pathways governing AML development (Lessard and Sauvageau 2003; Wang 
et al. 2010).  
 Outline of experiments described in Chapter 5 5.2
Cited2 has been shown to be critical for the maintenance of HSC functions 
(Kranc et al. 2009) however, the oncogenic potential of Cited2 in 
leukaemogenesis and in the maintenance of LSC functions remains to be 
investigated. The aim of this Chapter was to study the role of Cited2 in AML 
development. I generated CKO mice: Cited2fl/fl Vav-iCre with haemopoietic 
specific Cited2 deletion and Cited2fl/fl Mx1-Cre with pIpC induced Cited2 
deletion and respective Controls. To investigate the transformation ability 
of HSPCs lacking Cited2 expression, I employed in vitro RTTA with ectopic 
expression of fusion genes MLL-ENL, AML1-ETO9a or co-expression of Meis1 
and Hoxa9. I have shown that HSPCs lacking Cited2 displayed reduced 
transformation potential and failure to generate transplantable AML in 
lethally irradiated syngeneic recipients. Additionally, overexpression of Mcl-
1 in Cited2Δ/Δ cells bypassed their defective transformation potential. 
Hence, the data in this Chapter provide evidence that Cited2 is essential for 
leukaemic transformation at least in part via Mcl-1 regulation.  
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 Results 5.3
5.3.1 Investigating the transformation potential of HSPCs 
lacking Cited2 
To investigate the potential of HSPCs lacking Cited2 to generate 
transformed colonies, I employed RTTA. I generated mice lacking Cited2 
specifically in the haemopoietic cells using the Vav-iCre system that 
efficiently deletes the floxed gene during early haemopoietic development 
in the embryos (de Boer et al. 2003b; Mortensen et al. 2011; Du et al. 2012). 
BM cells from the Cited2fl/fl Vav-iCre mice (referred as Cited2Δ/Δ) and 
Cited2fl/fl mice without Vav-iCre (referred as Control) were isolated and 
enriched for HSPCs by positive selection for the expression of c-Kit (CD117) 
using microbeads (Figure 5.2). The HSPCs were transduced with retroviruses 
carrying the fusion genes (MLL-ENL, AML1-ETO9a) or co-expressing Meis1 and 
Hoxa9 and Control vector (MSCV neo) by a centrifugation process called 
spinoculation (detail description in section 2.5.1). During spinoculation, 
primary cells were cultured in cytokines (SCF-20ug/ml, IL-3-10ug/ml and IL-
6-10ug/ml) supplemented culture media (IMDM, 10%FBS, Penicilin-100U/ml, 
Streptomycin-100ug/ml) that promotes cell division. The cells transduced 
with fusion genes were positively selected for puromycin and/or neomycin 
resistant gene cassette and plated into methycellulose medium 
supplemented with specific cytokines (GM-CSF, SCF, IL-3, IL-6) and 
puromycin or neomycin. The number and morphology of transformed 
colonies generated were analysed after 6-7 days and then the colonies were 
serially re-plated to examine transformation potential in vitro (Zeisig and So 
2009). 
HSPCs from Cited2fl/fl without Vav-iCre (Control) mice were transduced with 
empty vector (MSCV neo) along with MLL-ENL or Meis1-Hoxa9. HSPCs 
transduced with MSCV neo formed less colonies compared to the number of 
colonies formed by MLL-ENL or Meis1-Hoxa9 transduced HSPCs (Figure 5.3A). 
The colonies generated by HSPCs transduced by MSCV neo lacked the 
transformation morphology and failed to generate colonies during serial re-
plating, whereas MLL-ENL and Meis1-Hoxa9 transduced cells generated 
compact, immature transformed colonies and retained the continued ability 
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of serial re-plating (Figure 5.3B). These results showed that the HSPCs upon 
retroviral transduction of oncogenic fusions generated transformed colonies 
and retained the potential for serial re-plating in vitro.  
Cited2Δ/Δ HSPCs transduced with retrovirus expressing MLL-ENL yielded a 
smaller number of neomycin resistant colonies compared to Control at first 
plating into methycellulose (CFC-1) (Figure 5.4A). The colonies formed by 
MLL-ENL transduced cells lacking Cited2 appeared morphologically non-
transformed and failed to generate colonies upon re-plating (Figure 5.4D). 
MLL-ENL transduced Control cells successfully generated compact 
transformed CFC-blast colonies and maintained the ability to generate 
colonies through serial re-plating (Figure 5.4A and 5.4D). Number of 
compact transformed colonies generated by Cited2Δ/Δ HSPCs transformed by 
either Meis1-Hoxa9 or AML1-ETO9a oncogenic fusions were reduced to a 
great extent compared to Control (Figure 5.4B and 5.4C). Meis1-Hoxa9 or 
AML1-ETO9a transduced Cited2Δ/Δ cells gave rise to less compact colonies 
(Figure 5.4D). The colonies with AML1-ETO9a, lacking Cited2, eventually 
expired at CFC-3, while transformed Control cells continued forming 
colonies during serial re-plating (Figure 5.4C). In vitro RTTA using three 
different oncogenic fusions shows the lack of transformation potential of 
cells lacking Cited2 compared to its Control. Collectively, the results 
indicate that Cited2 is essential for transformation of cells in vitro and 
formation of pre-LSCs. 
5.3.2 Immunophenotypic characterisation of transformed 
colonies 
Meis1-Hoxa9 induced leukaemia is categorised as M2 (i.e. AML with 
maturation) under the FAB classification (Kroon et al. 1998). The leukaemic 
cells are characterised by high expression of c-Kit and co-expression of Gr-1 
and/or CD11b cell surface markers (Kroon et al. 1998; Lessard and 
Sauvageau 2003; Wang et al. 2010). To examine the immunophenotypic 
characteristics of pre-LSCs generated by in vitro RTTA, Meis1-Hoxa9 
transformed HSPCs forming puromycin- and neomycin-resistant colonies 
were harvested at each CFC assay and analysed for pre-LSC markers (c-Kit, 
CD11b and Gr-1)(Kroon et al. 1998; Lessard and Sauvageau 2003; Wang et al. 
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2010) using flow cytometry. Meis1-Hoxa9 transduced HSPCs from colonies 
lacking Cited2 and Control were stained for expression of primitive cell 
marker c-Kit and mature myeloid markers CD11b and Gr-1. HSPCs from both 
Cited2Δ/Δ and Control colonies expressed c-Kit and were positive for both 
myeloid markers CD11b and Gr-1 (Figure 5.5A and 5.5B). The percentage of 
c-Kit+ cells isolated from transformed colonies lacking Cited2 was similar to 
the Control (Figure 5.5A). There was no difference in the percentage of c-
Kit+/Gr-1+/CD11b+ cells derived from colonies lacking Cited2 and colonies 
with WT levels of Cited2 expression (Figure 5.5B). Though a decrease in 
percentage of c-Kit+Gr-1+CD11b+ cells in the Meis1-Hoxa9 transformed 
Cited2Δ/Δ cells compared to Control cells was observed, it was not 
statistically significant. These results show that there was no significant 
difference in the immunophenotypic characteristics of pre-LSCs lacking 
Cited2 compared to Control. Cited2-deficient cells transformed with Meis1-
Hoxa9 resulted in immunophenotypically similar, but reduced numbers of 
transformed colonies with diverse self-renewal potential compared to 
Control. This might possibly be due to defects in apoptosis or in self-renewal 
properties of HSPCs lacking Cited2.    
5.3.3 Investigating the transformation potential of cells 
lacking Cited2 by complementation of Cited2 
In the previous section (5.3.1), I have shown that transduction of HSPCs 
lacking Cited2 with co-expression of Meis1 and Hoxa9 leads to decreased 
numbers of colonies and eventually exhaustion of colony forming potential. 
To further investigate if the reduced ability of leukaemic transformation in 
vitro is due to Cited2 deletion, I co-transduced HSPCs from Cited2Δ/Δ mice 
and Cited2fl/fl Control mice (without Vav-iCre) with Meis1-Hoxa9 and 
lentivirus carrying Cited2 or empty vector (Figure 5.6A). This experiment 
also ruled out the possibility of loss of HSPCs in mice lacking Cited2 and 
hence no target cells available for leukaemic transformation. Puromycin and 
neomycin resistant Meis1-Hoxa9 transformed cells were further sorted for 
GFP+ (Cited2 overexpression or empty vector) and serially re-plated to 
assess the in vitro transformation potential. Cells lacking Cited2 and Control 
co-transduced with empty vector and Meis1-Hoxa9 generated transformed 
colonies during the first three re-platings (Figure 5.6B). Eventually, the 
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number of colonies formed by transformed Cited2Δ/Δ cells reduced compared 
to Control (Figure 5.6B). However, cells with WT level of Cited2 expression 
co-transduced with empty vector and Meis1-Hoxa9 continued to generate 
compact transformed colonies through serial re-plating (Figure 5.6B). 
Cited2Δ/Δ and Control HSPCs co-transduced with Meis1-Hoxa9 and Cited2 
transgene successfully generated compact and transformed CFC-blast 
colonies (Figure 5.6B). Ectopic expression of Cited2 in Cited2Δ/Δ HSPCs 
yielded compact CFC-blast colonies and was able to continuously transform 
cells in vitro in serial re-plating assay compared to colonies generated by 
transduced HSPCs lacking Cited2 that appeared non-transformed (Figure 
5.6C). These results together imply that Cited2-deficient HSPCs failed to 
generate transformed colonies and ectopic expression of Cited2 in Cited2Δ/Δ
HSPCs generated transformed colonies and retained the potential to self-
renew in vitro. Therefore, Cited2 expression is critical for transformation of 
HSPCs and to generate pre-LSCs. 
5.3.4 Lack of transformation potential of Cited2 deficient cells 
to generate AML in vivo 
To dissect the role of Cited2 in the maintenance of AML in vivo, I employed 
a genetic knockout approach by using inducible Cre. I generated Cited2fl/fl 
Mx1-Cre mice where inducible acute deletion of Cited2 is achieved by pIpC 
treatment. Upon pIpC treatment, Mx1 promoter is activated resulting in 
Cre-mediated deletion of Cited2. Following Cited2 deletion, Cited2 
promoter controls the expression of LacZ in pIpC treated Cited2fl/fl Mx1-Cre 
cells demonstrating efficient gene deletion (Kranc et al. 2009). To generate 
pre-LSCs with the potential to develop disease resembling human AML in the 
mouse model, HSPCs isolated from untreated Cited2fl/fl Mx1-Cre mice and 
Cited2fl/fl without Mx1-Cre (Control) were transduced with Meis1-Hoxa9 
using the spinoculation protocol described in section 2.2.3. Transduced cells 
were positively selected for puromycin and neomycin resistance and plated 
onto methylcellulose to produce transformed colonies. The cells harvested 
from transformed colonies were serially re-plated until CFC-3 to generate 
pre-LSCs (Figure 5.7A).  
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Meis1-Hoxa9 transformed cells from Cited2fl/fl Mx1-Cre and Cited2fl/fl 
colonies that expressed c-Kit and myeloid markers Gr-1 and Mac-1 that are 
termed as pre-LSCs were assessed for their leukaemogenic potential.  At 
CFC-3, cells were isolated and sorted for expression of c-Kit, Gr-1 and 
CD11b using multi-colour flow cytometry. 200,000 sorted cells from 
untreated Cited2fl/fl Mx1-Cre and Control colonies along with 500,000 
support-BM cells were transplanted into lethally irradiated syngeneic B6.SJL 
(CD45.1+) recipients (Figure 5.7A). 9 out of 16 mice transplanted with pre-
LSCs derived from Meis1-Hoxa9 transduced Control HSPCs developed AML 
with a latency period of 6-10 months, while none of the mice transplanted 
with pre-LSCs derived from untreated Cited2fl/fl Mx1-Cre mice developed 
leukaemia (Figure 5.7B). Mice transplanted with pre-LSCs from Meis1-Hoxa9 
transduced Control cells showed appearance of leukaemic cells expressing c-
Kit, Gr-1 and CD11b in the PB as characterised by immunopheneotypic 
analysis. Mice developing leukaemia were sacrificed when they appeared 
moribund and analysed for AML phenotype. Mice with AML displayed organ 
infiltration in the spleen and immunophenotypic analysis of the blood, BM 
and spleen from leukaemic mice showed abundance of leukaemic cells 
characterised by expression of c-Kit+, Gr-1+ and CD11b+ (Figure 5.7D-F). 
However, there was no trace of mobilised leukaemic cells in the PB of mice 
transplanted with pre-LSCs from untreated Cited2fl/fl Mx1-Cre mice (Figure 
5.7F). Pre-LSCs from CFC-3 of untreated Cited2fl/fl Mx1-Cre mice had partial 
deletion of Cited2 shown by LacZ staining (Figure 5.7C). This partial 
deletion of Cited2 might be induced by the cytokines and stressful culture 
conditions and was sufficient to modulate the disease development 
potential of pre-LSCs. Additional deletion could have been triggered in vivo 
by irradiation that activates the interferon type I/II signalling (Leong 1996; 
Burnette et al. 2011). These results show that HSPCs transformed with 
retrovirus containing Meis1 and Hoxa9 induced transplantable AML in vivo 
and partial deletion of Cited2 in these cells reduced their ability to 
generate disease upon transplantation. 
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5.3.5 Mcl-1 enhances the ability of Cited2-deficient cells to 
undergo leukaemic transformation 
Next, I wished to identify the molecular mechanism through which Cited2 
functions during leukaemic transformation. Cited2 deletion in progenitor 
cells resulted in significant 4.2 fold decreased expression of Mcl-1 
suggesting defective survival of HSCs in turn led to their loss in Cited2-
deficient foetal liver (Chen et al. 2007). Also, unpublished work from Prof. 
Kranc’s lab found Mcl-1 down-regulated in Cited2Δ/Δ cells (Dr. Guitart, 
unpublished data and Prof. Kranc personal communication). Notably, 
deletion of Mcl-1, similar to the deletion of Cited2, results in the inability of 
haemopoietic progenitors to undergo leukaemic transformation (Glaser et 
al. 2012). Therefore, I tested the hypothesis that Mcl-1 over-expression can 
bypass defective transformation of Cited2Δ/Δ c-Kit+ cells. To investigate the 
requirement for Cited2 in the development, establishment and maintenance 
of LSCs, I employed a mouse model of AML. In this model, HSPCs are 
transduced with retroviruses expressing oncogenic fusions, undergo serial 
re-plating and generate pre-LSCs, which upon transplantation give rise to 
LSCs causing leukaemia (Figure 5.8A). To this end, I crossed Cited2fl/fl Vav-
iCre mice to Mcl-1 transgenic mice in which the over expression of Mcl-1 is 
driven by haemopoiesis-specific Vav promoter (in collaboration with Prof. 
Suzanne Cory, WEHI) (Campbell et al. 2010b). These crosses gave rise to 
Cited2fl/fl Vav-iCre mice, Cited2fl/fl Vav-iCre Mcl-1+ and Control mice. BM c-
Kit+ cells from these mice transduced with oncogenic fusions MLL-ENL, AML-
ETO9a or co-expressing Meis1 and Hoxa9 were subjected to the serial re-
plating transformation assay as described in Figure 5.8A. While Control cells 
gave rise to transformed colonies efficiently as expected, Cited2Δ/Δ cells 
failed to generate transformed colonies (Figure 5.8B). However, Cited2Δ/Δ
cells over-expressing Mcl-1 transgene could be serially re-plated and 
generated colonies with a transformed phenotype (Figure 5.8B). Cited2Δ/Δ
colonies over expressing Mcl-1 were morphologically indistinguishable from 
Control transformed colonies (Figure 5.8C). Additionally, ectopic expression 
of Mcl-1 in Cited2Δ/Δ cells led to enhanced transformation potential when 
co-transduced with Meis1 and Hoxa9 (Figure 5.9A) and the cells formed 
morphologically transformed compact colonies similar to Control HSPCs 
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(Figure 5.9B). Therefore, these results demonstrated that over expression of 
Mcl-1 bypassed the defective transformation potential of Cited2Δ/Δ HSPCs.   
 Discussion 5.4
5.4.1 Cited2 is essential for the transformation of HSPCs in 
vitro and AML generation in vivo 
Cited2 is induced by various stimuli including cytokines, growth factors and 
serum (Sun et al. 1998). Cited2 has a critical role in regulating 
embryogenesis and adult haemopoiesis (Bamforth et al. 2001; Bamforth et 
al. 2004; Chen et al. 2007; Qu et al. 2007; Kranc et al. 2009; Du et al. 2012; 
Du and Yang 2013). Impaired expression of Cited2 (increased/decreased 
expression based on the type of cancer) is associated with various solid 
tumours (Sun et al. 1998; Futaki et al. 2003; Chou et al. 2006; Bai and 
Merchant 2007; Chou et al. 2012). However, the function of Cited2 in cancer 
formation and leukaemogenesis is unclear. 
Alongside Cited2 being critical for regulating functions of adult HSCs (self-
renewal, apoptosis and quiescence) (Kranc et al. 2009; Du et al. 2012), a 
recent study showed an increase in Cited2 expression in leukaemic cells 
from MLL-AF9 induced AML mouse model (Sykes et al. 2011). Also, elevated 
levels of CITED2 are observed in CD34+ human AML samples compared to 
normal CD34+ cells (Prof. K. Kranc, personal communication). Taken 
together these preliminary results suggest a potential role of Cited2 in AML. 
I investigated if expression of Cited2 is essential in the generation and 
maintenance of AML LSCs both in vitro and in vivo, using a murine model 
generated by RTTA. Transformation of HSPCs from Control mice with 
oncogenic fusions, MLL-ENL, AML1-ETO9a or co-expression of Meis1-Hoxa9 
successfully generated compact transformed colonies in vitro compared to 
Control HSPCs transduced with MSCV-neo (Control vector). This validated 
the transformation potential of HSPCs retrovirally transduced by oncogenic 
fusions (MLL-ENL, Meis1-Hoxa9, AML1-ETO9a) in agreement with previous 
publications (Cozzio et al. 2003; Lessard and Sauvageau 2003; So et al. 
2003; Somervaille and Cleary 2006; Gibbs et al. 2012). HSPCs lacking Cited2 
displayed defective transformation potential in vitro. Cited2-deficient 
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HSPCs transduced with oncogenic fusions generated dramatically reduced 
numbers of colonies which appeared morphologically non-transformed (not 
dense) compared to transformed HSPCs from Control mice (which looked 
very compact), irrespective of the oncogenes. However, the severity of the 
transformation defects was dependent on the oncogenic fusions. Meis1-
Hoxa9-transduced cells lacking Cited2 formed colonies that retained the 
ability to generate transformed colonies during initial re-plating, but 
eventually expired after CFC-5. Conversely, MLL-ENL transduced HSPCs 
lacking Cited2 had a striking phenotype, i.e. they formed few colonies at 
CFC-1 and failed to generate colonies when re-plated, exhibiting impaired 
self-renewal ability assessed by serial re-plating assay compared to its 
Control. Immunophenotypic analyses of both Cited2 deficient and Control 
HSPCs transformed by Meis1-Hoxa9 showed an equal percentage of pre-LSCs 
phenotype with expression of c-Kit, Gr-1 and CD11b. These results 
confirmed that presence of the target cells for oncogenic transformation in 
mice lacking Cited2. Further, the Cited2 deficiency resulted in their 
defective transformation ability.  
Acute deletion of Cited2 results in severe loss of HSCs and primitive 
progenitors causing fatal BM failure (Kranc et al. 2009). To rule out the 
possibility that Cited2Δ/Δ HSPCs were apoptotic due to lack of Cited2 and 
hence failed to survive during transformation resulting in reduced colony 
number, I ectopically expressed Cited2 along with Meis1 and Hoxa9 in the 
Cited2Δ/Δ HSPCs. Additional expression of Cited2 in Meis1-Hoxa9 transduced 
Cited2Δ/Δ HSPCs regained the ability to transform and successfully generate 
CFC-blast like colonies in serial re-plating. This showed that transformation 
defects in the Cited2Δ/Δ cells were specific for the Cited2 deletion and could 
be rescued by Cited2 complementation. Previous publications showed that 
Cited2 deletion resulted in survival defects of HSPCs (Kranc et al. 2009; Du 
et al. 2012). Therefore, Cited2 overexpression studies and the 
immunophenotypic analysis of Cited2-deficient colonies from section 5.3.3 
demonstrated that the target cells (HSPCs) for the oncogeneic 
transformation were available in Cited2-deficient mice (from the Cited2 
Vav-iCre) and also showed that these cells were able to regain the 
transformation potential in the presence of Cited2. Additionally, primitive 
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haemopoietic cells lacking Cited2 showed decreased Mcl-1 expression 
(Preliminary data from Prof. Kranc’s lab). The reduced expression of Mcl-1 
in Cited2Δ/Δ cells might therefore explain the lack of their transformation 
ability. 
Furthermore, to investigate the requirement of Cited2 in the generation of 
AML in vivo I conducted transplantation experiments. In a period of 6 
months, more than 50% of the recipients transplanted with Meis1-Hoxa9 
transduced pre-LSCs from Control mice developed AML. The spleen 
infiltration, elevated PB counts and leukaemic blast cells in PB, BM and 
spleen that were immunophenotypically stained for c-Kit, Gr-1 and Mac-1 
confirmed AML development. However, none of the recipients of pre-LSCs 
from Meis1-Hoxa9 transduced with untreated Cited2fl/fl Mx1-Cre mice 
(inducible CKO mouse) developed AML in the time frame of 6 months. 
Retrospectively, the analysis of gene deletion in pre-LSCs from CFC-3 
showed partial deletion (30%-40%) of Cited2 as analysed by LacZ expression 
that was sufficient to prevent the generation of AML in vivo. The partial 
deletion of Cited2 in untreated Cited2fl/fl Mx1-Cre pre-LSCs, when 
transplanted into the lethally irradiated mice, could possibly have further 
Cre activation triggering additional deletion due to stimulation of type I/II 
interferon signalling due to irradiation or superficial infection of mice 
(Leong 1996; Onoguchi et al. 2007; Burnette et al. 2011).  
Studies show that Foxo3a is essential for the maintenance of self-renewal 
properties of HSCs and also inhibits Hif1-induced apoptosis by stimulating 
Cited2 expression in fibroblasts and breast cancer cell lines (Bakker et al. 
2007; Miyamoto et al. 2007). It is known that Cited2 functions as a negative 
feedback loop controlling the Hif-1α activity and that deletion of Hif-1α on 
a background of Cited2 deletion partially rescued the defective HSC 
functions (Bhattacharya et al. 1999; Xu et al. 2007; Du et al. 2012). 
Together, these previous studies and the results presented in this Chapter 
suggest the possibility that deletion of Cited2 may have resulted in 
accumulation of Hif-1α levels, in turn leading to increased Hif-1α-induced 
apoptosis. This revealed that the possible block of AML generation in Cited2 
deficient pre-LSCs is due to the Cited2-mediated inhibitory effects of 
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Foxo3a on Hif-1α-induced apoptosis. It is noteworthy that Cited2 deletion in 
HSCs affect other TFs including cyclin-dependent kinase inhibitor p57, Erg1, 
Stat5 and Myc that play a critical role in the maintenance of HSC quiescence 
and survival properties (Wang et al. 2009; Du et al. 2012). Further studies 
need to be carried out investigating the mechanistic pathway mediated by 
Cited2 during AML transformation. 
5.4.2 Transformation defect in HSPCs lacking Cited2 is 
rescued by overexpression of Mcl-1 
Cited2 deletion results in the loss of HSCs and defective multilineage 
haemopoietic potential (Kranc et al. 2009; Du et al. 2012). This HSC defect 
is attributed at least in part to the increased p53 activity (Kranc et al. 
2009). HSPCs lacking Cited2 failed to generate transformed colonies in vitro 
and did not induce AML in the in vivo murine models. Mcl-1, a BCL-2 family 
member is an anti-apoptotic gene essential for the survival of HSCs and AML 
LSCs (Opferman et al. 2005; Campbell et al. 2010a; Glaser et al. 2012). 
HSPCs overexpressing Mcl-1 in the background of Cited2 deficiency were 
investigated for their transformation potential. Ectopic expression of Mcl-1 
in Cited2Δ/Δ HSPCs co-transduced with Meis1 and Hoxa9 regained the 
transformation potential compared to Cited2Δ/Δ cells. Meis1 and Hoxa9 
transduced HSPCs from Control mice generated similar numbers of colonies 
compared HSPCs overexpressing Mcl-1, therefore Mcl-1 overexpression did 
not seem to have an advantage over Control HSPCs. RTTA experiments 
showed that MLL-ENL, AML1-ETO9a or Meis1-Hoxa9 transduced HSPCs from 
Cited2∆/∆ Mcl-1+ mice generated increased numbers of morphologically 
transformed CFC-blast like colonies compared to colonies generated by 
Cited2Δ/Δ cells and restored the self-renewal potential as assessed by serial 
re-plating. 
Cited2 and Mcl-1 have similar expression profiles, both are highly expressed 
in HSCs and their expression is decreased in more differentiated progenitor 
cells (Opferman et al. 2005; Kranc et al. 2009). Inducible deletion of Cited2 
or Mcl-1 in the CKO mouse model resulted in similar phenotypes, including 
fatal BM failure, loss of haemopoietic progenitor population and failure of 
engraftment in lethally irradiated recipients (Opferman et al. 2005; Kranc et 
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al. 2009). I have shown in the previous section that deletion of Cited2 
results in inability of transformation of HSPCs transduced with oncogenic 
fusions. Similarly, deletion of Mcl-1 resulted in increased death rate in 
HSPCs transformed using oncogenic fusions in culture and knockdown of Mcl-
1 cleared AML cells resulting in prolonged survival of the mice (Glaser et al. 
2012). Previous studies (Opferman et al. 2005; Kranc et al. 2009; Glaser et 
al. 2012) taken together with the results described in this Chapter indicate 
that Cited2 is essential for leukaemic transformation of HSPCs at least in 
part by regulating the expression of Mcl-1. However, at this point we cannot 
rule out the possibility that apoptotic HSPCs in Cited2Δ/Δ mice display 
defective leukaemic transformation potential that is bypassed by 
overexpression of anti-apoptotic gene Mcl-1, independent of Cited2. Gene 
analyses studies will give more insight into molecular mechanisms of Cited2-
Mcl-1 pathway.      
 Conclusion 5.5
In this Chapter, I have shown that Cited2 plays a critical role in the 
transformation ability of HSPCs. Deletion of Cited2 results in reduced 
transformation potential of HSPCs and failure to generate transplantable 
AML in lethally irradiated syngeneic recipients. Additionally, my results 
show that Mcl-1 overexpressing cells are able to bypass the transformation 
defects in Cited2Δ/Δ cells. This supports the idea that Cited2 is essential for 
leukaemic transformation at least in part by regulating Mcl-1. 
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Figure 5. 1: Schematic representation of Hif-mediated apoptotic pathway regulated by 
hypoxia and Foxo3a 
Figure 5. 2: Schematic representation of RTTA. 
BM cells from the Cited2fl/fl Vav-iCre and control mice are enriched for haemopoietic stem and 
progenitor cells (HSPCs), transduced with retrovirus expressing fusion genes AML1-ETO9a, 
MLL-ENL or co-expression of Meis1 and Hoxa9 are serially re-plated to form pre-LSCs. At 
CFC-3, pre-LSCs are injected in to lethally irradiated mice that generate LSCs and 
transplantable AML. 
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Figure 5. 3: Retroviral transformation of HSPCs from wild type (WT) mice. 
(A) Number of colonies formed during serial re-plating of WT HSPCs transformed with MSCV 
neo, MLL-ENL and Meis1-Hoxa9. Results are represented as mean ± SD, n=3 and statistical 
analysis was performed by two-tailed student's t tests assuming unequal variance, p value ≤ 
0.0005 (***). (B) Representative images of colonies formed by WT HSPCs transformed with 
MSCV neo, MLL-ENL and Meis1-Hoxa9 at CFC-3. 
MSCV neo                                 MLL-ENL                             Meis1-Hoxa9 
B
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Figure 5. 4: Retroviral transformation of HSPCs from Cited2Δ/Δ and Control mice. 
Number of colonies formed during serial re-plating of Cited2Δ/Δ and Control HSPCs transformed 
with (A) MLL-ENL (B) Meis1-Hoxa9 and (C) AML1-ETO9a. Results are represented as mean ± 
SD, n=3 and statistical analysis was performed by two-tailed student's t tests assuming unequal 
variance, p value ≤ 0.005 (**) and p ≤ 0.0005 (***). (B) Representative images of colonies 
formed by Cited2Δ/Δ and Control HSPCs transformed with MLL-ENL at CFC-1, AML1-ETO9a 
and Meis1-Hoxa9 at CFC-3. 
MLL-ENL  
AML1-ETO9a 
Meis1-Hoxa9 
Control  Cited2Δ/Δ  D 
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Figure 5. 5: Immunophenotypic characterisation of Meis1 and Hoxa9 transformed 
colonies. 
Percentage of (A) c-Kit+ cells and (B) c-Kit+, Gr-1+ and Mac-1+ cells from Cited2Δ/Δ and Control 
HSPCs transformed with Meis1-Hoxa9. Results are represented as mean ± SD, n=3. 
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Figure 5. 6: Transformation potential Cited2Δ/Δ cells with complimentary expression of 
Cited2  
(A) Schematic representation of RTTA of Cited2Δ/Δ and Wt HSPCs transformed with Meis1-Hoxa9 
with ectopic expression of Cited2. Cited2Δ/Δ and Wt HSPCs are co-transduced with Meis1-Hoxa9 and 
Cited2 or Control vector expression GFP. Meis1- Hoxa9 transformed cells positively selected for 
puromycin and neomycin resistance are further sorted for GFP by flow cytometry and serially re-
plated to test the transformation potential. (B) Number of transformed colonies generated during serial 
re-plating of Cited2Δ/Δ and Wt HSPCs with ectopic expression of Cited2 and Control vector 
transformed with Meis1-Hoxa9. Results are represented as mean ± SD, n=3. (C) Representative 
images of colonies formed by Meis1-Hoxa9 transformed Cited2Δ/Δ and Wt HSPCs selected for 
expression of Cited2 and Control vector at CFC-3. 
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Figure 5. 7: AML development potential of Cited2Δ/Δ pre-LSCs in vivo  
(A) Schematic representation of RTTA of Cited2Δ/Δ and Control HSPCs transformed with Meis1-
Hoxa9, sorted for pre-LSCs and transplanted into lethally irradiated recipients. Cited2Δ/Δ and 
Control HSPCs co-transduced with Meis1-Hoxa9 were serially re-plated until CFC-3 to generate 
pre-LSCs. The pre-LSCs were further sorted for cell surface markers (c-Kit, Gr-1 and CD11b) by 
flow cytometry and 200,000 sorted pre-LSCs along with 500,000 support BM was transplanted 
into lethally irradiated recipients (B) Kaplan Meier survival curve representing the percentage of 
survival of recipients transplanted with Cited2Δ/Δ and Control pre-LSCs. Blocked dots represent 
recipients with Cited2Δ/Δ pre-LSCs (n=14) and empty dots represent recipients with Control pre-
LSCs (n=16). (C) Percentage of LacZ+ pre-LSCs from CFC-3 that were stained for FDG 
expression. Representative FACS plots of  (D) BM, (E) Spleen and (F) PB from the recipients 
transplanted with Cited2Δ/Δ (n=3) and Control (n=3) pre-LSCs. 
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Figure 5. 8: Transformation potential Cited2Δ/Δ, Cited2Δ/Δ Mcl-1+, Cited2+/+Mcl-1+ and 
Control cells 
(A) Schematic representation of RTTA of Cited2Δ/Δ, Cited2Δ/Δ Mcl-1+, Cited2+/+Mcl-1+ and 
Control mice transformed with MLL-ENL, Meis1-Hoxa9 and AML1-ETO9a (B) Number of 
transformed colonies generated during serial re-plating of Cited2Δ/Δ, Cited2Δ/Δ Mcl-1+, 
Cited2+/+Mcl-1+ and Control HSPCs transformed with Meis1-Hoxa9, MLL-ENL and AML1-
ETO9a. Results are represented as mean ± SD, n=2. (C) Representative images of colonies 
formed by Meis1-Hoxa9 and AML1-ETO9a transformed Cited2Δ/Δ, Cited2Δ/Δ Mcl-1+ and Control 
HSPCs at CFC-3 and MLL-ENL at CFC-1.  
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Figure 5.9: Transformation potential Cited2Δ/Δ cells with complimentary expression of 
Mcl-1  
(A) Number of transformed colonies generated during serial re-plating of Cited2Δ/Δ and Wt HSPCs 
with ectopic expression of Mcl-1 and Control vector transformed with Meis1-Hoxa9. Results are 
represented as mean ± SD, n=3. (B) Representative images of colonies formed by Meis1-Hoxa9 
transformed Cited2Δ/Δ and Wt HSPCs selected for expression of Mcl-1 and Control vector at CFC-3. 
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 Final discussion 6.1
Hypoxia and hypoxia signalling pathways are believed to play an important 
role in the regulation of HSC functions (Parmar et al. 2007; Kranc et al. 
2009; Simsek et al. 2010; Takubo et al. 2010; Miharada et al. 2011; Kocabas 
et al. 2012; Singh et al. 2013; Gezer et al. 2014). Both isoforms of Hif-α and 
their target genes (e.g. Vegf, Meis1, Cited2) have been shown to be 
important in murine embryonic development (Maltepe et al. 1997; Adelman 
et al. 1999; Bamforth et al. 2001; Gruber et al. 2007; Chen et al. 2008). 
Takubo and colleagues demonstrated evidence suggesting that Hif-1α 
expression is important in the maintenance of HSC functions under stressful 
conditions of serial transplantation and aging (Takubo et al. 2010). 
However, the role of the other isoform of Hif-α, Hif-2α, in HSC functions 
was unknown. Hence, the following work focused on understanding the 
importance of Hif-2α and the interplay between Hif-1α and Hif-2α in 
regulating HSC functions. Results presented in this thesis show that 
expression of Hif-2α, or both Hif-1α and Hif-2α, within HSCs is dispensable 
for their normal functions under the stressful conditions of serial 
transplantation and aging. However, Hif-2α is essential for the maintenance 
of HSC functions in a non-cell-autonomous manner, specifically in males and 
possibly regulated via Hif-1α.  
In a separate, but related study, the current work examined the role of the 
hypoxia-inducible gene, Cited2, in the development of AML. The data 
presented in this thesis strongly suggest that Cited2 is required for the 
formation of LSCs and in the development of AML. Additionally, 
overexpression of Mcl-1, an anti-apoptotic gene (Dzhagalov et al. 2008; 
Campbell et al. 2010b; Glaser et al. 2012), increases the leukaemic 
transformation potential of the cells lacking Cited2. Hence, Cited2 is 
required for the transformation potential of HSPCs potentially via Mcl-1.  
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6.1.1 Hif-2α is dispensable for the maintenance of cell-
autonomous HSC functions 
To dissect the role of Hif-2α in the maintenance of HSC functions in a cell-
autonomous manner, mice with conditional deletion of Hif-2α were studied. 
The results demonstrated that HSCs without Hif-2α sustained normal 
multilineage haemopoiesis and self-renewal properties (Chapter 3). Under 
stressful conditions of serial transplantation, HSCs lacking Hif-2α 
successfully repopulated secondary and tertiary recipients (Chapter 3). 
Furthermore, Hif-2α-deficient HSCs were examined for age induced stress 
response. Lethally irradiated recipients were transplanted with BM cells 
lacking Hif-2α and were analysed at 24 weeks of age. This experiment 
showed that age-induced stress in Hif-2α-deficient HSCs did not affect the 
maintenance of HSC functions (Chapter 3). These results, taken together, 
demonstrate that cell-autonomous expression of Hif-2α in HSCs is 
dispensable for their normal functions. This is in agreement with recent 
published evidence where we showed that a mouse model with Hif-2α 
deletion during embryogenesis in the haemopoietic cells (Vav-iCre) 
successfully maintained adult HSC functions and retained steady state 
multilineage haemopoiesis (Guitart, Subramani et al, Blood, 2013). 
Previously it was shown that global deletion of Hif-2α severely affected 
survival of mice with increased perinatal lethality and multiple organ 
pathologies, including pancytopenia (Scortegagna et al. 2003a). Another 
study showed that Hif-2α was essential for regulation of Epo in the kidney 
and maintenance of erythroid progenitors in adult mice (Gruber et al. 2007). 
A recent publication provided evidence that high levels of systemic Epo 
expression resulted in altered fate-choices of HSCs and primitive progenitors 
with increased erythroid-biased lineages and suppressed non-erythroid 
lineages (Grover et al. 2014). Given that Hif-2α regulates Epo expression, 
which has downstream effects on HSC/progenitor fate choices, it is 
intriguing that the current work using serial transplantation studies 
demonstrates that acute deletion of Hif-2α is dispensable for the 
maintenance of HSC functions in a cell-autonomous manner. The serial 
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transplantation studies conducted in Chapter 3 demonstrated that HSCs 
lacking Hif-2α were capable of long-term multilineage reconstitution in 
lethally irradiated recipients.  The current work also showed that age-
induced stress in HSCs lacking Hif-2α did not affect their potential of 
multilineage haemopoiesis. Additional evidence demonstrated that HSCs 
from Hif-2αfl/fl Vav-iCre successfully maintained long-term reconstitution 
properties when transplanted into lethally irradiated mice (Guitart, 
Subramani et al, Blood, 2013). Hence, taken together, the results from 
Chapter 3 showed that unlike Hif-1α (Takubo et al. 2010), Hif-2α is not 
critical for regulating HSC functions in a cell-autonomous manner including 
stressful conditions of aging and serial transplantation.  
Gathered from the previous publications, global deletion of Hif-2α in mice is 
embryonic lethal (Scortegagna et al. 2003a; Gruber et al. 2007). Hence, the 
current study employed a CKO approach with inducible-Cre (Mx1-Cre) that 
allowed for acute deletion of Hif-2α in adult mice in haemopoietic cells, BM 
microenvironment (Kuhn et al. 1995; Schneider et al. 2003; Walkley and 
Orkin 2006; Walkley et al. 2007), thus bypassing the embryonic lethality. 
The use of Cre-inducible deletion of conditional alleles of Hif-2α  provided a 
valuable tool to address the haemopoietic-specific role of Hif-
2α. Importantly, the administration of pIpC and resultant acute deletion of 
Hif-2α allowed for HSC-specific deletion within transplanted Hif-2α ∆/∆  donor 
derived BM cells with flexibility of pIpC-induced deletion following the 
successful engraftment of HSCs from Hif-2α∆/∆ mice into the recipient BM, 
thus, addressing the function of Hif-2α in regulating the long-term HSC 
reconstitution. pIpC has been reported to interfere with cell-cycle status 
(Lundberg et al. 2007) and altering the BM microenvironment, thus creating 
an additional stress. Taking into account the possible stress that is induced 
by pIpC, the data in the Chapter 3 showed that HSCs did not require cell-
autonomous Hif-2α to maintain their normal functions under stressful 
conditions of altered BM niche due to pIpC administration.     
A recent study on human HSPCs showed that knockdown of HIF-2α using 
shRNA  (short-hairpin RNA) resulted in defective long-term repopulation 
potential (Rouault-Pierre et al. 2013). The HIF-2α  knockdown in human 
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CD34+ cells resulted in a decrease in proliferative capability and erythroid 
colony formation in vitro, coupled with impaired reconstitution capacity in 
part due to an increase in ROS production and increased ER stress resulting 
in subsequent apoptosis (Rouault-Pierre et al. 2013). However, this study 
had several caveats such as the use of a single shRNA to knockdown HIF-2α  
whose specificity for HIF-2α  was not validated. Currently, there are 
numerous publications highlighting the importance of off-target effects in 
shRNA studies (Grimm et al. 2006; Jackson and Linsley 2010; Kaelin 2012).  
In addition, all experiments were conducted in normoxia, further adding 
complexity to the interpretation of the resultant data. Collectively the 
current work and that of colleagues within the field (Rouault-Pierre et al. 
2013) suggest distinct roles of Hif-2α-dependent signalling in mouse and 
human HSCs/HSPCs.  Nevertheless, further studies are required to rule out 
the possibility of system-dependent discrepancies (haematopoiesis-specific 
conditional gene knockout in mice versus shRNA mediated knockdown in 
human ex vivo samples). Indeed the field would benefit from a detailed 
comparative study of Hif-2α  in regulating HSC functions in both human and 
mouse models to further clarify the system-dependent variability in the 
requirement of Hif-2α in HSC maintenance. 
6.1.2 Hif-1α and Hif-2α are dispensable for maintenance of 
cell-autonomous HSC functions 
Given that Hif-2α deletion did not affect the cell-autonomous HSC functions 
(Chapter 3) and the lack of Hif-1α had a mild phenotype under steady state 
(Takubo et al. 2010), we decided to delete both Hif-1α and Hif-2α  in 
haemopoietic system. HSCs lacking the expression of both Hif-1α and Hif-2α 
maintained repopulation potential and successfully generated mature 
haemopoietic lineages (Chapter 3). Serial transplantation experiments 
showed that Hif-1α− and Hif-2α−defecient HSCs retained self-renewal 
potential and long-term multilineage haemopoiesis in secondary and tertiary 
recipients (Chapter 3). Additionally, age-induced stress in lethally irradiated 
mice transplanted with BM cells lacking both Hif-1α and Hif-2α did not 
affect the maintenance of HSC functions (Chapter 3). In contrast to 
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published work  (Takubo et al. 2010), the current work demonstrated that 
cell-intrinsic Hif-α-regulated hypoxia signalling is not absolutely essential 
for the maintenance of HSC functions even under stressful conditions of 
serial transplantation and aging.  
Hif-1α and Hif-2α have been shown to be important in regulating cellular 
and systemic hypoxia (Semenza 1999; Coleman and Ratcliffe 2007; Gruber et 
al. 2007; Kaelin and Ratcliffe 2008). Both Hif-1α and Hif-2α are critical for 
embryogenesis and early development (Maltepe et al. 1997; Iyer et al. 1998; 
Ryan et al. 1998; Tian et al. 1998; Adelman et al. 1999; Adelman et al. 
2000; Peng et al. 2000; Compernolle et al. 2002; Scortegagna et al. 2003a; 
Ramirez-Bergeron et al. 2006; Gruber et al. 2007). Hif-2α is induced by ROS 
and has been shown to be important in regulating the oxidative-stress 
response, while Hif-1α is believed to be a master regulator of metabolism 
(Gruber et al. 2007; Simsek et al. 2010; Takubo et al. 2010; Kocabas et al. 
2012). Previously, Hif-1α has been shown to be important in regulating HSC 
cell cycle quiescence (Takubo et al. 2010). Although, HSCs lacking Hif-1α 
maintained normal steady-state haemopoiesis, during stressful conditions of 
serial transplantation and aging, loss of HSCs and their cell cycle quiescence 
in a p16Ink4a/p19Arf-dependent manner was reported (Takubo et al. 2010). 
Results from Chapter 3 showed that additional deletion of Hif-2α along with 
Hif-1α did not mimic the LSK chimerism or loss of HSCs during serial 
trasplantation and aging observed in Hif-1αΔ/Δ mice (Takubo et al. 2010), 
suggesting that increased Hif-2α expression may be driving the loss of 
quiescent HSC phenotype in the absense of Hif-1α. In support, a more 
recent study reported increased levels of Hif-2α expression in the Hif-1α-
deficient cells (Kocabas et al. 2012). However, a more recent study 
suprisingly revealed that expression of Hif-1α in HSCs/progenitors remains 
stable reglardless of their cell-cycle status (Nombela-Arrieta et al. 2013). 
Another recent publication studied the effect of Hif-1α deletion in the 
vascular-endothelial cadherin (VEC)-expressing endothelial cells, which are 
the precursors to HSCs using VEC-Cre (Imanirad et al. 2014). VEC-Cre 
deleted Hif-1α during early embryogenesis and displayed reduced donor-
derived LSK cells in primary recipients, but successfully reconstituted 
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secondary recipients (Imanirad et al. 2014).  Thus providing data that are 
contradicting to previously published work by Takubo et al (Imanirad et al. 
2014).  The Hif-1αΔ/Δ (VEC-Cre) mice had reduced haemopoietic progenitor 
cells in the AGM region at E10, but these mice matured to adulthood and 
displayed normal adult haemopoiesis (Imanirad et al. 2014). Furthermore, 
studies in the human system, using HIF-1α knockdown in haemopoietic stem 
and progenitor cells, showed that these cells efficiently maintained their 
self-renewal properties during serial transplantation (Rouault-Pierre et al. 
2013). Hence, the role of Hif-1α in regulation of HSC self-renewal under 
stress conditions is unclear and merits further investigation. 
Several downstream Hif-1α and Hif-2α targets, including Cited2, Vegf, 
Cripto and Foxo3a, were shown to be critical for cell-autonomous HSC 
maintenance (Chen et al. 2007; Miyamoto et al. 2007; Kranc et al. 2009; 
Takubo et al. 2010; Miharada et al. 2011; Rehn et al. 2011). These Hif-
target genes are likely to be regulated by other Hif-independent pathways 
and this possibly explains the lack of functional defects in HSCs lacking both 
Hif-1α and Hif-2α expression. Supporting the role of Hif-independent 
pathways regulating the transcriptional activation of Hifs, a study showed 
that inducible deletion of Meis1, a transcriptional activator of Hif-1α 
(Simsek et al. 2010), in murine HSCs led to loss of HSC functions, including 
loss of BM repopulation following transplantation, with decreased levels of 
Hif-1α and Hif-2α expression (Kocabas et al. 2012). However, the defective 
HSC phenotype was not rescued with stabilisation of Hif-1α and Hif-2α by 
cobalt chloride (Kocabas et al. 2012). Collectively, the results in Chapter 3 
demonstrated that the Hif-2α was dispensible in cell autonomous manner 
for normal HSCs functions. Hence, suggesting that the loss of HSCs in Meis1-
deficient mice was due to the increased level of ROS and other pathways 
regulated by Meis1 and not because of the defective Hif-1α and Hif-2α 
expression.  
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6.1.3 Hif-2α  plays an essential role in non-cell-autonomous 
HSC maintenance in a gender-specific manner 
To examine the role of Hif-2α in the BM niche regulating non-cell-
autonomous HSC functions, acute deletion of Hif-2α was studied using an 
inducible Mx1-Cre mouse model. The use of Mx1-Cre system allowed for the 
possibility of induced Hif-2α deletion in fully developed adult BM and 
haemopoietic cells and thus provided a valuable tool to understand the 
effect of acute deletion of Hif-2α on HSC functions. The analysis of the 
expression of Hif-1α and Hif-2α in various BM niche cells showed that Hif-2α 
is expressed at high levels in endothelial cells compared to OBs and 
mesenchymal-like cells (Chapter 4). The current work demonstrated that 
induced deletion of Hif-2α in the BM niche and in HSCs resulted in 
decreased HSCs and progenitor cells, particularly in males but not in 
females (Chapter 4). The lack of Hif-2α specifically impaired HSCs and 
primitive progenitors and did not affect mature cell numbers or functions. 
This is in agreement with a previous study by Scrotegagna et al that showed 
impaired repopulation potential and reduced WBC count in mice lacking Hif-
2α expression (Scortegagna et al. 2003a). However, at this point we cannot 
rule out the possible influence of Hif-2α deletion outside the BM niche (e.g. 
kidney, liver or other interferon responsive organs) on the HSC and 
progenitor phenotype that is observed in Hif-2α−deficient males. Further, 
the data demonstrated that there was no extramedullary haemopoiesis or 
apoptotic defects identified in the Hif-2α−deficient HSCs. It is plausible that 
lack of Hif-2α expression might result in increased differentiation of HSCs 
and progenitor cells accounting for reduced HSPCs. A detailed study of the 
cell cycle status of HSCs and progenitor compartments will reveal the 
mechanisms of Hif-α regulation of HSC differentiation state in the BM niche. 
Therefore, the results from Chapter 4 showed that although the BM lacking 
Hif-2α successfully maintained long-term multilineage reconstitution 
properties, expression of Hif-2α in the BM niche is necessary in a non-cell-
autonomous manner for maintenance of HSCs in males. 
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Results in this thesis revealed a surprising gender biased requirement of Hif-
2α for HSC maintenance in a non-cell-autonomous manner. Several studies 
have demonstrated the correlation between steroid hormones and hypoxia 
signalling in various cell types, including HSCs and BM niche (Fried et al. 
1974; Medina et al. 1993; Samuels et al. 1999; Thurmond et al. 2000; 
Tsuzuki et al. 2013). Females treated with oestradiol displayed elevated 
LSKs and increased repopulation potential (Tsuzuki et al. 2013). This effect 
of oestrogen on LSKs might equip HSCs with resistance to lack of Hif-2α 
expression, particularly in females explaining the impaired HSCs in Hif-2αΔ/Δ 
males shown in Chapter 4.  
The hypoxia inducible gene, Vegf, is highly expressed in perichondrial cells 
and chondrocytes of the HSC niche and helps to maintain HSC functions 
(Chan et al. 2009). Furthermore, Rankin and colleagues showed that 
enhanced stabilisation of α-subunits of Hifs by Vhl deletion, specifically in 
the endosteal niche cells, led to the expansion of niche cells and an 
increase in HSC numbers (Rankin et al. 2012). This defective HSC phenotype 
is mediated by Hifs as co-deletion of Hif-1α and Hif-2α rescued the 
haemopoietic defects (Rankin et al. 2012).  Rankin et al. showed that Epo 
was one of the important components of the HSC niche and deletion of Vhl 
or MT1-MMP (matrix metalloproteinase) in the BM niche affected Epo levels 
and resulted in defective HSC functions (Nishida et al. 2012; Rankin et al. 
2012). Hence it is possible that Hif-2α, a master regulator of Epo, is critical 
for the maintenance of HSC functions in the BM niche. MT1-MMP has also 
been shown to induce Hif-1α expression and to be important for postnatal 
haemopoiesis (Nishida et al. 2012). Gathered from these previous 
publications and the results presented in this thesis, it is evident that Hifs 
play a key role in maintaining HSC functions in a non-cell-autonomous 
manner by regulating their niche.  
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6.1.4 Hif-2α  plays an essential role in the regulation of non-
cell-autonomous HSC functions in a Hif-1α-dependent 
manner 
Additional deletion of one allele or both alleles of Hif-1α together with Hif-
2α specifically rescued decreased progenitors and HSCs observed in Hif-
2α∆/∆ males (Chapter 4). However, deletion of one allele of Hif-1α was 
sufficient to rescue the reduced progenitor cells in Hif-2αΔ/Δ males. In 
contrast, deletion of both alleles of Hif-1α did not have an effect on the 
decreased progenitor cells in Hif-2αΔ/Δ males (Chapter 4). These results 
suggested that in the absence of Hif-2α,  Hif-1α  plays a dose-dependent 
role in maintaining HSC functions in a non-cell-autonomous manner that is 
gender biased. From the previous study by Takubo and colleagues it is 
evident that deletion of one allele of Vhl stabilised Hif-1α and induced 
quiescence in HSCs and progenitor cells, but over-stabilisation of Hif-1α in 
VhlΔ/Δ mice resulted in defective HSC repopulation potential and apoptosis 
(Takubo et al. 2010). However, Cited2, a negative regulator of Hif-1α is 
critical for the maintenance of HSC function partly via Ink4a/Arf and Trp53 
(Kranc et al. 2009). These studies support the dose-dependent regulation of 
HSC functions by Hifs. Further, the results in Chapter 4 showed that the 
deletion of Hif-1α and Hif-2α results in a cell-type-specific phenotype and 
Hif-α signalling is influenced by various factors, including gender 
contributing to the complexity of the mechanism. 
Various publications have shown evidence that the BM is hypoxic and 
harbours a hypoxic gradient (Parmar et al. 2007; Kubota et al. 2008; Lo 
Celso et al. 2009). Concordantly, a recent finding measured the pO2 levels in 
the BM niche and showed that the BM niche is hypoxic (Spencer et al. 2014). 
This study demonstrated the existence of an oxygen gradient in the BM 
niche with peri-sinusoidal being most hypoxic and endosteal being least 
hypoxic, questioning the previous theories postulating that the endosteal 
niche is the least oxygenated (Spencer et al. 2014). However, another 
recent publication argues against the idea of existence of hypoxic gradient 
in the BM niche analysed by the imaging studies and a routinely used 
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hypoxic dye (Pimo) (Nombela-Arrieta et al. 2013). Interestingly, it was 
reported that exposure to irradiation or chemotherapeutic stress resulted in 
increase of pO2 levels and no detectable hypoxic gradient across BM niches 
after 2 days of irradiation (Spencer et al. 2014). Considering this recent 
finding, there is a possibility that the effect of irradiation on the hypoxic 
state might influence the expression and stabilisation of Hifs and other 
hypoxic targets in the irradiated BM niche. However, the disappearance of 
the hypoxic gradient in the irradiated BM niche was limited to short time (2 
days) read out after irradiation. The lack of the oxygen gradient was 
attributed to the reduced BM cellularity and the demand for ample blood 
flow (Spencer et al. 2014). Hence, this might be a temporary environment 
created for short time span after irradiation due to the loss of BM 
cellularity. To address this, a detailed investigation of hypoxic status of the 
irradiated niche at various time points tracking cell recovery and oxygen 
levels is essential. Moreover, the lack of hypoxic gradient did not affect the 
homing of HSPCs (Spencer et al. 2014). It is also not clear if HSCs dictate the 
oxygen gradient of their niche by cell-intrinsic hypoxia signalling. Therefore, 
a more detailed analysis of long-term effects of irradiation on the hypoxic 
nature of the BM niche and on HSCs will facilitate with the understanding of 
its influence on serial transplantation analysis. Additionally, published 
evidence suggested that Hif expression in HSPCs was independent of oxygen 
concentration in the BM niche (Nombela-Arrieta et al. 2013). Notably HIF-1α 
expression was reported in CD34+ cells from normoxic culture (Rouault-
Pierre et al. 2013).  These studies suggested that Hif-α isoforms are induced 
and stabilised by oxygen-independent pathways. Therefore, a more detailed 
understanding of the BM hypoxic gradient and its effect on hypoxia 
signalling together with its influence on HSC niche functions is essential.    
6.1.5 Proposed model of HSC niche 
The HSC niche is heterogenous and has been subdivided into two main 
groups, the vascular and the endosteal niche (Scadden 2006; Parmar et al. 
2007; Morrison and Spradling 2008; Lo Celso et al. 2009; Chow et al. 2011; 
Ding et al. 2012; Nishida et al. 2012; Rankin et al. 2012; Nombela-Arrieta et 
al. 2013; Spencer et al. 2014). The localisation of HSCs in the BM niche is 
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currently under debate. Previous studies, including imaging studies provided 
evidence supporting the possibility of the osteoblastic niche serving as the 
HSC niche (Calvi et al. 2003; Lo Celso et al. 2009; Miyamoto et al. 2011). 
Alternatively, another study showed that deletion of Scf specifically from 
the endothelial and perivascular BM niche resulted in the depletion of HSCs 
(Ding et al. 2012). This study supports the close proximity of HSCs to 
endothelial and perivascular niche. A more recent study shed light on the 
distinct niches supporting HSCs and progenitor cells (Ding and Morrison 
2013). Endothelial cell-specific deletion of chemokine, Cxcl12 in mice 
showed depletion on HSCs, while deletion of Cxcl12 in perivascular cells 
depleted HSCs and progenitor cells (Ding and Morrison 2013).  The evidence 
of the hypoxic status of the BM niche is unclear. Previous studies 
demonstrated the existence of oxygen gradient in the BM niche by using 
Pimo and measuring the expression of Hif-1α   (Parmar et al. 2007; Kubota 
et al. 2008; Suda et al. 2011). These studies suggested that the osteoblastic 
niche was the most hypoxic and endothelial niche the least hypoxic region 
(Parmar et al. 2007; Kubota et al. 2008; Suda et al. 2011). However, more 
recently although the hypoxic nature of the BM was confirmed (32mm Hg), 
levels of pO2 gradient have been shown to be different. In particular, peri-
sinusodial region had lowest pO2, while highest pO2 was reported in the 
endosteal region (Spencer et al. 2014). The current work demonstrated that 
Hif-2α is highly expressed in the endothelial cells compared to osteoblastic 
or mesenchymal-like cells in the BM niche (Chapter 4).  Taken together, the 
evidence from previous literature and the results from Chapter 4 suggest 
that it is more likely the Hif-2α is regulating the HSC functions through the 
endothelial niche. Hence, taking into account the recent publications (Ding 
and Morrison 2013), HSCs and progenitors have distinct niches. HSCs are 
residing close to the vasculature and vascular niche that is highly hypoxic 
and has high levels of Hif-2α expression (Chapter 4) and the progenitors are 
in close proximity to the osteoblastic niche that is less hypoxic with low 
levels of Hif-2α expression (Figure 6.1). 
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Figure 6. 1: A proposed model of HSC niche. 
6.1.6 The role of Cited2 in leukaemic transformation 
Cited2, a hypoxia-inducible gene, has been shown to be critical during 
embryogenesis and in the regulation of adult HSC functions, including self-
renewal, apoptosis and quiescence (Bhattacharya et al. 1999; Chen et al. 
2007; Qu et al. 2007; Kranc et al. 2009; Du et al. 2012; Du and Yang 2013). 
While some studies supported the role of Cited2 as a tumour suppressor (Bai 
and Merchant 2007; van Agthoven et al. 2009), other studies provided 
evidence for oncogenic properties of Cited2 (Sun et al. 1998; Futaki et al. 
2003; Chou et al. 2006; Sykes et al. 2011; Chou et al. 2012). Preliminary 
data from our lab suggested that CITED2 expression is elevated in CD34+
cells from human AML cells (Personal communication, Prof. Kranc). 
Concordantly, another study reported an increase in the expression of 
Cited2 in MLL-AF9-induced LSCs (Sykes et al. 2011). In order to understand 
the role of Cited2 in leukaemogenesis, the current work examined the 
transformation potential of Cited2-deficient HSPCs by retroviral 
introduction of an oncogenic fusion in an in vitro AML model. Results from 
Chapter 5 showed that Cited2Δ/Δ HSPCs retrovirally transduced with MLL-
ENL, AML1-ETO9a or Meis1 and Hoxa9 displayed defective transformation 
potential in vitro and failed to generate colonies during serial re-plating 
(Chapter 5). Additionally, Meis1-Hoxa9 transduced HSPCs with partial 
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deletion of Cited2 failed to generate AML in a period of 6 months when 50% 
of the control developed AML in lethally irradiated syngeneic recipients. 
Survival defects have been reported in Cited2Δ/Δ HSCs (Kranc et al. 2003; 
Kranc et al. 2009). Hence both HSCs and LSC lacking Cited2 might share the 
defective survival phenotype that could explain the transformation defects 
of HSPCs lacking Cited2.  
Several TFs, such as Bmi-1, Meis1 and Pu.1 have been shown to be 
important in regulating HSC functions and their expression is critical for 
generation of LSCs and transplantable AML (Lessard and Sauvageau 2003; 
Rosenbauer et al. 2004; Azcoitia et al. 2005; Iwasaki et al. 2005; Wong et al. 
2007; Smith et al. 2011; Kocabas et al. 2012). The results from Chapter 5 
showed that Cited2, an essential regulator of HSC functions, is also required 
for the transformation and generation of LSCs. To overcome the drawback 
that lack of HSCs and progenitor cells in the Cited2fl/fl Mx1-Cre mice, I used 
a haemopoietic-specific deletion of Cited2 in Cited2fl/fl Vav-iCre mice that 
lacked the Cited2 expression from early embryogenesis throughout 
adulthood. Cited2fl/fl Vav-iCre mice had depleted HSCs, but similar number 
of primitive progenitors compared to the controls (Guitart et al. 
unpublished data). Therefore, Cited2fl/fl Vav-iCre mice, with unaffected 
number of primitive progenitor population provided target cells for the 
leukaemic transformation.  
The severity of the transformation defects observed in Cited2Δ/Δ HSPCs in 
Chapter 5 was dependent on the oncogenic signalling. Cited2Δ/Δ HSPCs 
transduced with MLL-ENL that is upstream of multiple Hox genes (Smith et 
al. 2011), failed to generate colonies during initial re-plating, while 
Cited2Δ/Δ HSPCs transformed with Meis1-Hoxa9 managed to serially re-plate 
but with fewer colonies compared to the Control. This suggests that MLL 
fusion induced activation of multiple non-Hox (Smith et al. 2011), that could 
be potentially dependent on Cited2, thus regulating LSC self-renewal. 
However, a downstream target of MLL, such as Meis1-Hoxa9-induced 
leukaemic transformation is less dependent on Cited2 signalling compared 
to MLL-ENL. Hence, the Cited2 deletion has a drastic effect on 
transformation of HSPCs by MLL fusion that activate downstream target 
genes including, Meis1 and Hoxa9 affecting a broad spectrum of TFs. 
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Conversely, deletion of Cited2 in HSPCs had less severe effects on their 
transformation potential when co-transduced by Meis1 and Hoxa9, 
downstream targets of MLL.  
6.1.7 A possible role of the Cited2-Mcl-1 pathway in leukaemic 
transformation 
Mcl-1, an anti-apoptotic gene, is down regulated in Cited2Δ/Δ embryos and in 
adult HSCs (Chen et al. 2007)(Guitart et al, unpublished data and Prof. 
Kranc personal communications). Mcl-1, with similar expression profile to 
Cited2, has been shown to be important for leukaemic transformation and 
AML generation potential (Zhou et al. 1998; Dzhagalov et al. 2008; Campbell 
et al. 2010b; Glaser et al. 2012). Hence, to test the possible Cited2-Mcl-1 
pathway during AML development, Cited2Δ/Δ HSPCs with overexpression of 
Mcl-1 were transformed using oncogenic fusion proteins. Overexpression of 
Mcl-1 in Cited2Δ/Δ HSPCs resulted in increased numbers of transformed 
colonies and restored self-renewal potential assessed by serial re-plating 
(Chapter 5). Collectively, the data suggest that Cited2 is essential for 
leukaemic transformation and for generation of LSCs in vivo, at least in part 
by regulating the expression of Mcl-1.  
Studies have shown that Hif-1α-mediated apoptotic pathway is regulated by 
Cited2 via Foxo3a (Bakker et al. 2007). Cited2 deletion has been reported to 
cause survival defects and decreased expression of Mcl-1 (Chen et al. 2007; 
Kranc et al. 2009). The elevated expression of Cited2 is reported in AML 
(Sykes et al. 2011). Moreover, MCL-1 has also been associated with poor 
prognosis and drug resistance in AML, ALL, CLL and melanoma (Beroukhim et 
al. 2010; Schwickart et al. 2010). Therefore, the current work focused on 
deciphering the role of Cited2 and Mcl-1 in leukaemic transformation. The 
results in this thesis demonstrated that the survival defects in Cited2Δ/Δ
HSPCs was bypassed by the overexpression of Mcl-1 enabling their 
transformation potential (Chapter 5). Hence, this study suggests that Cited2 
regulates the transformation potential of HSPCs potentially via Mcl-1 (Figure 
6.2). More research is essential to explore the molecular mechanisms 
regulating LSC generation via the Cited2-Mcl-1 pathway.  
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 Future studies 6.2
6.2.1 Hif-signalling in regulating HSC niche 
Hif-2α is essential for the HSC functions in a non-cell-autonomous manner 
possibly via Hif-1α in a gender-dependent manner. However, the specific 
roles of Hif-1α or Hif-2α in heterogeneous HSC niche cell maintenance and 
in influencing HSC functions are unclear. The HSC niche is thought to be 
hypoxic, with an oxygen-gradient existing in different niches (Parmar et al. 
2007; Kubota et al. 2008; Simsek et al. 2010; Takubo et al. 2010; Rehn et al. 
2011; Spencer et al. 2014). Studies showed that HSCs reside in the close 
proximity to the vasculature, which is relatively highly hypoxic (Lassailly et 
al. 2013; Nombela-Arrieta et al. 2013; Spencer et al. 2014). However, 
recent imaging study showed that HSCs are hypoxic irrespective of their 
location in the niche and retained Hif-1α expression suggesting hypoxia as a 
cell-intrinsic property of HSCs (Nombela-Arrieta et al. 2013). Hence, further 
understanding of the expression pattern of Hif-1α or Hif-2α and hypoxic 
nature of the HSCs and their niche is essential to rectify the contradictions 
within the field. This can be achieved by live imaging of the HSC niche and 
gene expression analysis of various niche cells by microarray experiments. 
Additionally, metabolic studies have shown that under hypoxic conditions, 
cells adapt to the low oxygen tension through predominant glycolytic 
metabolism over Krebs cycle (Simsek et al. 2010; Luo et al. 2011; Suda et 
al. 2011). Therefore, a detailed analysis of the metabolic status of the niche 
cells will provide with additional evidence of their hypoxic status. Further 
understanding of Hif-α in regulating the HSC niche could be achieved by 
conditional gene knockout studies by the deletion of Hif-1α or Hif-2α in 
niche cells that express the highest levels of the Hif proteins and activate 
Hif-dependent signalling pathways. To achieve conditional gene deletion 
specifically in endothelial cells, Tie2-Cre deleter and Lepr-Cre will be 
employed. Cxcl12 (Cxcl12-Cre) and PDGFR-β (PDGFR-β Cre) deleter will 
allow specific deletion in perivascular cells. Additionally, use of inducible 
Cre (Osterix-Cre) or Collagen (Col2.3-Cre) deleter in osteoblastic cells and 
Nestin-Cre deleter to delete in MSCs will address the requirement of Hifs in 
HSC niche functions. These further studies will shed light on the 
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characterisation along with the functionality of Hif-α in regulating the 
heterogeneous population of HSC niche and in-turn HSC functions. 
6.2.2 The mechanisms of Hif-α  signalling in the HSC niche 
that is differentially regulated in males and females 
Detrimental effects of Hif-2α deletion from the BM microenvironment on 
the HSCs and progenitor cells specifically in males in a non-cell-autonomous 
manner (Chapter 4) suggest a discrepancy between the male and female 
HSC niche. This is supported by research on the relationship between Hif 
signalling and sex steroids that affect the BM niche to eventually influence 
HSC functions (Fried et al. 1974; Medina et al. 1993; Thurmond et al. 2000; 
Tsuzuki et al. 2013). However, this surprising gender-biased requirement of 
Hif-2α in non-cell-autonomous HSC maintenance has to be explored to 
understand the complex Hif signalling pathways. It would be useful to 
determine the expression of Hif-1α or Hif-2α in male and female HSC niches 
by performing a gene expression analysis of HSC niche cells from male and 
female mice along with niche cells that lack Hif-1α and/or Hif-2α 
expression in specific BM niches using inducible Cre mouse models.  Recent 
advancement in the imaging techniques, such as two-photon 
phosphorescence lifetime microscopy is a valuable tool (Lo Celso et al. 
2009; Spencer et al. 2014). Live imaging of mouse models for the expression 
of Hif-α in HSCs and their BM niche will provide more understanding of 
physiological hypoxia signaling. Additionally, functional analyses of male 
and female HSC niches by studying their potential to support HSC functions 
under physiological and stressful conditions of transplantations and aging 
will uncover the gender variability in HSC niche.  
6.2.3 The role of Hifs in regulating LSCs and their niche in 
haematological malignancies 
Hypoxia and HIF signalling are important in malignant haemopoiesis 
(Semenza 2009; Luo et al. 2011; Zhang et al. 2012). Elevated expression of 
HIF-1α is often associated with poor prognosis of various human cancers 
(Keith et al. 2012). Hif-1α has been shown to be selectively required for 
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survival of LSCs (Wang et al. 2011). HIF-2α knockdown in human AML 
samples resulted in decreased engraftment of human AML cells as shown in 
xenotransplant experiments (Rouault-Pierre et al. 2013). However, the 
mechanism governing AML development by Hif signalling is unclear. 
Additionally, the interaction of the niche and LSCs in regulating AML has not 
been explored. Some evidence suggested a cytokine-mediated effect on the 
osteoblastic niche in leukaemia (Reynaud et al. 2011; Frisch et al. 2012). 
More research is necessary to discover the unique features of the leukaemic 
niche in promoting tumourigenesis. This can be achieved by retroviral 
transduction transformantion AML model, where pre-LSCs generated by 
transduction of oncogenes or oncogenic fusions are transplanted into 
syngeneic recipients lacking Hif-α expression particularly in the niche cells. 
By monitoring their ability to develop AML and detailed analysis of 
Leukaemic mice will provide valuable data in understanding the influence of 
Hifs in the generation of LSCs and their niche. Additionally, functional 
analysis of the BM niche in transgenic AML mouse models (Flt3-ITD knock-in 
or MLL-AF9 knock-in) will uncover the mechanistic role of HSC niche 
components and Hif signalling on LSC generation and maintenance.  
6.2.4 The role of Cited2 in leukaemogenesis 
Cited2 expression is critical for embryogenesis, adult haemopoiesis and 
leukaemogenesis (Bamforth et al. 2001; Chen et al. 2007; Kranc et al. 2009; 
Sykes et al. ; Chou et al. 2012). Cited2 is essential for LSC formation and 
generation of transplantable AML (Chapter 5). ChIP sequencing for Cited2 in 
FDCP-mix cells has shown that Cited2 is binding the promoter region of Mcl-
1 (Preliminary data, Prof. Kranc’s lab). Unpublished data showed that 
deletion of Cited2 reduced the expression of Mcl-1 expression in HSCs 
(Guitart et al, Preliminary data). Mcl-1 overexpression bypassed 
transformation defects of Cited2-deficient HSPCs suggesting Mcl-1 as a 
downstream target of Cited2. However, the binding partners of Cited2 
remain unknown. Hence, ChIP-sequencing on pre-LSCs (generated by 
transformation of HSPCs with oncogenic fusions) will identify the region 
where Cited2 binds Mcl-1 and further sequencing studies will be carried out 
to identify the binding partners of Cited2 and Mcl-1. Given that Cited2 is a 
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critical gene in regulating various physiological and pathological conditions, 
discovery of its interactors and downstream targets are of prime 
importance. ChIP-sequencing experiment will reveal the downstream targets 
of Cited2 that will be functionally validated by gene knockout and knock-in 
studies. Furthermore, mass spectrometric analysis of Cited2 protein 
performed using primitive haemopoietic cells and pre-LSCs will identify the 
interactors of Cited2, thus uncovering the mechanistic pathways regulated 
by Cited2 in the maintenance of HSC and LSC functions. Despite deletion of 
Cited2 being detrimental on HSCs, heterozygous deletion of Cited2 does not 
result in HSC loss or damage its functions (Subramani et al, unpublished 
data). Interestingly, partial deletion of Cited2 resulted in failure to develop 
AML as shown in Chapter 5. Therefore, understanding the mechanistic 
pathways regulated by Cited2 will explore the potential of Cited2 as a 
therapeutic target for AML. Additionally, AML development and generation 
of LSCs serve as a paradigm for understanding the mechanism behind various 
tumour developments and provides with new therapeutic approaches to 
tackle tumourigenesis. Collectively, current study provided functional 
evidence for Cited2 regulating the transformation properties of HSPCs 
possibly via Mcl-1. The potential Cited2-Mcl-1 pathway needs to be further 
validated by mechanistic studies (Figure 6.2). 
Figure 6. 2: A proposed model of Cited2-Mcl-1 pathway in LSC generation. 
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Appendices 
Appendix 1: Representative FACS plot with gating strategy for the analysis of HSCs 
and primitive progenitors. 
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Appendix 2: Representative FACS plot with gating strategy for the analysis of mature 
lineages. (A) Myeloid cells, (B) B-cells and (C) Erythroid cells in the BM and (D) T-cells 
in the thymus of WT mice.  
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Appendix 3: Representative FACS plot with gating strategy for the analysis of BM 
niche from WT mice.  
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